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NOX nicotinamide adenine dinucleotide phosphate oxidase 
O2 oxygen 
O2- superoxide 
ODU optical density unit 
OH- hydroxyl radical 
ONOO- peroxynitrite 
OXPHOS oxidative phosphorylaytion  
p70S6K p70 ribosomal S6 kinase  
PAGE polyacrylamide gel electrophoresis 
PAI plasminogen activator inhibitor 
pAMPK phosphorylated AMPK 
PBS phosphate buffered saline  
PCA principal component analysis 
PCR polymerase chain reaction 
PDE phosphodiesterase 
PDGF platelet-derived growth factor  
PDK1 phosphoinositide-dependent protein kinase 1  
PEPCK phosphoenolpyruvate carboxylkinase 
PGC-1α PPAR-γ co-activator-1α 
PGI2 prostacyclin 
phox phagocyte oxidase 
Pi inorganic phosphate 
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PI3K phosphatidylinositol 3-kinase 
PIK3R2 phosphoinositide-3-kinase, regulatory subunit 2 (β) 
PKB protein kinase B 
PKC protein kinase C  
PMSF phenylmethylsulfonylfluoride 
PPAR-γ peroxisome proliferator-activated receptor-γ 
PRKAA AMPK catalytic α-subunit 
PRKAG AMPK regulatory γ-subunit 
PSS physiological salt solution 
PtdIns phosphatidylinositol 
PTEN phosphatase and tensin homologue  
qRT-PCR quantitative reverse transcription polymerase chain reaction 
RAR retinoic acid receptor  
RAS renin-angiotensin system  
rcf relative centrifugal force 
RIN RNA Integrity Number  
RNA ribonucleic acid  
ROS reactive oxygen species 
rpm revolutions per minute 
rRNA ribosomal RNA  
RT reverse transcription 
SBP systolic blood pressure 
SDHAL1 succinate dehydrogenase complex, subunit A, flavoprotein pseudogene 1 
SDHC succinate dehydrogenase complex, subunit C, integral membrane protein, 
15kDa 
SDS sodium dodecyl sulphate 
SEM standard error of the mean  
Ser serine 
SHIP2 SH2 domain-containing inositol-5-phosphatase  
SHRSP stroke prone spontaneously hypertensive rat 
SOD superoxide dismutase 
SOS son-of-sevenless  
STRAD STE-20 related adaptor protein 
T2D type 2 diabetes 
TCA tricarboxylic acid  
TCF transcription factor 
TGF transforming growth factor  
Thr threonine 
TNF-α tumour necrosis factor-α  
tPA tissue plasminogen activator  
TPP triphenylphosphonium 
TSC tuberous sclerosis complex 
ubiq ubiquinol 
UCP uncoupling protein  
v/v volume/volume 
VCAM-1 vascular cell adhesion molecule-1 
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VEGF vascular endothelial growth factor 
VSMC vascular smooth muscle cell 
vWF von Willebrand factor  
w/v weight/volume 
WHO World Health Organisation  
ZMP 5’-aminoimidazole-4-carboxamide ribonucleotide  
Zn zinc 
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Summary 
 
There is increasing evidence to support a role for vascular oxidative stress in the 
development of endothelial dysfunction and coronary artery disease (CAD). The 
prevalence of CAD in patients with type 2 diabetes (T2D) is more than ten times greater 
than in the general population and CAD patients with T2D display poorer clinical 
outcomes than those without. Previous investigations carried out within this laboratory 
have demonstrated endothelial dysfunction and elevated superoxide (O2-) production 
throughout the vessel wall in saphenous veins from patients with advanced CAD. 
However, the molecular basis for these findings was not investigated, nor was the effect of 
T2D. Consequently, the aim of this study was to investigate a number of molecular 
determinants of oxidative stress in primary human saphenous vein endothelial cells 
(HSVECs) from CAD patients both with and without T2D, the hypothesis being that 
oxidative stress leads to endothelial dysfunction in CAD and is exacerbated in those 
patients with T2D. 
 
Initial experiments confirmed the findings of previous studies, revealing significantly 
elevated O2- levels and impaired endothelium-dependent relaxation in portions of 
saphenous vein from patients with CAD related to those from healthy control subjects. In 
addition, results demonstrated more severe endothelial dysfunction in vessels from CAD 
patients with T2D relative to those CAD patients without this additional cardiovascular 
risk factor.  
 
Attempts to characterise cellular sources of elevated O2- production in the endothelium of 
patients with CAD revealed that while HSVEC endothelial nitric oxide synthase (eNOS) is 
not a major source of O2- generation in CAD, nicotinamide adenine (phosphate) 
dinucleotide (NAD(P)H) oxidase contributes to excess O2- production in the endothelium 
of patients with this cardiovascular disease.  
 
Further cellular investigation revealed a significant increase in expression of mitochondrial 
superoxide dismutase (SOD2) in HSVECs from CAD patients, in particular those with 
T2D. Mitochondrially-derived reactive oxygen species (mtROS) are reported to contribute 
to oxidative stress and endothelial dysfunction in CAD and T2D and, as such, this increase 
in SOD2 expression is likely to represent an adaptive response to elevated mitochondrial 
O2- production. In addition, analysis of gene expression microarray data revealed 
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differential expression of a number of genes potentially linked to mitochondrial function, 
serving to support a key role for mitochondrial dysfunction in the pathogenesis of CAD 
and T2D.  
 
Additional molecular studies focused on AMP-activated protein kinase (AMPK). Proposed 
as a candidate target for therapeutic intervention in endothelial dysfunction, AMPK 
stimulates eNOS, leading to nitric oxide (NO) production in cultured endothelial cells. 
Furthermore, it has recently been reported that endothelial AMPK is activated in a mtROS-
mediated manner. With SOD2 expression data indicating an increase in mtROS production 
in the endothelium of patients with CAD, AMPK activity was investigated and compared 
in HSVECs isolated from these patients and control subjects. AMPK activity
 
was 
significantly greater in cells from patients with CAD, despite no change in activity of 
upstream kinases, LKB1 and Ca2+/calmodulin-dependent kinase kinase (CaMKK). On 
stratifying CAD patients according to the presence of T2D, AMPK activity was found to 
be significantly increased in the endothelium of those patients with CAD and T2D as 
compared to those with CAD alone. Given the potentially elevated levels of mtROS 
production in the endothelium of patients with CAD, it seemed likely that endothelial 
AMPK activation in CAD patients was occurring in an mtROS-mediated manner and that 
this activation was enhanced in those CAD patients with T2D who display more severe 
endothelial dysfunction and increased SOD2 expression, consistent with increased mtROS 
production. In order to test this hypothesis, HSVECs isolated from vessels of CAD patients 
were treated with the mitochondria-targeted antioxidant, MitoQ10. Results demonstrated a 
significant decrease in AMPK activation in cells from those CAD patients with T2D on 
treatment with MitoQ10. The same effect was not seen in cells from CAD patients without 
T2D. These findings indicate that AMPK is activated in a mtROS-mediated manner in 
endothelial cells isolated from CAD patients with T2D and suggest a role for the kinase in 
defence against oxidative stress and endothelial dysfunction in these individuals. 
 
In summary, a wide range of molecular techniques have been employed to investigate 
cellular mechanisms underlying the oxidative stress and endothelial dysfunction associated 
with CAD. Results suggest mitochondria contribute to the increased O2- production and 
endothelial dysfunction observed in vessels from CAD patients. In addition, findings 
indicate a novel, mtROS-mediated activation of AMPK in the endothelium of patients with 
CAD and T2D. Therefore, mitochondria-targeted antioxidants, used in combination with 
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pharmacological activators of AMPK, may have enhanced potential in prevention and 
treatment of coronary artery disease in patients with type 2 diabetes.  
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1. Introduction 
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1.1 Cardiovascular Disease 
 
Cardiovascular disease (CVD) refers to disorders of the heart and circulatory system and 
represents a major cause of morbidity and mortality in the world today. Indeed, according 
to the World Health Organisation (WHO), an estimated 17.5 million, or approximately 
30% of total global deaths resulted from CVD in 2005 and of these deaths, 7.6 million 
were due to coronary artery disease (CAD) (1). Furthermore, in the United Kingdom in 
2006, the calculated annual direct cost of the care of patients with CAD was around £3.2 
billion, with the indirect cost of loss of productivity even greater at over £3.9 billion (2). 
Consequently, the identification and characterisation of molecular mechanisms 
contributing to the pathogenesis of CAD is highly desirable. 
 
In addition to CAD, stroke, peripheral vascular disease and renal failure / end stage renal 
disease are among cardiovascular disease phenotypes. CVD aetiology is observed to be 
multifactorial in nature with lifestyle, environmental and genetic factors implicated (3-6). 
Hypertension, type 2 diabetes mellitus and atherosclerosis are often observed in early 
development of CVD and are considered major modifiable risk factors for disease (3;4). 
Further modifiable risk factors include hypercholesterolaemia, obesity and those associated 
with low socioeconomic status, such as cigarette smoking, sedentary lifestyle, unhealthy 
diet and alcohol consumption (2). Conversely, aging, family history of CVD, gender and 
ethnicity represent non-modifiable disease risk factors (3) (Figure 1.1). Recent WHO 
statistics suggest that the major modifiable CVD risk factors account for around 80% of 
new CAD and stroke cases (1), highlighting the overwhelming need for research into 
conditions such as type 2 diabetes. 
 
 
1.1.1 Type 2 Diabetes Mellitus 
 
It is universally recognised that diabetes mellitus increases CVD risk (7;8). One of the 
most common chronic diseases, diabetes mellitus results from a combination of defects in 
insulin secretion and action (9) and affects more than 180 million people worldwide, a 
number predicted to more than double by 2030 (10). While microvascular complications of 
the condition, such as nephropathy and retinopathy, are well documented, macrovascular 
complications, including diseases of coronary arteries, peripheral arteries and carotid 
26 
 
 
 
 
 
 
 
 
 
genetic factors
diet • smoking •
sedentary lifestyle
hypertension • type 2 diabetes • obesity •
age • lipids • genetic background
atherosclerosis
CAD / myocardial 
infarction
stroke peripheral 
vascular disease
chronic renal 
failure
ENVIRONMENT
RISK FACTORS
TRAIT
PHENOTYPE
 
 
 
 
Figure 1.1. Cardiovascular Disease Risk Factors. Multiple interactions between genetic and 
environmental factors result in the target organ damage characteristic of cardiovascular disease. 
Adapted from (3). 
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vessels are reaching epidemic proportions (7). Diabetic macrovascular disease is observed 
to have a more severe course with greater prevalence of multiple vessel coronary artery 
disease and more diffuse, elongated atheromas in affected blood vessels (11-14). With the 
NHS reportedly spending £1 million an hour, 10% of its yearly budget, treating the 
condition and its complications (15), diabetes mellitus represents a major public health 
concern. 
 
There are two major diabetes mellitus categories; type 1 and type 2. Type 1 diabetes is 
characterised by a lack of insulin production, rendering patients absolutely dependent on 
exogenous insulin. This form of the disease accounts for only 5%-10% of all diabetes cases 
and its diagnosis is made most commonly in childhood. Type 1 diabetes is thought to result 
from the autoimmune destruction of the insulin-producing pancreatic β-cells of the islets of 
Langerhans. Type 2 or non-insulin dependent diabetes mellitus represents the far more 
common form of the disease, usually with onset in adult life and associated with insulin 
resistance and relative insulin deficiency, as opposed to the absolute deficiency observed in 
type 1 (9). Type 2 diabetes (T2D) is a heterogenous disorder with clinical expression 
requiring interaction between genetic and environmental factors (16). 
 
There are currently over 2.5 million people with diabetes in the United Kingdom and it is 
believed a further half a million cases remain undiagnosed (17). Recent findings suggest 
that the prevalence and incidence of diabetes in the U.K. has increased over the past 
decade and is mainly attributable to an increase in T2D (18). Patients with type 2 diabetes 
have almost twice the risk of CVD of non diabetic individuals after adjustment for other 
cardiovascular risk factors (19). Consequently, while the relative burden of CVD 
attributable to traditional risk factors, such as smoking, hypertension and 
hypercholesterolaemia, has declined in recent years, findings, such as those from The 
Framingham Heart Study, suggest an increasing prevalence of T2D has led to an increase 
in the proportion of CVD due to diabetes mellitus (20;21). Furthermore, after their first CV 
event, patients suffering from T2D and CAD consistently display poorer clinical outcomes 
than their non diabetic counterparts (22-27), potentially the result of impaired insulin-
related metabolism (28), increased oxidative stress and/or an altered inflammatory 
response (29). Indeed, the mortality rate for patients with T2D has been observed to be 
almost twice as high as those without (30) with around 65% of deaths in these individuals 
related to CAD or stroke (8). 
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1.1.1.1 Hormonal Regulation of Metabolic and Hemodynamic Homeostasis 
 
A continuous supply of glucose is necessary to ensure appropriate function and survival of 
all organs. Glucose homeostasis is regulated primarily by the opposing actions of insulin 
and glucagon, hormones secreted by pancreatic β-cells and α-cells respectively (31;32). 
Under physiological conditions, insulin secretion is increased in response to elevated blood 
glucose (i.e. after consumption of a meal). Insulin acts to maintain normoglycaemia by 
stimulating glucose uptake, utilisation and storage in classical insulin responsive tissues, 
namely skeletal muscle, adipose tissue and liver, and by reducing glucose production via 
inhibition of hepatic gluconeogenesis (33;34). Conversely, stimulation of glucagon 
secretion occurs during periods of hypoglycaemia when the hormone promotes hepatic 
glucose production and ultimately raises blood glucose levels (31;32) (Figure 1.2). Type 2 
diabetes develops as a consequence of failure to regulate glucose metabolism efficiently. 
 
In addition to its role in regulation of glucose metabolism, insulin has an important role in 
cardiovascular physiology, regulating vascular tone by stimulating production of the 
vasodilator, nitric oxide (NO) (35), and the vasoconstrictor, endothelin-1 (ET-1) (35-38), 
from the vascular endothelium. As such, the insulin resistance of T2D contributes to 
endothelial dysfunction, a common feature of cardiovascular diseases, and thus is a 
potential contributor to the pathogenesis of vascular disease in type 2 diabetes (39). 
 
 
1.1.1.2 Insulin Secretion 
 
At a cellular level, elevated blood glucose triggers exocytosis of insulin secretory vesicles 
and release of insulin into the bloodstream. During normal insulin secretion, glucose 
transporter 2 (GLUT2) facilitates the entry of glucose into the pancreatic β-cells. Once 
inside the cell, glucose is converted by a specific glucokinase to glucose 6-phosphate 
before being metabolised to form adenosine triphosphate (ATP). The resultant alteration in 
the ATP:ADP (adenosine diphosphate) ratio causes inhibition of ATP-sensitive potassium 
channels in the cellular membrane. The ensuing inhibition of potassium efflux results in 
depolarisation of the β-cell and activation of voltage-sensitive calcium channels, enabling 
an influx of calcium. It is this increase in the intracellular calcium concentration which 
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Figure 1.2. Regulation of Glucose Metabolism. Insulin is secreted from the β-cells of the 
pancreas in response to elevations in plasma glucose. The hormone decreases glucose production 
from the liver (gluconeogenesis), and increases glucose uptake, utilisation and storage in fat 
(adipose tissue) and skeletal muscle, thus reducing plasma glucose levels. Glucose is stored as 
glycogen in liver and muscle and as lipid in adipocytes. When plasma glucose levels fall (during 
fasting or exercise), glucagon promotes the release of stored and newly synthesised glucose into the 
bloodstream. In this way glucose homeostasis is maintained (34). The fat cell is important in 
metabolic regulation, releasing free fatty acids (FFAs) which reduce glucose uptake in muscle, 
insulin secretion from the β-cell, and increase glucose production from the liver. The fat cell can 
also secrete adipokines, such as leptin, adiponectin and tumour necrosis factor-α (TNF-α), which 
regulate food intake, energy expenditure and insulin sensitivity (34;40). Figure from (34). 
Reprinted with permission from Macmillan Publishers Ltd: Nature; 414(6865):799-806, copyright 
2001. 
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stimulates fusion of the insulin-containing secretory vesicles with the plasma membrane, 
resulting in the pulsatile release of insulin into the bloodstream (9;34) (Figure 1.3). 
 
 
1.1.1.3 Insulin Signalling 
 
In addition to serving as a primary regulator of glucose and cardiovascular homeostasis, 
insulin regulates gene transcription, protein synthesis and cell proliferation and 
differentiation (34;41). On its release, the hormone binds to a high affinity transmembrane 
receptor, promoting phosphorylation of intrinsic tyrosine kinases (42), resulting in 
activation of insulin receptor substrates (IRS) (43). Subsequent downstream signalling 
events ultimately determine which physiological response occurs (34;41;44;45) (Figure 
1.4).  
 
In conventional insulin-sensitive tissues, the hormone acts through Akt / protein kinase B 
(PKB) to promote translocation of glucose transporter 4 (GLUT4) which facilitates glucose 
uptake (46;47) (Figure 1.4). A second, PKB-independent pathway, involving the Cbl 
protooncogene, has also been reported to facilitate insulin-stimulated glucose transport 
(48-50) (Figure 1.4).  
 
Acting through PKB, insulin is able to stimulate glycogen synthesis through inhibition of 
glycogen synthase kinase-3 (GSK3) (51) (Figure 1.4). Gluconeogenesis in the liver is 
inhibited by insulin via phosphatidylinositol (PtdIns) 3-kinase (PI3K)-mediated 
suppression of the genes for the key gluconeogenic enzymes, phosphoenolpyruvate 
carboxylkinase (PEPCK) (52) and glucose-6-phosphatase (G6Pase) (53). In addition, 
insulin inhibits lipolysis by reducing cyclic adenosine monophosphate (cAMP) levels 
through PKB-mediated activation of  phosphodiesterase 3B (PDE3B) (54).  
 
Insulin activates cellular protein synthesis via the mTOR (mammalian target of rapamycin) 
complex 1 (mTORC1) (55-57) and exerts mitogenic effects by means of the mitogen-
activated protein kinase (MAPK) cascade (58) (Figure 1.4). 
 
In cardiovascular tissue, the MAPK signalling pathway also stimulates the secretion of ET-
1 (36-38) (Figure 1.4), in addition to the cellular adhesion molecules, vascular cell 
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Figure 1.3. Insulin Secretion. Insulin secretion in β-cells is triggered by rising blood 
glucose levels. Starting with the uptake of glucose by the glucose transporter 2 (GLUT2), 
the glycolytic phosphorylation of glucose causes a rise in the ATP:ADP ratio. This rise 
subsequently activates the potassium (K+) channel which depolarises the membrane, 
causing the calcium (Ca2+) channel to open, allowing Ca2+ ions to flow in to the cell. 
Elevated Ca2+ levels result in insulin exocytosis (9;34). G6Pase, glucose-6-phosphatase 
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adhesion molecule-1 (VCAM-1) and E-selectin (59), while PKB directly phosphorylates 
and activates endothelial nitric oxide synthase (eNOS), leading to production of NO 
(35;60;61) (Figure 1.4). 
 
 
1.1.1.4 Insulin Resistance 
 
Insulin resistance describes a decreased sensitivity and / or responsiveness to metabolic 
actions of insulin (34;40). Insulin resistance is present and precedes the development of 
T2D in the majority of patients (62) and is characterised by a variety of defects in insulin 
signalling, including decreases in receptor concentration and kinase activity, the 
concentration and phosphorylation of IRS, PI3K and PKB activity, glucose transporter 
translocation, and the activity of intracellular enzymes (40;63;64). In many cases, insulin 
resistance can be attributed to an increase in visceral adiposity (62;65-67) (Figure 1.2). 
 
The underlying pathogenic mechanisms by which visceral adiposity contributes to the 
etiology of insulin resistance and T2D are complex and still partially undetermined but 
studies have shown that on comparison with peripheral fat, visceral fat is more resistant to 
the metabolic effects of insulin and more sensitive to lipolytic hormones (68;69). 
Consequently, visceral adipocytes contribute to elevated free fatty acid (FFA) levels in the 
circulation. FFAs adversely affect the insulin signalling cascade, inhibiting glucose uptake, 
glycogen synthesis and glucose oxidation, while stimulating hepatic gluconeogenesis (70) 
(Figure 1.2). These effects have been attributed to the ability of FFAs to promote 
accumulation of triglycerides and fatty acid-derived metabolites (diacylglycerol, fatty acyl-
CoA and ceramides) in non-adipose cells, such as hepatocytes and myocytes, a 
phenomenon termed ‘lipotoxicity’ (67;71). Recent evidence suggests elevated 
concentrations of FFAs may also induce endoplasmic reticulum stress (increased unfolded 
protein response due to the disruption of the smooth operation of endoplasmic reticulum) 
which in turn has been implicated in the development of peripheral insulin resistance (72). 
 
Increased visceral adiposity is often accompanied by a disproportionate increase in pro-
inflammatory adipokines (73;74), including tumour necrosis factor-α (TNF-α) (75;76) 
(Figure 1.2), monocyte chemoattractant protein (MCP-1) (77), interleukin-6 (IL-6) (78) 
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Figure 1.4. Overview of Insulin Signalling – continued overleaf 
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Figure 1.4. Overview of Insulin Signalling. The interaction of insulin with its receptor on the outer surface of the plasma membrane activates the protein-tyrosine 
kinase activity associated with the β subunit of the receptor. The receptor then phosphorylates itself and insulin receptor substrate-1 (IRS-1) which binds the 
regulatory p85 subunit of phosphatidylinositol (PtdIns) 3-kinase (PI3K). The catalytic p110 subunit of PI3K then phosphorylates PtdIns-4-5-biphosphate (PtIns (4,5) 
P2) at the plasma membrane, thus converting it to PtdIns-3,4,5-triphosphate (PtdIns (3,4,5) P3). The increased amount of PtdIns (3,4,5) P3 results in recruitment of 
AKT / protein kinase B (PKB) and phosphoinositide-dependent protein kinase 1 (PDK1) to the membrane. This positions PDK1 and PKB such that PDK1 can 
phosphorylate (activate) PKB on Thr 308. Activated PtdIns (3,4,5) P3 also triggers activation of the mammalian target of rapamycin complex-2 (mTORC2) which 
further phosphorylates PKB at Ser 473 for maximum activation. PDK1 additionally acts to activate the atypical protein kinase C (aPKC) isoforms, PKC-ζ and –λ, 
which appear to be required for insulin-stimulated glucose transport in classically insulin-responsive tissues. Activity of the PI3K pathway is partly determined by 
phosphatidylinositol-3-phosphatases such as phosphatase and tensin homologue (PTEN) and the SH2 domain-containing inositol-5-phosphatase (SHIP2). Protein 
tyrosine phosphatases, including PTP1B, that dephosphorylate the insulin receptor and IRS-1, also play an important role in negative regulation of insulin-signalling 
pathways. Effects of PKB activation include phosphorylation of glycogen synthase kinase-3 (GSK3) which reduces GSK3 activity, thus enhancing the conversion of 
blood glucose to glycogen. Another downstream effect of activated PKB is activation of the mTOR complex 1 (mTORC1) which acts to control cellular translation 
machinery by phosphorylation of p70 ribosomal S6 kinase (p70S6K) and the inhibitor of the initiation factor 4E for eukaryotic translation (eIF4E), resulting in its 
activation. Insulin binding also results in activation of the adaptor protein, Grb-2 which recruits the Son-of-sevenless (SOS) exchange protein to the plasma 
membrane for activation of Ras, thus stimulating gene transcription and cellular proliferation or differentiation through the mitogen-activated protein kinase 
(MAPK) cascade. In addition, binding of insulin to its receptor causes tyrosine phosphorylation of the Cbl protein which, in most insulin responsive cells, is 
associated with the adaptor protein, CAP. This results in the Cbl-CAP complex being recruited to a region of the plasma membrane termed a lipid raft. Here, Cbl 
interacts with the adaptor protein, Crk, which is constitutively associated with the Rho-family guanide nucleotide exchange factor, C3G. C3G in turn activates the G-
protein, TC10 which acts to promote glucose transporter 4 (GLUT4) translocation to the membrane. This occurs in parallel with activated PKB which 
phosphorylates the Rab GTPase-activating protein, Akt substrate of 160kDa (AS160) and its paralogue, TBC1D1, also promoting translocation of GLUT4 and 
uptake of glucose from blood. In cardiovascular tissue, the MAPK pathway controls secretion of ET-1 in the vascular endothelium while PKB directly 
phosphorylates endothelial nitric oxide synthase (eNOS), thus stimulating NO production (34;45). 
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and interleukin-8 (IL-8), all of which have been implicated in the development of insulin 
resistance (79). Unlike these adipokines, adiponectin, which signals via AMP-activated 
protein kinase (AMPK) (80), is found at decreased concentrations in visceral obesity, 
resulting in a reduction in its insulin-sensitising effects in liver and muscle (81;82) (Figure 
1.2).  
 
Under conditions of insulin resistance, the β-cells of the pancreas initially compensate, 
facilitating an increase in insulin secretion to prevent the hyperglycaemia of T2D. 
However, as insulin resistance worsens, β-cell compensation becomes less effective and 
hyperglycaemia of progressively greater magnitude occurs as the patient progresses 
towards frank type 2 diabetes (83). 
 
 
1.1.1.5 Type 2 Diabetes Mellitus & Cardiovascular Disease 
 
Recent medical literature has highlighted the importance of insulin resistance in increasing 
CVD risk (62;84-86), a risk which gradually increases as an individual progresses from 
insulin resistance to T2D (62). Insulin resistance is associated with a dramatic 
downregulation of the insulin signalling pathway leading from PI3K, PDK1 and PKB to 
phosphorylation and activation of eNOS. However, the MAPK pathway remains 
unaffected, perhaps allowing for some of the detrimental effects of chronic 
hyperinsulinemia on cellular growth in the vasculature (39). In the endothelium, a decrease 
in PI3K signalling and an increase in MAPK signalling may lead to decreased production 
of NO and increased secretion of ET-1, characteristic of the endothelial dysfunction of 
many cardiovascular diseases (39;87). 
 
The elevated circulating FFA levels of visceral obesity and insulin resistance are also 
known to contribute to diabetic vascular complications by reducing eNOS activity and 
increasing reactive oxygen species (ROS) production in the vasculature (39;88). FFA-
associated ROS production is known to enhance protein kinase C (PKC) activity and 
increase formation of advanced glycation end-products (AGEs) which interact with AGE-
binding receptors to promote atherosclerosis directly through changes in the function of 
endothelial, macrophage and smooth muscle cells (39;88;89). Furthermore, circulating 
adipokines recruit and activate inflammatory cells, thus perpetuating a systemic 
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inflammatory milieu which can strongly affect vascular function and development of 
atherosclerosis (90).  
 
It has been reported that visceral adiposity and insulin resistance impair thrombolysis via a 
mechanism involving increased levels of plasminogen activator inhibitor-1 (PAI-1) (65;91-
94). Levels of this atherogenic factor have been observed to be particularly high in patients 
with T2D (91;92), serving as a predictor for CVD (95;96). 
 
In addition, hyperglycaemia itself is implicated in the pathogenesis of diabetic 
macrovascular disease (97;98), facilitating PKC activation and AGE formation (88;89;99) 
in a similar manner to FFAs. AGEs induce ROS production and promote vascular 
inflammation through activation of nuclear factor κB (NF-κB) which enhances expression 
of VCAM-1 and MCP-1 (87;88). Acute hyperglycaemia can also reduce eNOS activation 
and NO production, thus contributing to endothelial dysfunction and the vascular 
complications of type 2 diabetes (100). 
 
 
1.1.1.6 Genetics & Environment 
 
There is a wealth of evidence to support a profound influence of genetic factors on the 
development of T2D, including twin studies which reveal an approximate 70% 
concordance in monozygotic twins, as compared to 20-30% in dizygotic twins (101;102). 
Furthermore, the life-time risk of developing the disease is around 40% in offspring of one 
parent with T2D but is seen to approach 70% if both parents have the disease (103). Large 
ethnic differences in the prevalence of T2D have also been explained by way of a genetic 
component (104;105). Additionally, there are a number of relatively uncommon 
monogenic forms of  T2D, known as maturity onset diabetes of the young (MODY), which 
have roughly the same phenotypic expression as the adult onset form and follow a clear 
Mendelian mode of inheritance (106) (Table 1.1). While the incidence of MODY is not 
precisely known, it is believed to account for < 5% of all T2D cases, the remainder being 
attributed to polygenic defects (9). 
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Type Gene Chromosome Defect 
MODY 
1 
hepatic nuclear 
factor-4α 
(HNF4A) 
20q progressive β-cell failure 
MODY 
2 
glucokinase 
(GCK) 
7p impaired glucose-regulated insulin 
secretion 
MODY 
3 
hepatic nuclear 
factor-1α 
(HNF1A) 
12q progressive β-cell failure 
MODY 
4 
insulin promoter 
factor 1 (IPF1) 
13q impaired pancreatic development, 
impaired glucose-mediated stimulation 
of insulin gene transcription 
MODY 
5 
hepatic nuclear 
factor-1β 
(HNF1B) / 
hepatic 
transcription 
factor 2 (TCF2) 
17 cen-q progressive β-cell failure,  
renal disease 
MODY 
6 
NEUROD1 2q abnormal β-cell development and 
function 
 
 
Table 1.1. Common Variants in MODY Genes. There are a minimum six forms of MODY, each 
caused by mutations in a distinct gene. Common to all forms is that they result in impaired insulin 
secretion. MODY patients are identified clinically as having a form of non-insulin dependent 
diabetes mellitus, characterised by a mild to moderate insulin secretory deficiency, an autosomal 
dominant mode of inheritance and onset at less than 25 years of age in some family members 
(106;107). 
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Attempts to define the more common, polygenic form of T2D, including linkage analysis, 
candidate gene studies and, more recently, genome wide association studies (GWAS), have 
identified a number of genes as being associated with the disease (16;108) (Table 1.2). Of 
particular interest are the results from several recent GWAS on both T2D and its risk 
factor, obesity, which have revealed at least eighteen genes consistently associated with 
T2D (109-118). Many of these genes implicate pancreatic β-cell function in disease 
pathogenesis whereas only one appears clearly associated with insulin resistance (16) 
(Table 1.2). It is likely these discoveries represent but a small proportion of the genetic 
variation underlying the susceptibility to the disorder and further investigation will be 
required to provide a more complete picture of the genetic complexity of T2D. 
 
While type 2 diabetes has a strong genetic component, its development is triggered by 
environmental factors in genetically susceptible individuals. The epidemic increase in T2D 
prevalence across the globe in the past 50 years can be ascribed to a change in environment 
as the world advances towards a more affluent, westernised lifestyle and the calorie rich 
diet and physical inactivity with which it is associated (9). One explanation for the 
interaction between genes and environment in polygenic T2D etiology is outlined in the 
thrifty genotype hypothesis (119) and concerns evolution of a genotype which conferred 
survival benefits in the past but is detrimental in the current environment. An opposing 
theory, the so called thrifty phenotype hypothesis (120), proposes that the condition 
represents an adult metabolic response to foetal malnutrition. 
 
 
1.1.1.7 Treatment of Type 2 Diabetes Mellitus 
 
Lifestyle modifications targeting weight reduction, and in particular reduction in visceral 
adiposity, have been shown to be beneficial as a first-line approach in treating glycaemic 
abnormalities and reducing the risk for diabetes and CVD (121-123). However, 
pharmacological therapies are used adjunctively in patients at higher risk and in those 
noncompliant with lifestyle modification (62). 
 
Given the key role of insulin resistance in the development of T2D, development of 
pharmaceuticals has been primarily focused on insulin sensitising agents. At present, two 
classes of insulin sensitising agents are in use: biguanides, including metformin, and the 
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Year of Major 
Publication 
Reference Suggested Gene Disease 
Mechanism 
2000 (113;114;117;124) PPARG* insulin sensitivity 
2000 (125) CAPN10** glucose transport 
2003 (113;114;117;126) KCNJ11* β-cell dysfunction 
2006 (113;114;117;127;128) TCF7L2 β-cell dysfunction 
2007 (113;114;117;129;130) CDKAL1 β-cell dysfunction 
2007 (113;114;117;131) CDKN2A/2B β-cell dysfunction 
2007 (113;114;117;128-
132) 
HHEX/IDE β-cell dysfunction 
2007 (113;114;117;128;130) SLC30A8 β-cell dysfunction 
2007 (113;114;117;131) IGF2BP2 β-cell dysfunction 
2007 (113;114;117) WFS1* unknown 
2007 (133) TCF2* unknown 
2007 (109;110) FTO obesity 
2008 (112) MC4R obesity 
2008 (111;118) NOTCH2 unknown 
2008 (111;118) ADAMTS9 unknown 
2008 (111;118) THADA unknown 
2008 (111;118) TSPAN8/LGR5 unknown 
2008 (111;118) CDC123/CAMK1D unknown 
2008 (111;118) JAZF1 unknown 
2008 (115;116) KCNQ1 β-cell dysfunction 
 
Table 1.2. Type 2 Diabetes Susceptibility Genes. PPARG, peroxisome proliferator-activated 
receptor gamma; CAPN10, calpain 10; KCNJ11, potassium inwardly rectifying channel, subfamily 
J, member 11; TCF7L2, transcription factor 7-like 2; CDKAL1, CDK5 regulatory subunit 
associated protein 1-like 1; CDKN2A/B, cyclin-dependent kinase inhibitor 2A/B; HHEX, 
haematopoietically expressed homeobox; IDE, insulin-degrading enzyme; SLC30A8, solute carrier 
family 30 member 8; IGF2BP2, insulin-like growth factor 2mRNA binding protein 2; FTO, fat 
mass and obesity associated; MC4R, melanocortin 4 receptor; NOTCH2, Notch homolog 2 
Drosophila; ADAMTS9, ADAM metallopeptidase with thrombospondin type 1 motif, 9; THADA, 
thyroid adenoma associated; TSPAN8, tetraspanin 8; LGR5, leucine-rich repeat-containing G 
protein-coupled receptor 5; CDC123, cell division cycle 123 homolog; CAMK1D, 
calcium/calmodulin-dependent protein kinase ID; JAZF1, juxtaposed with another zinc finger gene 
1; KCNQ1, potassium voltage-gated channel, KQT-like subfamily, member 1. *, indicates a 
biological candidate gene confirmed by GWAS. **, indicates gene implicated in type 2 diabetes by 
considerable functional and genetic evidence but not by GWAS. All other genes have been 
identified by GWAS. Adapted from (16). 
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thiazolidinediones (134). Metformin is relatively more active in the suppression of hepatic 
glucose production, exerting a portion of its effect through AMPK (135-137). Metformin 
has been shown to have a beneficial effect on cardiovascular outcomes (138-140). 
Thiazolidinediones act on the peroxisome proliferator-activated receptor-γ (PPAR-γ) and 
are more active in stimulation of muscle glucose uptake (141;142). They are also known to 
activate AMPK (143) and enhance vascular function, ameliorating the dyslipidemia and 
inflammatory milieu of T2D (144). In addition, certain antihypertensive therapies, known 
to act on the renin-angiotensin system (RAS), such as angiotensin converting enzyme 
(ACE) inhibitors and angiotensin-II receptor blockers (ARBs), have been shown to have 
beneficial effects in T2D. Treatment of type 2 diabetics with lipid-lowering statins has also 
been shown to be of therapeutic benefit (39;40).  
 
 
 
1.2 The Vascular Endothelium 
 
More than a trillion endothelial cells line the luminal surface of the human vasculature, 
representing a critical interface between circulating blood and tissue (145-148). An 
important endocrine organ, the endothelium plays a pivotal role in maintaining 
cardiovascular homeostasis under physiological conditions by releasing a number of 
vasoactive substances which act to regulate vascular tone, antiproliferation and 
antiaggregation, in addition to limiting increases in blood pressure, controlling tissue blood 
flow and inflammatory responses and maintaining blood fluidity (146-148). The 
endothelium releases these vasoactive substances in response to mechanical stimuli, such 
as pressure and shear stress, and various hormonal stimuli, such as insulin (39;87;146). 
Endothelium-derived substances with vasodilatory and antiproliferative effects include, 
endothelium-derived hyper-polarisation factor (EDHF) (149;150), NO (151;152) and 
prostacyclin (PGI2) (153), while ET-1 (154), angiotensin II (Ang II) and ROS are among 
those mediators which exert vasoconstrictor effects (87). All forms of cardiovascular 
disease have been shown to be associated with some degree of endothelial dysfunction 
(87;146).  
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1.2.1 Endothelial Dysfunction 
 
Endothelial dysfunction describes the situation when a shift in the equilibrium between 
vasodilators and vasoconstrictors occurs, allowing vasoconstrictor and proliferative effects 
to predominate, leading to the development of hypertension, atherosclerosis, platelet 
aggregation and ischemia (87;145-148;155). With respect to functional investigation, the 
term endothelial dysfunction generally relates to an impaired maximal dilative response 
and/or an impaired sensitivity to endothelium dependent vasodilators such as 
acetylcholine, bradykinin and calcium ionophore, under conditions of preserved response 
to endothelium-independent dilators including sodium nitroprusside (87;146). 
 
Endothelial dysfunction is an early and independent predictor of poor prognosis in most 
forms of CVD (87;156-158), with alterations in endothelial function consistently found in 
hypertension, atherosclerosis, CAD, T2D and obesity (39;87;157-162). An increasing body 
of evidence suggests oxidative stress underlies the endothelial dysfunction of CVD. 
 
 
 
1.3 Oxidative Stress in Cardiovascular Disease 
 
1.3.1 Reactive Oxygen Species 
 
All layers of the vascular wall have enzymatic systems capable of producing ROS and, 
under physiological conditions, these ROS act as important signalling molecules (146), 
stimulating vascular smooth muscle cell (VSMC) and endothelial cell mitogenic and 
apoptotic signalling (163-166). ROS is a collective term encompassing both oxygen 
radicals and certain nonradicals which act as oxidising agents and/or are easily converted 
into radicals. ROS include the superoxide anion (O2-), the hydroxyl radical (OH-), NO, 
lipid radicals (LOO-), hydrogen peroxide (H2O2), hypochlorous acid (HOCl) and 
peroxynitrite (ONOO-) (167). Principal among these ROS is the superoxide anion, formed 
from the univalent reduction of oxygen, its unpaired electron renders it highly reactive and 
unstable with a short half-life. Superoxide acts as both an oxidising agent, being reduced to 
42 
H2O2 (168), and a reducing agent, donating its extra electron to form ONOO- with NO 
(169) (Figure 1.5). 
 
 
1.3.2. Nitric Oxide 
 
Nitric oxide, first identified as endothelium-derived relaxing factor (EDRF) (151;152),  is a 
potent signalling molecule and vasodilator, responsible for mediating many functions of 
the endothelium, including control of vascular tone, inhibition of platelet aggregation and 
leukocyte adhesion, and suppression of VSMC proliferation (145;147;148). Each of these 
events has been implicated in the initiation and progression of atherosclerosis and NO is 
therefore considered an anti-atherosclerotic agent (147;155;170). 
 
A freely diffusible molecule with a short half-life of 6-10 seconds in vivo, vascular NO is 
formed from L-arginine by the constitutively expressed endothelial isoform of NOS which 
requires Ca2+/calmodulin, flavin adenine dinucleotide (FAD), flavin mononucleotide 
(FMN), nicotinamide adenine dinucleotide phosphate (NADPH) and tetrahydrobiopterin 
(BH4) as cofactors (147;148;161;171-173). Endothelial NOS is activated in response to 
elevated cytosolic Ca2+ which occurs on exposure to various stimuli, including shear stress. 
In addition, eNOS is known to be activated by hormones (including insulin) and platelet-
derived substances and agonists, such as bradykinin and acetylcholine (161;174). It has 
recently been demonstrated that eNOS is regulated by reversible phosphorylation and both 
PKB and AMPK have been shown to phosphorylate and activate the enzyme at serine 1177 
(Ser1177) in cultured endothelial cells (175;176).  
 
On its release from endothelial cells, NO diffuses to the lumen of the vessel where it exerts 
its effects on platelet and blood element functions, and to adjacent VSMCs where it 
induces vasodilation and inhibits vascular remodelling and smooth muscle cell 
proliferation via activation of soluble guanylyl cyclase, present in the cytosol. Activation 
of guanylyl cyclase causes an increase in intracellular cGMP, which in turn activates 
protein kinase G (PKG), leading to reduced intracellular calcium and vasodilation (177) 
(Figure 1.6). While this represents the predominant sensing pathway for NO in the 
vasculature, it has been reported that under certain conditions, NO may cause vasodilation 
by activation of K+ channels (178). 
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Figure 1.5. Oxidative Stress in Cardiovascular Disease. Environmental and physiological factors 
lead to the generation of superoxide (O2-) in the vasculature. O2- is enzymatically converted to 
hydrogen peroxide (H2O2) by superoxide dismutases (SODs) and further processed by catalase and 
glutathione peroxidase (GPx). However, excess O2- can generate a number of other reactive oxygen 
species (ROS), disrupting the balance of nitric oxide (NO) and ROS. Increased oxidative stress 
leads to reduced NO bioavailability, associated with endothelial dysfunction and cardiovascular 
disease (CVD). Adapted from (167). 
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Figure 1.6. Nitric Oxide Signalling in the Vessel Wall. Nitric oxide (NO), produced in the 
endothelial cell (EC), acts to regulate vascular tone and inhibit platelet aggregation and leukocyte 
adhesion (177;178). BH4, tetrahydrobiopterin; Ca2+, calcium; cGMP, cyclic guanosine 
monophosphate; ECM, extracellular matrix; eNOS, endothelial nitric oxide synthase; GMP, 
guanosine monophosphate; GTP, guanosine triphosphate; K+, potassium; O2-, superoxide anion; 
PDE, phosphodiesterases; PKG, protein kinase G; VSMC, vascular smooth muscle cell. 
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Given its cardioprotective function and fundamental role in maintaining vascular 
homeostasis, loss of endothelial NO bioavailability is a maladaptive event and, 
unsurprisingly, represents a common manifestation of endothelial dysfunction 
(87;148;161). Indeed, decreased NO bioavailability has been observed in T2D (179), 
hypertension (180), hypercholesterolaemia (181) and cigarette smoking (182). Reduction 
of NO bioavailability in the endothelium may be the result of impaired NO production due 
to reduced expression of eNOS (183), lack of substrate or cofactor (171-173), or alterations 
in cellular signalling leading to reduced eNOS activation (184). However, the reduced 
endothelial NO bioavailability associated with CVD has been reported to occur as a 
consequence of elevated ROS production under conditions of oxidative stress (161;167). 
 
 
1.3.3 Oxidative Stress 
Oxidative stress describes the condition wherein an excessive production of ROS 
overwhelms endogenous anti-oxidant defence mechanisms (Figure 1.5). The resultant 
elevation in ROS levels has a detrimental effect on cellular function, a consequence of 
ROS-induced damage to lipid membranes, enzymes and nucleic acids (167). CAD and its 
risk factors, including T2D, are characterised by excess vascular production of ROS 
(167;185). One of the earliest measurable consequences of oxidative stress in human 
subjects is impaired endothelium-dependent vasodilation which occurs a result of 
accelerated NO degradation by ROS (167).  
 
The most likely candidate for accelerating NO degradation is O2-. When present in excess, 
the superoxide anion rapidly inactivates NO (186), yielding the highly reactive radical, 
ONOO- as a by-product. Peroxynitrite is more stable than either NO or O2- and is a potent 
oxidant, capable of inducing oxidation of deoxyribonucleic acid (DNA), proteins and lipids 
(187;188) (Figure 1.5). 
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1.3.4 Reactive Oxygen Species: Sources in The Vasculature 
 
Principal sources of ROS in the vasculature include NAD(P)H) oxidase (189-191), 
xanthine oxidase (167;192) and the mitochondrial electron transport chain (193-196). In 
addition, ‘uncoupled’ eNOS produces O2- rather than NO under conditions of substrate (L-
arginine) or co-factor (BH4) deficiency (170;173) (Figure 1.5). Other potential sources of 
ROS include arachidonic acid pathway enzymes, such as lipoxygenase and 
cyclooxygenase, cytochrome p450s, peroxidases and other haemoproteins (167). 
 
 
1.3.4.1 Endothelial Nitric Oxide Synthase 
 
Under conditions of oxidative stress, eNOS may generate O2- rather than NO, a 
phenomenon termed eNOS uncoupling (Figures 1.5 and 1.6). Nitric oxide generation is 
dependent on eNOS homodimerisation in the presence of BH4. However, BH4 is highly 
susceptible to oxidative degradation by ONOO- and in the absence of its cofactor, eNOS 
fails to dimerise fully, resulting in uncoupling of the enzyme and amplification of oxidative 
stress (197) (Figure 1.5 and 1.6). Uncoupled eNOS has been shown to contribute to 
increased superoxide production and endothelial dysfunction in a number of CVDs, 
including CAD (161) and T2D (179). 
 
 
1.3.4.2 NAD(P)H Oxidase 
 
NAD(P)H oxidase is the predominant source of O2- in the human vasculature, catalysing 
the one electron reduction of oxygen using NADH or NAD(P)H as the electron donor 
(189;191). The enzyme was originally characterised in neutrophils but is present in 
VSMCs (198;199) and endothelial cells (200-202). A multisubunit enzyme, vascular 
NADPH oxidase consists of membrane integrated cytochrome b558 and a number of 
cytosolic regulatory components; p47phox, p67phox, p40phox (where phox represents 
phagocyte oxidase) and the GTP-binding protein, Rac1. The cytochrome b558 is itself 
comprised of two subunits, p22phox and nicotinamide adenine dinucleotide phosphate 
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oxidase (NOX) protein, NOX2 (gp91phox) or a functional isoform of this differentially 
expressed catalytic subunit (189;190) (Figure 1.7). Vascular NADPH oxidase is a 
constitutive enzyme but can also be regulated in VSMCs by humoral factors such as Ang II 
and a number of growth factors, including TNFα and platelet-derived growth factor 
(PDGF) (190;203-205). In the endothelium, activity of the enzyme is upregulated by shear 
stress caused by increased blood flow (201). 
 
Vascular NAD(P)H oxidase-stimulated O2- production has been shown to be positively 
correlated with endothelial dysfunction and clinical risk factors for CVD in humans (206) 
and inhibition of the enzyme is seen to improve endothelial function in both rat and human 
blood vessels (207). 
 
Antisense inhibition of the constitutively expressed p22phox subunit of NAD(P)H oxidase 
identified it as being critical for enzymatic function (199) and significantly increased 
p22phox protein levels and upregulation of p22phox messenger ribonucleic acid (mRNA) 
have been shown to be associated with enhanced NAD(P)H oxidase activity in vessels 
from patients with CAD (208). Consequently, common genetic polymorphisms within both 
promoter and coding regions of the p22phox gene (CYBA) have been the object of 
considerable research, the hypothesis being that they confer important functional effects, 
contributing to interindividual variation in enzyme activity. Studies have shown that a 
number of these allelic variants are associated with cardiovascular disease (209-211).  
 
NAD(P)H oxidase NOX subunit expression varies among vascular cells. Endothelial cells 
predominantly express the NOX4 isoform with expression of NOX2 occurring to a lesser 
extent (212). Subunit expression has been shown to be associated with CAD, correlating 
with severity of atherosclerosis (212) and with features of plaque stability in human 
coronary arteries (213). Recent studies have demonstrated that NOX2 and NOX4-based 
NAD(P)H oxidases are the predominant contributors to oxidative stress in coronary 
arteries from patients with advanced CAD (208), while NOX5 has been identified as a 
novel, calcium-dependent source of ROS in these vessels (214). 
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Figure 1.7. Structure of the Active NAD(P)H Oxidase Complex. Vascular NAD(P)H oxidase is 
a heterodimer, consisting of  membrane-bound p22phox and NOX subunits and cytoplasmic 
subunits, p67phox, p47phox and p40phox. Rac1 is required for assembly of the subunits. The NAD(P)H-
binding domain is predicted to be on one side of the membrane, while superoxide (O2-) generation 
is predicted to occur on the other. The oxidase may be located either on the plasma membrane or 
on intracellular membranes (190;191). ECM, extracellular matrix. Adapted from (190). 
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1.3.4.2.1 NAD(P)H Oxidase In Type 2 Diabetes Mellitus 
 
It has been shown that elevated O2- production in human blood vessels from patients with 
T2D is mediated by upregulated NAD(P)H oxidase activity (179). Increased activity of the 
enzyme has also been implicated in the impaired endothelium-dependent vasodilation 
observed in the OLETF rat, a model of T2D (215). In addition, a number of in vitro studies 
have demonstrated that the hyperglycaemia and AGE formation characteristic of T2D 
increases NAD(P)H oxidase-induced O2- production in endothelial cells (216-218). 
Furthermore, increased protein levels of p22phox, p47phox and p67phox have been observed in 
human vessels from patients with T2D (179) while p22phox mRNA was shown to be 
upregulated in vessels from streptozotocin-induced diabetic and OLETF rats (215;219). 
The specific mechanisms underlying enhanced NAD(P)H oxidase activity in T2D are yet 
to be fully elucidated but recent studies have indicated a crucial role for protein kinase C. 
A recognised stimulant of NAD(P)H oxidase activation, activity of PKC is increased as a 
result of hyperglycaemia (220;221). 
 
 
1.3.4.3 Mitochondria 
 
The oxidative phosphorylation (OXPHOS) pathway is essential for energy production in 
mitochondria of eukaryotic cells. Enzymes of the inner mitochondrial membrane transfer 
electrons along the electron transport chain (ETC) which generates a proton gradient, 
enabling ATP synthase to generate ATP. Under physiological conditions, this process 
produces ROS as byproducts, a result of the one electron reduction of molecular oxygen 
(O2) to superoxide (196;222;223) (Figure 1.8). As such, a network of mitochondrial 
antioxidant systems is in place to protect against ROS-induced damage to mitochondrial 
proteins, lipids and nucleic acids (Figure 1.8). However, under conditions of oxidative 
stress, these antioxidant systems are overwhelmed, allowing ROS to exert their damaging 
effects and ultimately alter mitochondrial function (196;222). Increased production of  
mitochondrial ROS (mtROS), leading to accumulation of mitochondrial DNA (mtDNA) 
damage and progressive mitochondrial dysfunction, has been shown to be associated with 
vascular diseases, including CAD and T2D (88;222;224;225). 
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Figure 1.8. Mitochondrial Oxidative Phosphorylation and Superoxide Production. Oxidative 
phosphorylation (OXPHOS) is composed of 5 multiple subunit complexes embedded in the inner 
mitochondrial membrane. Electrons (e-) from reduced nicotinamide adenine dinucleotide (NADH) 
and flavin adenine dinucleotide (FADH2) pass through complex I (NADH dehydrogenase) and 
complex II (succinate ubiquinone oxidoreductase) respectively and are then shuttled to complex III 
(ubiquinol cytochrome oxidoreductase) via ubiquinol (ubiq). Cytochrome c (cyt c) transfers 
electrons from complex III to complex IV, with the reduction of molecular oxygen (O2) to water 
(H2O), a reaction inhibited by nitric oxide. Flow of electrons is accompanied by proton (H+) 
transfer across the inner mitochondrial membrane at complexes I, III and IV, creating an 
electrochemical gradient (∆ψ). Protons re-enter the mitochondrial matrix through complex V (ATP 
synthase) which utilises the proton-motive force to generate ATP. This force also drives ATP-ADP 
exchange by the adenine nucleotide translocase (ANT). Uncoupling proteins (UCPs) allow protons 
to return to the matrix, reducing ROS formation. Of the electrons entering the transport chain, it is 
estimated 2-4% are involved in superoxide (O2-) formation. Complex I leaks electrons to generate 
O2- in the matrix, whereas complex III generates O2- in both the matrix and intermembrane space. 
The P66Shc intermembrane protein has been identified as being involved in mitochondrial ROS 
production, subtracting electrons from cytochrome c to produce O2-. Superoxide is dismutated to 
hydrogen peroxide (H2O2) by superoxide dismutase 2 (SOD2) in the matrix and by SOD1 or SOD3 
in the intermembrane space. H2O2 is then reduced by enzymes such as glutathione peroxidase 
(GPx) which uses reduced glutathione (GSH) as an electron donor, resulting in oxidised glutathione 
(GSSG) formation (88;196;222;223). Pi, inorganic phosphate. Adapted from (88). 
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One important regulator of mtROS production is NO which, at physiological 
concentrations, modulates O2 consumption by inhibiting cytochrome c oxidase in a 
reversible
 
manner (88;226). In this way, NO is able to regulate the mitochondrial redox 
state, facilitating release of the O2- anion and other free radicals which act as NO-regulated 
signalling molecules (88;227). Nitric oxide-mediated inhibition of cytochrome c oxidase is 
also thought to underlie the increased mtROS production observed in hypoxic conditions 
(228). However, during periods of oxidative stress, mitochondrial NO reacts with O2- to 
form ONOO- which, in turn, enhances O2-  production by the ETC and disrupts 
mitochondrial integrity, thus contributing to the pathogenesis of vascular disease 
(88;222;223). 
 
Recent studies have also revealed a potential link between NAD(P)H oxidase-derived ROS 
and mitochondrial dysfunction in endothelial cells. Superoxide produced by NAD(P)H 
oxidase is believed to directly activate mitochondrial ATP-sensitive K+ channels or react 
with NO to form ONOO-, leading to respiratory complex damage and impaired 
mitochondrial function (229). 
 
 
1.3.4.3.1 Mitochondria in Type 2 Diabetes Mellitus 
 
Mitochondrial ROS have a fundamental role in the development and progression of 
endothelial dysfunction and macrovascular disease in T2D, with hyperglycaemia shown to 
increase generation of O2- from the mitochondrial ETC in endothelial cells (230). 
Intracellular hyperglycaemia causes an increase in the mitochondrial proton gradient, a 
consequence of electron donor (NADH and reduced flavin adenine dinucleotide, FADH2) 
overproduction by the citric acid cycle (also known as the tricarboxylic acid (TCA) cycle 
or citrate cycle). This, in turn, leads to increased mitochondrial production of ROS. 
Increased levels of mtROS are implicated in processes known to contribute to the 
pathogenesis of diabetic macrovascular disease, including PKC activation and AGE 
formation (88;222;230;231) (Figure 1.9). In addition, the elevated FFA flux and oxidation 
characteristic of visceral obesity and insulin resistance is known to induce mitochondrial 
ETC ROS production in endothelial cells (232) (Figure 1.9). 
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Figure 1.9. Insulin Resistance and Hyperglycaemia-induced Mitochondrial Superoxide 
Production in Activation of Atherogenic Signalling Pathways. Elevated mitochondrial 
superoxide (O2-) production caused by high glucose flux through endothelial cells, leads to 
increased protein kinase C (PKC) activation and advanced glycation end-product (AGE) formation. 
This results in downstream activation of nuclear factor κB (NF-κB) which induces transactivation 
of vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-
1). Transactivation of additional proatherogenic genes, such as plasminogen activator inhibitor-1 
(PAI-1) and transforming growth factor β1 (TGF-β1), occurs via a similar pathway. Increased flux 
of free fatty acids (FFAs), released from insulin-resistant adipocytes through vascular endothelial 
cells, also activates atherogenic signalling pathways, including PKC and AGE pathways. 
Futhermore, FFA-induced excess mitochondrial O2- production inactivates antiatherogenic 
enzymes such as prostacyclin (PGI2) synthase and endothelial nitric oxide synthase (eNOS) 
(88;222;230;231). Adapted from (88). 
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1.4 Mechanisms in Defence Against Oxidative Stress 
 
A number of endogenous anti-oxidant defence mechanisms, both enzymatic and non-
enzymatic, operate to limit ROS levels in the vasculature. Non-enzymatic anti-oxidant 
molecules include ascorbic acid (vitamin C), α-tocopherol (vitamin E) and glutathione, 
while superoxide dismutases (SODs), catalase and glutathione peroxidases (GPxs) 
represent important anti-oxidant enzymes which act to directly scavenge ROS, converting 
them to less reactive species (188;233) . 
 
 
1.4.1 Superoxide Dismutases 
 
The SODs represent the first and most important line of enzymatic anti-oxidant defence 
against ROS. A ubiquitous family of enzymes, SODs catalyse the conversion of O2- to 
H2O2 and O2 (188;233;234) (Figures 1.5 and 1.8). Three distinct isoforms of SOD have 
been identified in vascular tissue. The first isoform, cytosolic copper/zinc (Cu/Zn) SOD, is 
an unusually stable homodimer encoded by the SOD1 gene. SOD1 is believed to be the 
predominant SOD isoform in the endothelium and is thought to lower O2- concentrations 
from the nanomolar to picomolar range (188;233;234). A second isoform, encoded by 
SOD2, is localised in mitochondria (Figure 1.8). This mitochondrial SOD functions as a 
homotetramer and utilises manganese (Mn) as a cofactor (234). SOD3 encodes the 
extracellular SOD (ecSOD), a copper/zinc-containing tetramer which has a C terminal 
heparin-binding region and is principally located in arterial smooth muscle cells in the 
vascular wall (234). 
 
The importance of SODs as an anti-oxidant defence mechanism has been highlighted by 
gene transfer studies wherein SOD overexpression improved endothelial function 
(235;236) and provided protection against myocardial infarction (237). Overexpression of 
SOD2 has also been shown to prevent hyperglycaemia-associated production of O2-, 
activation of PKC and AGE formation (230), supporting a role for mtROS production in 
diabetic macrovascular disease. 
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Expression of SOD genes may be upregulated by mechanical, chemical or biological 
stimuli and downregulated in certain pathological conditions (234). In addition, SOD2 
expression is regulated post-transcriptionally by a specific RNA-binding protein (238). 
 
 
1.4.2 Catalase 
 
Catalase is the homotetrameric, haem-containing enzyme principally responsible for H2O2 
metabolism following dismutation of O2- by SOD (188;233). An intracellular anti-oxidase, 
catalase is primarily located in peroxisomes but also functions in the cytosol and catalyses 
the conversion of H2O2 to water and O2 (188;233;239) (Figure 1.5). Inherited catalase 
deficiency has been linked to elevated cardiovascular risk and increased incidence of 
diabetes mellitus in affected families (233). However, experimental investigation has 
provided evidence that catalase affords only moderate protection against oxidative stress 
(240) and while gene transfer studies showed reduced ROS production on co-expression of 
SOD and catalase, the relative contribution of each gene was not ascertained (241). 
 
 
1.4.3 Glutathione Peroxidases 
 
Glutathione, a tripeptide comprised of glutamate, cysteine and glycine, is the principal low 
molecular weight, non-protein thiol in the cell (188). Mainly found in the reduced state 
(GSH), glutathione has numerous functions in metabolism, signal transduction and gene 
expression (242). GSH acts as an electron donor and can directly scavenge ROS but also 
acts as a cofactor in the conversion of H2O2 to H2O by GPxs (188;233). 
 
The GPxs are a family of tetrameric enzymes with a role in both first and second line anti-
oxidant defence. Like catalase, GPxs act to reduce the H2O2 produced as a result of the 
dismutation of O2- by SOD, transferring electrons from GSH to H2O2 with the subsequent 
formation of H2O and O2 and conversion of GSH to oxidised glutathione disulphide 
(GSSG) (188;233;242;243) (Figures 1.5 and 1.8). 
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Despite the actions of first line anti-oxidant defence mechanisms, interactions between 
ROS and cellular macromolecules do occur, giving rise to reactive species capable of 
causing damage to lipids, proteins and nucleic acids. Detoxification of secondary oxidation 
products is therefore crucial and GPxs play their part, reducing lipid peroxides to their 
corresponding alcohols via the conjugation and oxidation of GSH (188;233;243) (Figure 
1.5). 
 
There are four known GPx isoforms, each containing selenocysteine at the active site 
(233). GPx1 knockout mice displayed increased susceptibility to ROS-induced oxidative 
stress (244), while induction of this isoform has been shown to offer protection against 
oxidative damage in endothelial cells (245). Furthermore, transgenic GPx1 expression was 
observed to impair endothelial dysfunction (246). Similarly, deficiency of GPx3 has been 
associated with decreased NO bioavailability and increased platelet-dependent thrombosis 
(233). 
 
Additional selonoproteins with similar anti-oxidant activities to GPxs include the 
thioredoxins (233), while the glutathione-s-transferases (GSTs) are examples of non-
selenocysteine containing enzymes of significant importance in secondary oxidative stress 
defence, acting to detoxify reactive electrophiles (233;243). 
 
 
 
1.5 AMP-activated Protein Kinase 
 
AMPK is a key molecule in the regulation of cellular energy homeostasis. A heterotrimeric 
serine-threonine kinase, human AMPK consists of a catalytic α-subunit and regulatory β- 
and γ-subunits, each of which has two or more isoforms which are encoded by distinct 
genes and are differentially expressed in various tissues (Figure 1.10) (247;248). AMPK is 
activated in response to metabolic stresses, such as glucose deprivation, hypoxia and 
exercise, which cause a decrease in the cellular energy charge (247-250). When ATP levels 
fall, there is a corresponding increase in intracellular AMP levels. When present at 
increased concentration, AMP binds to the γ-subunit of AMPK, allosterically activating the 
enzyme. AMP binding also promotes phosphorylation at a critical threonine residue 
(Thr172) of the α-subunit by an upstream kinase, generating full activation of AMPK (251) 
(Figure 1.10). This upstream AMPK kinase (AMPKK) has been identified as a complex 
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Figure 1.10. AMPK-regulated Pathways in Endothelial Cells. The AMPK heterotrimer consists 
of α-, β- and γ- subunits. The α-subunit is responsible for the catalytic activity of the enzyme, 
involved in transferring a phosphate (P) molecule from ATP to a target protein to activate or 
inactivate it. The α-subunit also contains a phosphorylation site for regulation of AMPK activity. 
The β- and γ- regulatory subunits are important for regulation and cellular localisation of the 
protein. Assembly of the heterotrimeric complex is essential for enzyme activity. When the γ-
subunit binds AMP, AMPK is allosterically activated and becomes a better substrate for LKB1. 
AMPK is also regulated by upstream kinase Ca2+ calmodulin-dependent kinase kinase β 
(CaMKKβ) and elevated free fatty acid (FFA) and reactive oxygen species (ROS) levels. Studies 
suggest AMPK activation improves hyperglycaemia-mediated endothelial dysfunction via a 
number of pathways, including endothelial nitric oxide synthase (eNOS) activation, protection 
against the adverse effects of ROS formation, FFA oxidation, and prevention of inflammation via 
the inhibition of nuclear factor κB (NF-κB). Adapted from (252). 
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between the tumour suppressor, LKB1, and two accessory subunits, STRAD (STE-20 
related adaptor protein) and MO25 (251;253;254).   
 
Activated AMPK (pAMPK) acts to restore cellular ATP levels via mechanisms including 
the insulin-independent translocation of GLUT4 to the plasma membrane in skeletal 
muscle and the subsequent activation of glycolysis (247;248;255). AMPK activation also 
promotes fatty acid oxidation, inhibition of acetyl CoA carboxylase (ACC) and fatty acid 
synthesis (256) and, as recently suggested, modulation of gene expression (257;258).  In 
addition, pAMPK mediates the effects of hormones, such as ghrelin (259), and adipokines, 
including resistin (248), leptin (260) and adiponectin (80;261), and is therefore involved in 
maintenance of energy balance at both the cellular and whole body level. Already a target 
for anti-diabetic drugs, metformin (137) and the thiazolidinediones (143), the finding that 
artificial activation of AMPK with 5-aminoimidazole-4-carboxamide ribonucleoside 
(AICAR) (262) can mimic the effects of repeated exercise / endurance training in mice 
(263) has led to heightened interest in the enzyme as a potential therapeutic target for 
intervention in obesity, T2D and cardiovascular diseases. 
 
More recently, mechanisms independent of bioenergetic changes have been shown to be 
involved in AMPK activation. A second AMPKK has been identified as Ca2+/calmodulin-
dependent protein kinase kinase (CaMKK), in particular the β isoform (CaMKKβ) 
(264;265), revealing increased intracellular Ca2+ as an alternative stimulus for AMPK 
activation. Additionally, signalling by ROS has been implicated in activation of the 
enzyme (228;266). Such findings imply AMPK may have a role outwith the regulation of 
energy homeostasis.  
 
 
1.5.1 AMP-activated Protein Kinase in Type 2 Diabetes Mellitus 
 
A key effect in the up-regulation of ATP-generating catabolic pathways by AMPK is the 
stimulation of glucose uptake which occurs as a result of increased translocation of 
GLUT4 to the plasma membrane, activation of GLUT1 at the plasma membrane and 
enhanced transcription of the GLUT4 gene. The latter effect may be responsible for 
increased expression of GLUT4 in response to endurance training which can subsequently 
lead to increased insulin-stimulated glucose uptake (247). With reduced insulin-stimulated 
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glucose uptake via GLUT4 a central feature of insulin resistance, the mechanism by which 
exercise and AMPK activation stimulate this process in an insulin-independent manner is 
currently of great interest in diabetes research. The exact manner in which AMPK mediates 
GLUT4 translocation remains to be fully elucidated but studies suggest a potential role for 
Akt substrate of 160kDa (AS160) (267;268) (Figure 1.4). 
 
As previously described, the hyperglycaemia of T2D results from a reduced ability of 
insulin to both repress glucose production by the liver and increase glucose uptake in 
peripheral tissues. Hepatic AMPK activation has been shown to down-regulate expression 
of the gluconeogenic enzymes PEPCK and G6Pase (269) and activation of the kinase is 
thought to underlie the ability of adiponectin to reduce hepatic glucose production (80). 
The transcriptional co-activator, TORC2, a target of AMPK, has recently been proposed as 
being involved in mediating this effect (270).  
 
By inhibiting fatty acid synthesis and stimulating fatty acid oxidation, AMPK activation 
reduces excessive storage of triglycerides, which in non-adipose cells results in the 
lipotoxicity associated with insulin resistance. AMPK inhibits fatty acid synthesis both 
acutely, by phosphorylating and inactivating the ACC1 isoform of acetyl-CoA carboxylase 
(262), and in the longer term by switching off expression of lipogenic genes, including 
ACC1 and fatty acid synthase (271). The kinase stimulates oxidation of fatty acids by 
phosphorylating and inactivating the ACC2 isoform of acetyl-CoA carboxylase. This 
lowers malonyl-CoA, thus relieving inhibition of fatty acid uptake into mitochondria (272). 
 
A further catabolic action of AMPK is the promotion of mitochondrial biogenesis via up-
regulation of PPAR-γ co-activator-1α (PGC-1α) (273). Again, this is likely to prove 
beneficial in insulin resistant states where a deficit in mitochondrial function is thought to 
predispose to development of T2D (225). 
 
In addition, AMPK activation is known to inhibit activation of the mTORC1 pathway by 
the insulin signalling pathway (Figure 1.4), via phosphorylation of the tuberous sclerosis 
complex (TSC), an upstream regulator of mTORC1 (55). The insulin-mTORC1 pathway is 
believed to exert a negative feedback effect on insulin signalling via activation of p70 
ribosomal S6 kinase (p70S6K) (see Figure 1.4) and subsequent phosphorylation and down-
regulation of IRS-1. Consequently, AMPK activation may increase insulin sensitivity by 
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inhibiting mTORC1 (55;247;274). This effect could explain the ability of AMPK activator, 
AICAR to mimic the effects of exercise in increasing muscle insulin sensitivity. 
 
AICAR was the first relatively specific compound shown to activate AMPK in intact cells 
(262). The nucleoside is taken up and accumulates inside the cell as the 
monophosphorylated nucleotide 5’-aminoimidazole-4-carboxamide ribonucleotide (ZMP), 
which activates AMPK without disturbing cellular adenine nucleotide ratios (262;275). As 
such, effects observed on administration of AICAR are not merely due to depletion of 
ATP. AICAR has been shown to reverse insulin resistance and lower blood pressure in 
animal models such as the ob/ob mouse (276), the fa/fa rat (277) and the high fat-fed rat 
(278). 
 
As previously mentioned, anti-diabetic drugs, metformin and the thiazolidinediones also 
activate AMPK. Neither activate the kinase directly, potentially achieving activation by 
inhibiting complex I of the ETC, thus increasing the cellular AMP:ATP ratio (279). 
However, as stated, the major target of the thiazolidinediones is the transcription factor, 
PPAR-γ. In adipocytes, the thiazolidinediones act on PPAR-γ to stimulate release of 
adiponectin and the effects of the drugs in reversing insulin resistance and improving 
glucose tolerance are greatly reduced in adiponectin knockout mice (280;281). Recent 
evidence suggests adiponectin acts primarily by activating AMPK, indicating the 
thiazolidinediones exert a portion of their therapeutic benefit via two independent 
mechanisms serving to activate AMPK (247). 
 
 
1.5.2 AMP-activated Protein Kinase in The Vascular Endothelium 
 
Activated AMPK is known to phosphorylate eNOS at Ser1177 in cultured endothelial cells 
(176;282) and has been shown to increase endothelium-dependent vasodilation in response 
to shear stress (283). Infection of endothelial cells with adenoviruses expressing dominant-
negative mutant AMPK has demonstrated a key role for AMPK in NO production in 
response to AICAR, hypoxia, ONOO-, metformin, adiponectin, shear stress, vascular 
endothelial growth factor (VEGF) and rosiglitazone (176;283-289). It has also been 
proposed that AMPK mediates adiponectin- and hypoxia-stimulated angiogenesis 
(290;291). Incubation with AICAR has recently been reported to reduce TNFα-stimulated 
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monocyte adhesion, NF-κB activation and mRNA expression of ICAM-1, VCAM-1 and E-
selectin in mouse brain endothelial cells (292;293), while metformin has been reported to 
have similar effects in human umbilical vein endothelial cells (HUVECs) (294), revealing 
the potential anti-atherogenic benefits of AMPK activation. With increasing evidence to 
suggest AMPK is activated in a ROS-mediated manner (228;266;289;295-297), it has been 
proposed that the enzyme exerts its beneficial effect on endothelial function by increasing 
NO bioavailability and facilitating an anti-oxidative response in the endothelium (252) 
(Figure 1.10). 
 
As stated, the endothelial dysfunction characteristic of T2D is associated with elevated 
levels of circulating FFAs (39;88;232). Activated AMPK phosphorylates and inhibits 
ACC, thus accelerating mitochondrial fatty acid oxidation (256). However, high levels of 
FFAs may trigger inhibition of AMPK (252) (Figure 1.10) and reduced AMPK activation 
has been linked to FFA-induced development of endothelial dysfunction in obese rats 
(298). Furthermore, AMPK activation inhibits fatty acid-induced increases in NF-κB 
transactivation in vascular endothelial cells (252;294), further supporting a protective role 
for the enzyme in atherogenic and inflammatory vascular disease. 
 
These downstream consequences of endothelial AMPK activation may explain the 
beneficial effects of metformin and the thiazolidinediones on vascular outcomes in patients 
with T2D and highlight why AMPK is increasingly recognised as a potential therapeutic 
target in defence against oxidative stress and prevention of endothelial dysfunction in 
cardiovascular diseases such as CAD and T2D. 
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1.6 Aims 
 
Previously, studies within this laboratory have demonstrated endothelial dysfunction and 
elevated O2- production in vessels from patients with advanced CAD (159). However, the 
molecular basis for this increase was not investigated, nor was the effect of type 2 diabetes. 
The aim of this study therefore, is to investigate a number of molecular determinants of 
oxidative stress and T2D in primary human vascular cells from patients with CAD, the 
hypothesis being that oxidative stress leads to endothelial dysfunction in CAD and is 
exacerbated in those patients with T2D. 
 
The specific aims of this study are: 
(1) to establish sources of O2- production in primary vascular cells isolated from 
patients with advanced CAD and determine how the presence of T2D affects their 
contribution to cellular ROS generation; 
(2) to examine the activity and activation of AMPK in primary cultures of endothelial 
cells isolated from patients with CAD and T2D; 
(3)  to investigate how T2D alters gene expression in the endothelium of CAD 
patients. 
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2. Materials & Methods 
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This chapter outlines general laboratory practices and methods that are common to more 
than one chapter. Each individual results chapter has a specific Materials & Methods 
section. 
 
 
2.1 General Laboratory Practice 
 
Laboratory equipment and reagents were of the highest available grades. A laboratory coat 
and latex powder-free gloves were worn during all procedures. Handling of hazardous 
reagents was in accordance with Control of Substances Hazardous to Health regulations, 
utilising laboratory spectacles, facemasks and fume hoods where necessary. 
 
Laboratory glassware was cleaned in Decon 75 detergent (Decon Laboratories Ltd.), rinsed 
with distilled water and dried in a 37ºC cabinet. Sterile, disposable plastic-ware utilised 
included 0.5 ml, 1.5 ml and 2 ml microcentrifuge tubes (Greiner Bio-One), 15 ml and 50 
ml Corning centrifuge tubes and 5 ml and 20 ml Universal containers (Sterilin). 
Laboratory-ware requiring sterilisation was autoclaved in a Priorclave Tactrol 2. 
 
Reagents were weighed using an Ohaus Portable Advanced balance (sensitive to 0.01 g), 
or a Mettler HK160 balance (sensitive to 0.0001 g). The pH of solutions was determined 
using a Mettler Toledo digital pH meter, calibrated on a regular basis with solutions of pH 
4.0, 7.0 and 10.0 prepared from buffer tablets [Sigma-Aldrich Company Ltd (Sigma), St 
Louis, MO, U.S.A.]. Volumes from 0.1 µl to 1,000 µl were dispensed using appropriate 
Gilson pipettes (Gilson Medical Instruments). Volumes from 1 ml to 25 ml were measured 
with sterile disposable pipettes (Corning) and a Gilson battery-powered pipetting aid. 
Distilled water (dH20) was used to prepare aqueous solutions unless otherwise indicated 
and a Jenway 1000 hotplate/stirrer used to aid dissolving and mixing. Vortexing was 
carried out using an FSA Laboratory Supplies WhirliMixer. Centrifugation of samples up 
to 2 ml was performed at 4 - 20ºC in an Eppendorf 4515 microcentrifuge while samples of 
larger volumes were centrifuged in a Sigma 4K15, compatible with 15 ml and 50ml 
centrifuge tubes, 20 ml Universal tubes and including carriers for standard reaction plates. 
A Julabo TW8 water bath was utilised for experiments requiring incubations from 37ºC to 
90ºC and a Grant SBB14 boiling water bath used where temperatures up to 100ºC were 
required. 
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For experiments involving ribonucleic acid (RNA), certified nuclease-free reagents and 
plastic-ware were used, including nuclease-free H2O (Ambion, Austin, TX, U.S.A.), 
Ambion RNase-free microcentrifuge tubes and RAININ nuclease-free pipette tips. Pipettes 
and benches were wiped with Ambion RNaseZap reagent prior to all RNA experiments. 
 
 
 
2.2 Recruitment & Clinical Assessment of Study Participants 
 
Recruitment and clinical assessment of patients was carried out by Dr Jane Dymott. 
 
Seventy nine patients with severe CAD from cardiothoracic pre-operative clinics were 
recruited. Twenty three patients had a history of T2D for at least 4 weeks prior to 
admission for surgery. Type 2 diabetes was defined as having fasting venous blood glucose 
≥ 6.1 mM or ≥ 10 mM two hours post oral glucose load (75 g). Nineteen control subjects 
free of evidence of CAD who were undergoing surgery for the removal of varicose veins 
were also recruited. The study was approved by the Glasgow West Ethics Committee and 
participants gave their written informed consent prior to participation.  
 
Demographic and clinical characteristics of patients and control subjects are given in Table 
2.1. As expected, patients with CAD were older and more likely to be on cardiovascular 
medication than control subjects. Total and low density lipoprotein (LDL) cholesterol 
levels were lower in patients with CAD compared to control subjects, consistent with lipid 
lowering therapy in the CAD patient group. High density lipoprotein (HDL) cholesterol 
levels were significantly greater in control subjects compared to patients. Patients with 
T2D had greater body mass index and greater percentage of glycosylated haemoglobin A1c 
but no other significant differences to patients without diabetes were observed. Forty three 
percent of patients with T2D were treated with metformin. 
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 CAD Controls 
 T2D 
 
n=23 
ND 
 
n=56 
P value 
T2D vs 
ND 
 
 
n=19 
P value 
CAD vs 
controls 
Age (years) 65±11 65±9 0.961 44±19 <0.001 
Sex (m:f) 20/3 45/11 0.747 8/11 0.001 
BMI (kg/m²) 31.7±5.2 28.6±4.7 0.026 26.5±1.9 0.004 
SBP (mmHg) 138±22 138±26 0.897 132±23 0.471 
DBP (mmHg) 73±13 80±11 0.065 84±12 0.162 
Total cholesterol 
(mmol/L) 
3.95±1.10 4.11±0.99 0.542 4.96±0.99 0.029 
LDL cholesterol 
(mmol/L) 
1.80±0.83 2.00±0.78 0.314 2.69±1.11 0.024 
HDL cholesterol 
(mmol/L) 
1.11±0.22 1.17±0.27 0.366 1.72±0.30 <0.001 
Triglycerides (mmol/L) 2.54±1.97 2.04±0.97 0.262 1.17±0.47 0.052 
CRP (mg/L) 2.5±2.9 5.0±10.5 0.280 3.5±4.2 0.843 
HbA1c (%) 7.2±1.3 5.6±0.4 <0.001 5.4±0.2 0.111 
Active smoking (y/n) 2/22 2/54 0.579 2/17 0.324 
ACEI/ARB (y/n) 18/5 32/24 0.122 1/18 <0.001 
Statin (y/n) 21/2 53/3 0.625 2/17 <0.001 
Metformin (y/n) 10/13 0/56 <0.001 0/19 <0.001 
 
Table 2.1. Characteristics of the Study Cohort. Continuous data are given as mean ± standard 
deviation irrespective of distribution or skewness. P values, however, derive from Student's t-test 
or Mann-Whitney U-test as appropriate. Comparison between categorical data was performed using 
Fisher's exact test. CAD, coronary artery disease; BMI, body mass index; SBP, systolic blood 
pressure; DBP. diastolic blood pressure; LDL, low density lipoprotein; HDL, high density 
lipoprotein; CRP, C-reactive protein; HbA1c, glycosylated haemoglobin A1c; ACEI, angiotensin-
converting enzyme inhibitor; ARB, angiotensin receptor blocker 
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2.3 Human Vascular Tissue 
 
Freshly obtained saphenous veins from patients undergoing coronary artery bypass graft 
(CABG) surgery were stored in sterile saline solution by the surgical team at Glasgow 
Western Infirmary until collection. Control vessels from patients undergoing elective 
varicose vein removal were stored in the same way by the surgical team at Glasgow’s 
Gartnavel General. Maximum storage time was 2 hours. Only non-varicosed portions of 
veins from control patients, as identified by the surgical team, were utilised. Samples were 
taken to the laboratory and cleaned of excess connective tissue. Endothelial cells were 
isolated from portions of vessels on the day of surgery and the remainder of samples stored 
at 4°C in a Krebs 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer 
[118 mM NaCl, 10 mM Hepes, pH 7.4, 25 mM NaHCO3, 4.7 mM KCl, 1.2 mM MgSO4, 
1.2 mM KH2PO4, 11 mM glucose, 10 µM indomethacin, 50 µM ethylenediamine tetra-
acetic acid (EDTA)] for study of endothelial function and O2- production the following 
day. 
 
 
 
2.4 Isolation & Culture of Primary Cells 
 
Primary cells were handled under sterile conditions using class II biological safety cabinets 
(Holten Safe 2010). Cabinets were cleaned before and after use with dH2O and 70% 
ethanol. Waste plastics and fluid were decontaminated by steeping for 24 hours in (10%) 
bleach before plastics were incinerated and fluids emptied into domestic waste drains. 
Cells were cultured in 100 mm x 20 mm cell culture dishes and 25 cm2, 75 cm2 and 150 
cm2 culture flasks with vented caps (Corning). 
 
 
2.4.1 Isolation of Primary Endothelial Cells from Human Saphenous 
Vein 
 
Human saphenous vein endothelial cells (HSVECs) were isolated on the day of surgery by 
standard collagenase digestion based on a modified version of the protocol described by 
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Jaffe and colleagues (299). In summary, saphenous veins were gently flushed of remaining 
blood with wash medium [Dulbecco’s Modified Eagle’s Medium (DMEM), 1000 mg/l 
glucose, without phenol red (Invitrogen™, Paisley, U.K.) and supplemented with 100 IU/ml 
penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine]. Veins were then filled with a 
solution of filter-sterilised collagenase [(Sigma), 2 mg/ml in wash medium] and the vessel 
incubated at 37°C in a sterile petri dish in 5% CO2 for 15 minutes. Endothelial cell 
suspensions were obtained by flushing the vein with wash medium and collecting flow-
through. Veins were then refilled with collagenase and incubated at 37°C for a further 10 
minutes. Collagenase was flushed through and cells collected and pelleted by 
centrifugation (2,000 x g, 5 minutes, room temperature). Cells were resuspended in 
complete Large Vessel Endothelial Cell Basal Medium (TCS Cellworks Ltd, Botolph 
Claydon, Bucks, U.K.), supplemented with 20% (v/v) foetal calf serum (FCS), 100 IU/ml 
penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine (endothelial cell growth 
medium), and then incubated for 24 hours before a complete medium change. Cells were 
cultured in complete growth medium and used between passages 1 and 5. 
 
 
2.4.2 Isolation of Primary Vascular Smooth Muscle Cells from Human 
Saphenous Vein 
 
Following HSVEC isolation, vessel portions were stored overnight at 4ºC in a HEPES-
containing buffer [DMEM, 1000 mg/l glucose, + L-glutamine, + 25 mM HEPES, + 
pyruvate (Invitrogen™), supplemented with 10% (v/v) FCS, 100 IU/ml penicillin, 100 
µg/ml streptomycin]. The following day human saphenous vein smooth muscle cells 
(HSVSMCs) were obtained from medial explants of these portions of saphenous veins 
according to the method described by Southgate and Newby (300). Briefly, segments of 
vein were cut longitudinally and pinned out with the endothelial surface uppermost. The 
medial layer was scored with a sterile scalpel, peeled away from the adventitial layer and 
then cut into 1mm2 size pieces using a McIlwain Tissue Chopper. Explants were then 
incubated at 37°C in 5% CO2 in minimal medium until they adhered to the flask 
(approximately 24 hours). Subsequently, explants were cultured in 7.5 ml of DMEM (4500 
mg/L glucose, + Glutamax-1), supplemented with 100 IU/ml penicillin, 100 µg/ml 
streptomycin and 20% (v/v) FCS (smooth muscle cell growth medium), at 37°C in 5% 
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CO2. Medium was changed once a week until HSVSMCs had migrated from the explants 
and then every 3 days for subsequent passages. 
 
 
2.4.3 Primary Cell Culture & Passage 
 
As stated, cells were maintained in complete growth medium. Confluent cultures of 
primary cells were passaged by trypsin-EDTA. Cells were washed twice in sterile 
Dulbecco’s calcium and magnesium free phosphate buffered saline (PBS, Lonza, Verviers, 
Belgium) and incubated at 37ºC in trypsin-EDTA (0.05% trypsin, 0.02% EDTA) for 5 
minutes or until the majority of cells had detached from the flask. The action of trypsin-
EDTA was then blocked by the addition of an equal volume of growth medium containing 
20% (v/v) FCS. Cells were harvested by centrifugation at 1,500 x g and resuspended in 
fresh growth media before plating. 
 
 
2.4.4 Immunocytochemical Characterisation of HSVECs & HSVSMCs 
 
HSVECs were identified by immunofluorescent staining for von Willebrand factor (vWF) 
and HSVSMCs by immunofluorescence for SMC-α-actin. Primary antibodies were mouse-
anti-human vWF (clone F8/86, MO616) and mouse-anti-human smooth muscle α actin 
(clone 1A4, M0851), both from Dako-Cytomation (Dako, Glostrup, Denmark). 
 
At passage 1 HSVECs and HSVSMCs were harvested and plated onto sterile coverslips in 
6 well plates. Sixteen hours later media were removed, cells washed twice in PBS and 
fixed in 4% paraformaldehyde for 5 minutes at room temperature. Cells were washed twice 
more in PBS and then incubated with the appropriate primary antibody (1:50 for anti-vWF 
and 1:2000 for anti-SMC-α-actin, both in 20% goat serum/PBS) at room temperature for 
30 minutes. This was followed by 3 washes in PBS. Cells were then incubated with goat-
anti-mouse IgG-fluoroscein isothiocyanate (FITC) conjugate (Dako) secondary antibody 
(1:200 in 20% goat serum/PBS) for 30 minutes at room temperature and washed a further 3 
times in PBS. Cell-free sides of coverslips were subsequently washed with dH2O, 
coverslips mounted in Vectashield (Vector Laboratories Inc., Burlingame, CA, U.S.A.), 
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containing propidium iodide for nucleic counter-staining, and cells visualised under a 
fluorescence microscope at x 40 and x 100 magnifications.  
 
 
2.4.5 Cryo-preservation of HSVECs 
 
At passage 3, cell cultures were harvested as described in section 2.4.3 and resuspended at 
a density of approximately 1 - 2 x 107 cells/ml in cryo-preservation media [complete 
culture media supplemented with 10% (v/v) dimethyl sulphoxide (DMSO, Fisher 
Scientific, Pittsburgh, PA, U.S.A.). Cell suspensions were aliquoted into sterile 2 ml cryo-
vials and cooled at a constant -1ºC/minute to -80ºC using isopropanol. Vials were then 
transferred to liquid nitrogen and stored until required for analysis.  
 
For resuscitation, vials were removed from the liquid nitrogen store and pre-warmed 
culture medium slowly added until contents thawed. Cells were then plated and DMSO-
containing medium replaced with fresh medium the following day. 
 
 
 
2.5 Extraction, Purification & Quantification of RNA from HSVECs 
 
2.5.1 RNA Extraction 
 
RNA was routinely extracted from HSVECs at passage 3.  
 
RNA was isolated using the RNeasy® Mini Kit (QIAGEN) and according to the 
manufacturer’s guidelines. Cells were pelleted, supernatants removed and pellets loosened 
by flicking the tube. Cells were then resuspended in one volume (600 µl) Buffer RLT 
containing 0.01% (v/v) β-mercaptoethanol. Samples were homogenised by repeated 
pipetting. One volume of 70% ethanol was added to the homogenised lysate and samples 
mixed well by pipetting. Up to 700 µl of sample was then applied to an RNeasy mini 
column placed in a collection tube and centrifuged for 15 seconds at 8,000 x g and room 
temperature. Flow-through was discarded and 700 µl Buffer RW1 added to columns. 
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Samples were then centrifuged as before and flow-through discarded. Columns were 
transferred to fresh collection tubes and 500 µl Buffer RPE added. Centrifugation was 
carried out as before to wash columns and flow-through discarded before another 500 µl 
Buffer RPE was added and samples centrifuged (2 minutes, 8,000 x g, room temperature) 
to dry the RNeasy silica-gel membrane. To eliminate the possibility of Buffer RPE 
carryover, collection tubes containing flow through were discarded and columns placed in 
fresh tubes for centrifugation at 14,000 x g (room temperature) for 1 minute. RNeasy 
columns were transferred to new collecting tubes and 40 µl RNase-free water pipetted 
directly onto the silica-gel membrane. Samples were then centrifuged for 1 minute at 8,000 
x g and room temperature to elute. To increase RNA yield, the elution step was repeated, 
re-using the original volume of RNAse-free water. RNA samples were stored at -70ºC until 
time of analysis. 
 
 
2.5.2 DNase Treatment of Extracted Total RNA 
 
In order to remove any contaminating DNA, extracted total RNA was treated with DNase 
using the TURBO DNA-free™ kit from Ambion and according to the manufacturer’s 
instructions. In summary, 0.1 volume (4 µl) 10 X TURBO DNase Buffer and 1 µl TURBO 
DNase (2 U/µl) were added to RNase-free tubes containing 40 µl RNA samples. Samples 
were then incubated at 37ºC for 25 minutes. Following incubation, 0.1 volume (4.4 µl) 
DNase Inactivation Reagent was added to tubes. Samples then underwent a further 2 
minute incubation at room temperature with occasional mixing, before a 1.5 minute 
centrifugation at 10,000 x g and 4ºC. Supernatants containing DNase treated total RNAs 
were transferred to fresh, RNase-free tubes and stored at -70ºC for downstream 
applications. 
 
 
2.5.3 RNA Quantification 
 
Total RNA concentrations were quantified using the NanoDrop® ND-100 
Spectrophotometer and ND-1000 v3.1.0 programme (Labtech International Ltd, Lewes, 
East Sussex, U.K.). For each sample, 2 µl total RNA was quantified. 
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2.6 Extraction & Quantification of Protein from HSVECs 
 
2.6.1 Protein Extraction 
 
Protein was routinely extracted from HSVECs at passage 3.  
 
For protein extraction, cells were permeabilised in 0.2% Triton X 100 (Sigma) and samples 
homogenised by at least 20 passes through a 21-gauge needle (0.8 mm diameter) fitted to a 
syringe. Protein samples were stored at -20ºC until required.  
 
 
2.6.2 Determination of Protein Concentration 
 
Protein concentrations were determined using a Pierce BCA (bicinchoninic acid) Protein 
Assay kit (Thermo Scientific, Waltham, MA, U.S.A.) according to the manufacturer’s 
instructions. Assays were performed in 96-well plates. Dilutions of an albumin protein 
standard (provided) ranging from 25 ng/µl – 2 µg/µl were made in PBS and used to 
generate a standard curve for each assay. Reagents A and B included in the kit were mixed 
at a ratio of 50:1 respectively before being added to protein samples and standards at a 
ratio of 8:1 (25 µl sample/standard, 200 µl BCA reagents mixture). Plates were 
subsequently protected from light in aluminium foil and placed at 37ºC for 30 minutes. 
Absorbance at 560 nm was determined for all wells using a Wallac Victor2 plate reader 
(Wallac, Turku, Finland). Both samples and standards were measured in duplicate and an 
average value calculated. Concentration of protein in each sample was then interpolated 
from the standard curve by Work-Out software (Wallac). 
 
 
2.6.3 Cell Lysate Preparation 
 
Passage 3 HSVECs were grown in 100 mm diameter cell culture dishes until confluent and 
then serum-starved overnight. Medium was removed and cell lysates prepared. Briefly, 0.4 
ml of ice-cold lysis buffer [50 mM Tri-HCl, pH 7.4 at 4ºC, 50 mM NaF, 5 mM Na4P2O7, 1 
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mM NaVO3, 1mM EDTA, 1mM ethylene glycol tetra-acetic acid (EGTA), 0.1 mM 
benzamidine, 0.1 mM phenylmethylsulfonylfluoride (PMSF), 5 µg/ml soybean trypsin 
inhibitor, 1% (w/v) glycerol, 1% (w/v) Triton X 100] was added and cell extract scraped 
off and transferred to a microcentrifuge tube. Extracts were then vortexed-mixed and 
centrifuged (14,000 x g, 1 min, 4ºC). Total protein concentration of each sample was 
determined as outlined in section 2.6.2. Cell lysates were stored at -20ºC when not required 
immediately. 
 
 
 
2.7 HSVEC mRNA Expression 
 
RNA was routinely isolated from passage 3 HSVECs as described in section 2.5. 
 
 
2.7.1 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
 
First strand complementary DNA (cDNA) was synthesised from 1 µg of DNase-treated 
total RNA using the TaqMan® Reverse Transcription Reagents kit from Applied 
Biosystems and following the manufacturer’s guidelines. RNA samples were reverse 
transcribed to cDNA in a 20 µl reaction containing a final concentration of 5.5 mM MgCl2, 
500 µM of each deoxyribonucleotide triphosphate (dNTP), 2.5 µM Random Hexamers, 0.4 
U/µL RNase Inhibitor, 1.25 U/µL MultiScribe Reverse Transcriptase and 1 X TaqMan® 
RT Buffer. Selected samples were used for negative control reactions which did not 
contain MultiScribe Reverse Transcriptase. Samples were then incubated at 25ºC for 10 
minutes to maximize primer-RNA template binding before being held at 48ºC for 30 
minutes to facilitate reverse transcription. Reverse Transcriptase was inactivated by 
incubating samples at 95ºC for 5 minutes before samples were placed on ice and diluted, in 
nuclease-free water, to a final volume of 50 µl. When not being used immediately, samples 
were stored at -20ºC. 
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2.7.2 TaqMan® Real-Time RT-PCR 
 
Real-time RT-PCR quantitation of samples was carried out via a two-step RT-PCR assay 
utilising TaqMan® Gene Expression Assays (Applied Biosystems).  
 
Prior to real-time RT-PCR reactions, an efficiency assay was performed for each gene of 
interest. Serial dilutions of pooled, neat cDNAs were set up in singleplex and multiplex 
reactions to determine whether the gene of interest amplified with equal efficiency to that 
of a reference/housekeeping gene [β-actin or glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH)]. Efficiencies, as calculated according to the manufacturer’s instructions (ABI 
PRISM 7700 Sequence Detection System User Bulletin #2), were considered to be equal if 
the absolute value of the slope was < 0.1. 
 
Following efficiency tests, multiplex reactions were carried out for genes of interest 
reacting with similar efficiency to a reference gene. Each multiplex reaction was of 5 µl 
volume, consisting of 2.5 µl TaqMan® Universal PCR Master Mix, 1 X VIC-labelled 
reference probe, 1 X FAM-labelled probe for gene of interest and 2 µl cDNA. Reactions 
were carried out in barcoded 384-well plates. For genes of interest with relative 
efficiencies dissimilar to those of reference genes, reactions were carried out in singleplex 
(with equal volumes of nuclease-free water in place of the relevant probe) but within the 
same plate. The 2-∆∆Ct comparative method (301) was used for the relative quantitation of 
gene expression according to the manufacturer’s instructions (ABI PRISM 7700 Sequence 
Detection System User Bulletin #2). 
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2.8 HSVEC Protein Expression 
 
Cell lysates were prepared and protein routinely isolated from passage 3 HSVECs as 
described in section 2.6. 
 
 
2.8.1 Western Blot Assessment of Protein Expression 
 
Protein samples were mixed with an equal amount of reducing loading dye (125 mM Tris 
pH 6.8, 4% (v/v) SDS, 10% (v/v) glycerol, 0.006% (v/v) bromophenol blue, 2% (v/v) β-
mercaptoethanol) and subsequently denatured by incubating them for 10 minutes at 99ºC. 
Equal amounts (in the range of 20 µg to 50 µg) of total protein were then resolved using 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS/PAGE). 12% 
polyacrylamide gels (containing 40% (v/v) polyacrylamide (30%), 11.25 mM Tris pH 8.8, 
0.1% (v/v) SDS, 300 µl ammonium persulphate (APS) and 30 µl TEMED) were used. A 
4% stacking gel (13.3% (v/v) polyacrylamide (30%), 3.75 mM Tris pH 6.8, 0.1% SDS, 
300 µl APS and 30 µl TEMED) was used with each gel. 15 µl of Amersham Rainbow 
Markers (GE Healthcare U.K. Ltd, Bucks, U.K.) were included in each blot. These protein 
molecular weight markers were either low range [2.5 kilodaltons (kDa) – 45 kDa] or full 
range (10 kDa – 250 kDa). 
 
Proteins were transferred onto Hybond-P nitrocellulose membranes (Amersham Bioscience 
U.K. Ltd) overnight at 90 milliAmps (mA) in transfer buffer containing 0.025 M Tris, 0.2 
M glycine, 20% (v/v) methanol, 0.01% (v/v) SDS. Membranes were then blocked (with 
shaking) in TBS-T [150 mM NaCl, 50 mM Tris, 0.1% (v/v) Tween-20] + 10% (w/v) fat-
free milk powder (blocking buffer) for approximately 6 hours before overnight incubation 
at 4ºC (with shaking) in a primary antibody solution. Primary antibodies were diluted to 
appropriate concentrations in blocking buffer. Membranes were then washed 6 times in 
TBS-T at room temperature with each wash lasting approximately 5 minutes. Secondary 
antibodies were also diluted in blocking buffer and incubated with membranes at room 
temperature for 2 hours with shaking. A further six 5 minute washes in TBS-T were then 
performed. 
75 
Proteins were visualised using Amersham™ ECL™ (enhanced chemiluminescence) Western 
Blotting Detection Reagents (GE Healthcare) as per the manufacturer’s instructions. Films 
were exposed for varying lengths of time, ranging from 30 seconds to overnight. 
 
 
2.8.2 Densitometric Quantification of Protein Bands 
 
Immuno-detected bands on photographic film were scanned on a Mercury 1200c scanner, 
using Adobe Photoshop software, to generate a digital image. Individual bands were 
labeled and demarcated by boxes using a drawing tool and the intensity of bands measured 
using Scion Image or ImageJ software and expressed in units of optical density per mm2 
(ODU/mm2). 
 
Two methods of background subtraction were used for densitometrical analyses. For blots 
with clean and constant background intensities, a ‘global’ background subtraction method 
was used. This involved drawing a box in an area of the image representative of the 
background, thus allowing the software to calculate the average intensity of pixellation in 
this box and subtracting this value from pixel intensity in all boxes containing bands. 
Alternatively, a ‘local’ background subtraction method was used for blots where the 
background intensity level was variable across the blot. Here, the software calculated an 
average background intensity for each box by measuring the average intensity of all pixels 
in a one pixel border around each box and subtracted this from each pixel in the box to 
determine band intensity. 
 
 
 
2.9 Statistical Analysis 
 
For clinical data and measurements in whole vessels, continuous data are given as mean ± 
standard deviation or median (interquartile range), unless otherwise indicated. Values 
stated are means ± standard error of the mean (SEM) for cellular data, unless otherwise 
indicated. For comparisons of a continuous variable between 2 experimental groups, paired 
and unpaired Student's t-tests and Mann-Whitney U-tests were applied as appropriate. For 
comparisons of a continuous variable in data sets with more than 2 groups, analysis of 
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variance (ANOVA) was applied, followed by the Tukey’s post-hoc test for all possible 
pairwise comparisons. Categorical data were analysed by Fisher's exact test. A P-value of 
less than 0.05 (two tailed) was considered significant. 
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3. Mechanisms of Oxidative Stress in Coronary 
Artery Disease 
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3.1 Introduction 
 
 
Levels of O2- have been shown to be elevated in vessels from patients with advanced CAD 
relative to those from control subjects with no documented CAD (159;208;302) and studies 
carried out within our laboratory have shown endothelial dysfunction to be associated with 
this elevated O2- production in saphenous veins from CAD patients (159). However, while 
these studies demonstrated elevated O2- generation throughout the vessel wall in patients 
with CAD (159), the molecular basis for this increase was not investigated nor was the 
effect of the additional CVD risk factor, T2D. 
 
Traditional methods for the detection of O2- in vascular tissue include lucigenin-enhanced 
chemiluminescence and fluorescence techniques involving the use of probes such as 
dihydroethidium (DHE). Employing these methods, vascular O2- production has been 
shown to be increased in a number of conditions recognised as risk factors for CVD and in 
which endothelial function is impaired, including T2D (303;304) and various forms of 
hypertension such as Ang II-induced hypertension (180;305) and that found in the stroke 
prone spontaneously hypertensive rat (SHRSP) (306;307). In addition, more recent 
applications of these techniques have succeeded in demonstrating increased levels of O2- in 
vascular tissue from patients with advanced CAD as compared to individuals with no 
documented vascular disease (159;208), as previously described. However, the validity of 
lucigenin-enhanced chemiluminescence assays has been questioned, with evidence to 
suggest that at high concentrations, lucigenin itself may act as a source for O2- via redox 
cycling (308;309). Similarly, DHE has been associated with potential artefacts (310). 
Consequently, the use of two independent methods for superoxide detection is considered 
necessary by most investigators in order to obtain reliable results. 
 
Cytochrome c reduction is another well established approach for measurement of O2- 
production. While this method is useful for quantifying O2- released in large amounts 
during the respiratory burst of neutrophils or by isolated enzymes, for other tissues, such as 
vessels and endothelial cells, where the level of O2- production is much lower, its 
application is more difficult as investigators find themselves operating at the lower limit of 
the assay’s sensitivity (311). 
 
In recent years, intracellular O2- production has increasingly been detected using DHE and 
high performance liquid chromatography (HPLC) (311;312) and/or electron paramagnetic 
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resonance (EPR) spectroscopy (311;313). Currently one of the most accurate methods for 
the detection of radical species, EPR detects the transitions of unpaired electrons in an 
applied magnetic field (311) and has been used in conjunction with cyclic hydroxylamine 
spin probes to investigate O2- levels in vascular tissue (314) and cultured endothelial cells 
(315-317). Cyclic hydroxylamines include 1-hydroxy-3-carboxy-2,2,5-tetramethyl-
pyrrolidine hydrochloride (CPH) and 1-hydroxy-3-methoxycarbonyl-2,2,5,5-
tetramethylpyrrolidine (CMH) and are effective scavengers of O2-, oxidised to form stable 
nitroxide radicals which can readily be detected by EPR (311). 
 
As stated previously (section 1.3), principal sources of O2- in the vasculature include 
uncoupled eNOS and NAD(P)H oxidase and inhibitors of these enzymes have been shown 
to reduce O2- production in saphenous veins from CAD patients (159;302;318). 
Preincubation of sections of saphenous vein with NG-nitro-L-arginine methyl ester (L-
NAME), an eNOS inhibitor, and diphenylene iodonium (DPI), an inhibitor of flavin-
containing oxidases such as NAD(P)H oxidases, caused significant reductions in vascular 
O2- generation in patients with CAD (302), suggesting they represent enzymatic sources of 
O2- generation in saphenous veins. Furthermore, incubation of saphenous veins with the 
NAD(P)H oxidase inhibitor, apocynin has been shown to improve endothelium-dependent 
relaxations in CAD patients, suggesting NAD(P)H oxidase contributes to O2- production 
and endothelial dysfunction in these patients (159). 
 
As previously outlined, mitochondria are major sites of ROS generation within cells of the 
vasculature. However, the precise contribution of mitochondria to total ROS production in 
the vessel wall and other cardiovascular tissues remains unclear, a consequence of limited 
efficacy of conventional antioxidants due to the difficulty associated with delivering them 
to mitochondria in situ (319). Furthermore, although specific antagonists of the respiratory 
chain, such as the complex I inhibitor, rotenone, or the complex III inhibitor, antimycin, 
can modify mitochondria-derived ROS production, they have confounding effects on 
mitochondrial ATP production and membrane potential, rendering interpretation of their 
effects on cellular ROS levels difficult (320).  
 
A recently developed mitochondria targeted ubiquinone, MitoQ10, has been shown to 
overcome the problem of direct delivery to the mitochondria. MitoQ10 is composed of a 
lipophilic triphenylphosphonium (TTP) cation covalently attached to an ubiquinol 
antioxidant (321;322). Lipophilic cations can easily move through phospholipid bilayers 
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without requiring a specific uptake mechanism and, as such, the TTP cation concentrates 
MitoQ10 several hundred fold within the mitochondria, driven by the large mitochondrial 
membrane potential (321-324) (Figure 3.1). Within mitochondria, MitoQ10 is reduced by 
the respiratory chain to its active ubiquinol form, a highly effective antioxidant which 
prevents lipid peroxidation and mitochondrial damage (321;323-325). MitoQ10 has been 
shown to prevent oxidative damage in endothelial cells in vitro (326) and to be effective 
against such damage in vivo, in rodent models of sepsis and reperfusion injury (327;328). 
 
 
 
The aims of the experimental work outlined in this chapter were as follows: 
 
1) to compare endothelial function and levels of O2- production in vessels from control 
subjects and CAD patients with and without T2D; 
2) to isolate and culture HSVECs and HSVSMCs from control subjects and patients 
with CAD; 
3) to compare levels of O2- production in HSVECs isolated from control subjects and 
CAD patients with and without T2D; 
4) to investigate SOD expression and characterise enzymatic sources of O2- 
production in HSVECs from CAD patients with and without T2D 
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Figure 3.1. Accumulation of MitoQ10 in Cells and Mitochondria. MitoQ10 accumulates (~10- to 
20-fold) within the cell driven by the plasma membrane potential ( p). Further accumulation 
(~150- to 200-fold) in mitochondria is driven by the mitochondrial membrane potential ( m). 
Within the mitochondrial matrix, MitoQ10 is reduced to the active antioxidant form, ubiquinol by 
the respiratory chain. Ubiquinol in turn acts to prevent lipid peroxidation. Antioxidant activity 
produces the ubiquinone form which is recycled back to ubiquinol by the respiratory chain 
(continual recycling). Adapted from (329). 
?? p - 70 mV 
MitoQ 10 
ubiquinol 
ubiquinone 
1
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3.2 Materials & Methods 
 
3.2.1 Study Participants 
 
Patients with CAD and control subjects were as described in section 2.2.  
 
 
3.2.2 Human Vascular Tissue & Primary Cell Culture 
 
Vascular tissue was obtained and prepared as described in section 2.3 and HSVECs and 
HSVSMCs isolated, characterised and cultured as outlined in section 2.4.  
 
 
3.2.3 Assessment of Endothelial Function 
 
Portions of saphenous vein were studied in organ bath chambers as outlined by Hamilton 
and colleagues (330). Vessels were cleaned of connective tissue and cut into 2–3 mm rings. 
Rings were then suspended on wires in 10 ml organ chambers filled with physiological salt 
solution [(PSS), 130 mM NaCl, 4.7 mM KCl, 14.9 mM NaHCO3, 1.18 mM KH2PO4, 5.5 
mM glucose, 1.17 mM MgSO4.7H2O, 1.6 mM CaCl2.2H2O, and 0.03 mM CaNa2EDTA, 
0.02 mM indomethacin dissolved in DMSO (pH 7.49 ± 0.1)], maintained at 37°C, and 
aerated with a mixture of 95% O2-5% CO2. The rings were connected to force transducers, 
and changes in isometric tension were recorded. Vessels were constricted with 
phenylephrine  and relaxation in response to the endothelium dependent vasodilatator, 
calcium ionophore A23187 (0.01-10 µM) was studied. Maximum relaxation was calculated 
and expressed as a percentage of constriction to phenylephrine. 
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3.2.4 Assessment of Vascular Superoxide Production 
 
Superoxide production was measured in 3-4 mm rings by chemiluminescence using 
lucigenin as described by Berry et al. (318). Samples were analysed in a liquid scintillation 
counter (Hewlett Packard Tricarb 2100TR). Readings were taken every 10 seconds for 3 
minutes and absolute counts quantified with a xanthine / xanthine oxidase calibration curve 
for O2- generation and standardised to wet weight of the tissue. Calibration curves were in 
the range of 28 nM to 280 nM xanthine and prepared by adding 20 µl xanthine oxidase (0.1 
U/ml), 5 µM lucigenin and increasing volumes of 20 µM xanthine to a scintillation vial 
containing 2 ml Krebs-Ringer HEPES (KRH) buffer (119 mM NaCl, 20 mM Na-HEPES, 
pH 7.4, 5 mM NaHCO3, 4.7 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4 (7H20), 10 mM 
glucose, NaH2PO4). Counts were reported as nmol/mg tissue/min. It has previously been 
shown that the lucigenin assay responds in the same way to O2- as the conversion of 
dihydroethidine to ethidium, with ethidium production being measured by its fluorescence 
(159). 
 
 
3.2.5 Assessment of HSVEC Superoxide Production 
 
3.2.5.1 Lucigenin-Enhanced Chemiluminescence 
 
For measurement of HSVEC O2- levels by lucigenin chemiluminescence, cells were grown 
in 100 mm diameter cell culture dishes until confluent and then serum-starved overnight. 
Medium was removed and cell lysates prepared as per section 2.6.3. Serum-free medium 
was removed following overnight incubation and replaced with 5 ml KRH buffer +/- 
MitoQ10 as indicated. Cells were then incubated for 1 hour at 37ºC in a CO2–free incubator 
and lysates prepared as previously described. Total protein concentration of each sample 
was determined by Pierce BCA Protein Assay kit according to the manufacturer’s protocol 
and using the Wallac Victor2 plate reader. 
 
Lucigenin (5 µM) was added to 350 µg lysate and samples analysed immediately in a 
Hewlett Packard Tricarb 2100TR liquid scintillation counter. Readings were taken every 
10 seconds for 3 minutes and absolute counts quantified with a xanthine/xanthine oxidase 
84 
calibration curve for O2- generation. Calibration curves were prepared as per section 3.2.3 
and were in the range of 28 nM to 280 nM xanthine. Counts were reported as nmol/mg 
lysate/min. 
 
 
3.2.5.2 Electron Paramagnetic Resonance Spectroscopy 
 
Passage 3 HSVECs were grown in 100 mm diameter cell culture dishes until confluent and 
then serum-starved overnight (unless otherwise indicated) before being incubated in the 
presence or absence of test substances (Table 3.1). Concentrations and incubation times for 
test substances were as previously optimised within the laboratory or from relevant 
literature where indicated. Cells were then detached using trypsin-EDTA as described in 
section 2.4.3. Numbers of cells from each dish were determined in triplicate using a 
Beckman Coulter AcT Diff II Haematology Analyser and an average value calculated. 
HSVECs were then diluted in PBS to a concentration of 5 x 106 cells/ml and test 
substances re-added at appropriate concentrations before addition of the spin probe, CMH 
(331;332) (Noxygen, Elzach, Germany) to a final concentration of 500 µM, determined 
optimal during previous studies within the laboratory. Cell suspensions were subsequently 
assessed in triplicate for O2- release in an EPR spectrometer (e-scan R Bruker BioSpin 
GmbH, Rheinstetten Germany). Between assessments, suspensions were stored at 37ºC in 
an Eppendorf® Thermomixer Compact, shaking at 800 rpm to ensure cells did not re-pellet. 
 
10 mM stock solutions of CMH dissolved in Krebs-HEPES buffer (99 mM NaCl, 4.69 mM 
KCl, 2.5 mM CaCl2.2H2O, 1.2 mM MgSO4.7H2O, 25 mM NaHCO3, 1.03 mM KH2PO4, 
5.6 mM D(+) glucose, 20 mM HEPES, pH 7.4) containing chelating agents, deferoxamine 
(25 µM, Sigma) and Na diethyldithiocarbamate trihydrate (5 µM, Sigma) were prepared 
daily and kept on ice. Krebs-HEPES buffer was prepared using double distilled water and 
ultra pure chemicals from Sigma with concentrations of Fe and Cu <0.0005 %. Prior to 
addition of chelators, buffer was sterile-filtered using a 0.22 µm filter system.  
 
EPR spectra and kinetics were recorded from cell suspensions in 50 µl glass capillary tubes 
(Hirschmann Laborgeräte, Eberstadt, Germany) at 37ºC. Instrument settings were: centre 
field, 3375 G; modulation amplitude, 2.27 G; sweep time, 5.24 seconds; sweep width, 60 
G; and 10 scans. Oxidation of CMH by O2- results in formation of the stable nitroxide  
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Test 
Substance 
Final 
Concentration  
Incubation 
Time 
Diluent Source 
apocynin 2.5 µM 1 hour DMSO Sigma-Aldrich, 
St Louis, MO, 
U.S.A. 
DTPP 
(328) 
1 µM I hour ethanol A generous gift 
from Dr M. P. 
Murphy, MRC 
Mitochondrial 
Biology Unit, 
Cambridge, U.K. 
DPI 5 µM 1 hour DMSO Sigma-Aldrich, 
St Louis, MO, 
U.S.A. 
L-NAME 1 mM 30 minutes dH2O Sigma-Aldrich, 
St Louis, MO, 
U.S.A. 
MitoQ10 
(328) 
1 µM 1 hour ethanol A generous gift 
from Dr M. P. 
Murphy, MRC 
Mitochondrial 
Biology Unit, 
Cambridge, U.K. 
rotenone 
(228) 
0.5 µM 2 hours DMSO Sigma-Aldrich, 
St Louis, MO, 
U.S.A. 
 
 
Table 3.1. Test Substances for Electron Paramagnetic Resonance Spectroscopy Experiments. 
DTPP, decyl triphenylphosphonium (TPP) bromide; dH2O, distilled water; DMSO, dimethyl 
sulphoxide; DPI, diphenyleneiodonium chloride; L-NAME, NG-nitro-L-arginine methyl ester 
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radical, 3-methoxy-carbonyl (CM) (331). Therefore, the amount of CM formed equals the 
concentration of the reacting oxidant species. The concentration of CM was determined 
from the amplitude of the low field component of EPR spectra according to a calibration 
curve, generated using standard solutions of the 3-carboxy-proxyl (CP) radical (Noxygen). 
CP standard solutions of 1 µM, 5 µM and 10 µM were prepared from a 1 mM stock 
solution of CP dissolved in Krebs-HEPES buffer. Counts were recorded once a minute for 
10 minutes and O2- formation recorded as µmol/minute. 
 
Measurements of the background activity of PBS +/- test substances to final 
concentrations, Krebs-HEPES buffer +/- chelators, and CMH dissolved in buffer with 
chelators to 500 µM were routinely carried out prior to assessment of HSVEC O2- release. 
Signals were not usually observed for PBS +/- diluents and buffer +/- chelators but due to 
normal auto-oxidation of the probe, CMH dissolved in buffer with chelators produced a 
low-level background signal which was noted and subtracted from all sample readings 
obtained that day. 
 
 
3.2.6 HSVEC mRNA Expression 
 
RNA was extracted from HSVECs as per section 2.5 and mRNA expression levels 
assessed as outlined in section 2.7. Applied Biosystems Custom TaqMan® Gene 
Expression Assays for eNOS (NOS3, Hs00167166_m1), p22phox (CYBA, 
Hs00164370_m1), SOD1 (Hs00166575_m1), SOD2 (Hs00167309_m1) and SOD3 
(Hs00162090_m1) were used with TaqMan® Endogenous Controls, β-actin (ACTB, 
4326315E) and GAPDH (4326317E) as indicated. Reactions were carried out in singleplex 
or multiplex as indicated. 
 
 
3.2.7 Western Blot Analysis 
 
Protein was isolated from HSVECs as outlined in section 2.6.1 and protein expression 
assessed by western blotting as described in section 2.8.1. 
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3.2.7.1 Primary Antibodies 
 
Primary antibodies utilised during this study are listed in Table 3.2. 
 
 
3.2.7.2 Secondary Antibodies 
 
Secondary antibodies utilised during this study are listed in Table 3.3. 
 
 
3.2.7.3 Densitometric Quantification of Protein Bands 
 
Densitometric quantification of protein bands was carried out as outlined in section 2.8.2. 
 
 
3.2.8 Relative Quantitation of HSVEC Mitochondria by qRT-PCR 
 
3.2.8.1 DNA Extraction 
 
Total DNA was isolated from HSVECs using the QIAamp® DNA Mini Kit (QIAGEN) 
according to the manufacturer’s protocol. Passage 3 HSVECs were pelleted and 
resuspended in PBS to a final volume of 200 µl before addition of 20 µl QIAGEN Protease 
(or proteinase K). 200 µl Buffer AL was then added to samples which were subsequently 
mixed by pulse-vortexing for 15 seconds. Samples were then incubated at 56ºC for 10 
minutes before 200 µl of 100% ethanol was added and samples mixed again by pulse-
vortexing for 15 seconds. Samples were then applied to a QIAamp Mini spin column 
placed in a collection tube and centrifuged for 1 minute at 6,000 x g. Flow-through was 
discarded and columns transferred to fresh collection tubes. 500 µl Buffer AW1 was then 
added to columns and centrifugation carried out as before. Columns were again transferred 
to clean collection tubes and flow-through discarded before 500 µl Buffer AW2 was added 
and samples centrifuged at 20,000 x g for 3 minutes. To eliminate the possibility of Buffer  
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Epitope Clonality Host 
Species 
Dilution Diluent   
(w/v in  
TBS-T) 
Source 
α-p22phox 
(MW1866)     
monoclonal mouse 1:250 5% fat-free 
milk powder 
Mast, Liverpool, 
U.K. 
α-p22phox 
(FL-195) 
polyclonal rabbit 1:200 5% fat-free 
milk powder 
Santa Cruz 
Biotechnology, CA, 
U.S.A.  
(sc-20781) 
α-p22phox monoclonal mouse 1:1000 5% fat-free 
milk powder 
A generous gift from 
Prof. M. T. Quinn, 
Montana State 
University, Montana, 
U.S.A. 
α-p22phox polyclonal rabbit 1:1000 5% fat-free 
milk powder 
A generous gift from 
Dr. F. Wientjes, 
University College 
London, London, 
U.K. 
α-p22phox monoclonal mouse 1:1000 5% fat-free 
milk powder 
A generous gift from 
Prof. D.G. Harrison, 
Emory University,  
Atlanta, Georgia, 
U.S.A. 
α-SOD2 monoclonal 
(clone: 2A1) 
mouse 1:3000 5% fat-free 
milk powder 
AbCam, Cambridge, 
U.K.  
(ab16956) 
 
Table 3.2. Primary Antibodies 
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Linked 
Molecule 
Epitope Host 
Species 
Dilution Diluent       
(w/v in TBST) 
Source 
HRP α-mouse IgG  rabbit 1:2000 5% fat-free 
milk powder  
Dako-Cytomation, 
Glostrup, Denmark 
(#P0260) 
HRP α-rabbit IgG  goat 1:5000 5% fat-free 
milk powder 
Vector 
Laboratories Inc., 
Burlingame, CA, 
U.S.A  
(#PI-1000) 
 
Table 3.3 Secondary Antibodies. IgG, immunoglobulin G 
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AW2 carryover, collection tubes containing flow-through were discarded and columns 
placed in fresh tubes for centrifugation at 20,000 x g for 1 minute. QIAamp Mini spin 
columns were transferred to new collection tubes and 200 µl Buffer AE added. Samples 
were then incubated at room temperature for 1 minute before being centrifuged at 6,000 x 
g for 1 minute to elute. To increase DNA yield, the elution step was repeated using the 
original volume of Buffer AE. DNA samples were stored at -20ºC until time of analysis. 
 
 
3.2.8.2 DNA Quantification 
 
DNA concentrations were quantified using the NanoDrop® ND-100 Spectrophotometer 
and ND-1000 v3.1.0 programme. For each sample, 2 µl DNA was quantified. 
 
 
3.2.8.3 Quantitation of Single-copy Mitochondrial & Nuclear DNA 
 
Using TaqMan® probes for single copy nuclear β-haemoglobin (HBB, Hs00758889_s1) 
and mitochondrially encoded cytochrome b (MT-CYB, Hs02596867_s1) genes, abundance 
of mtDNA relative to nuclear DNA was determined by calculating Ct (cycle threshold 
value) ratios for each patient, a variation on the method of Miller and colleagues (333). 
Singleplex TaqMan® real-time RT-PCR reactions were carried out as per section 2.7.2, 
using 2 µl DNA (12.5 ng/µl) in place of cDNA.  
 
 
3.2.9 Statistical Analysis 
 
Statistical analyses were performed as outlined in section 2.9. 
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3.3 Results 
 
3.3.1 Endothelial Function 
 
Endothelium-dependent relaxation was impaired in vessels of patients with CAD compared 
to those obtained from control subjects (maximum relaxation to A23187, 43 ± 16 vs 62 ± 
16%; P=0.001; Figure 3.2A). Patients with CAD and T2D had significantly reduced 
endothelium dependent relaxation compared to those with CAD alone (maximum 
relaxation to A23187, 34 ± 11% vs 47 ± 16%; P=0.008; Figure 3.2B).  
 
 
3.3.2 Vascular Superoxide Production 
 
Vascular O2- production was greater in patients with CAD compared to control subjects 
(0.752 ± 0.482 vs 0.431 ± 0.284 nmol/mg/min; P=0.001; Figure 3.3A), as assessed by 
lucigenin chemiluminescence. Within the group of patients with CAD there was no 
difference in vascular O2- generation in patients with and without T2D (0.640 ± 0.433 vs 
0.791 ± 0.502 nmol/mg/min; P=0.226; Figure 3.3B). 
 
 
3.3.3 Isolation & Characterisation of HSVECs & HSVSMCs 
 
HSVECS and HSVSMCs were successfully isolated from both control subjects and 
patients with CAD. HSVECs showed typical cobblestone morphology and demonstrated 
positive immunofluorescent staining for the endothelial cell marker, von Willebrand factor 
(Figure 3.4A). Similarily, HSVSMCs displayed characteristic ‘hill and valley’ morphology 
and phenotype was further confirmed by positive immunofluorescence for SMC-α-actin 
(Figure 3.4B). Unfortunately, HSVSMCs demonstrated prohibitively slow growth in 
culture and, consequently, all subsequent investigation was performed in HSVECs. 
 
 
92 
 
100
90
80
70
60
50
40
30
20
CAD
M
ax
im
u
m
 
R
el
a
xa
tio
n
 
to
 
A2
31
87
 
(%
)
controls
A P = 0.001
85
75
65
55
45
35
25
15
M
a
xi
m
u
m
 
R
e
la
xa
tio
n
 
to
 
A2
31
87
 
(%
)
T2DND
B P = 0.008
M
ax
im
u
m
 
R
el
a
xa
tio
n
 
to
 
A2
31
87
 
(%
)
M
ax
im
u
m
 
R
el
a
xa
tio
n
 
to
 
A2
31
87
 
(%
)
M
a
xi
m
u
m
 
R
e
la
xa
tio
n
 
to
 
A2
31
87
 
(%
)
M
a
xi
m
u
m
 
R
e
la
xa
tio
n
 
to
 
A2
31
87
 
(%
)
 
 
Figure 3.2. Vasorelaxation in Rings of Saphenous Vein. Vessel rings were constricted with 
phenylephrine and maximum relaxation to calcium ionophore A23187 examined and expressed as 
a percentage of constriction. (A) Endothelium-dependent relaxation was significantly impaired in 
vessels from patients with CAD (n=49) compared to vessels from controls (n=10). (B) Patients with 
CAD and type 2 diabetes (T2D, n=14) had significantly reduced endothelium dependent relaxation 
compared to those with CAD alone (ND, n=35).  
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Figure 3.3. Vascular Superoxide Production. Superoxide levels in rings of saphenous vein were 
measured by lucigenin chemiluminescence. (A) Vascular lucigenin chemiluminescence was 
significantly greater in patients with CAD (n=76) compared to controls (n=19), consistent with 
elevated superoxide production in these samples. (B) Within the group of patients with CAD, there 
was no statistically significant difference in vascular lucigenin chemiluminescence between 
patients with (T2D, n=22) and without (ND, n=54) type 2 diabetes. 
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Figure 3.4 Representative Photomicrographs Showing Vascular Cells in Primary Culture. (A) 
Endothelial cells were successfully isolated from portions of human saphenous vein, as determined 
by characteristic cobblestone morphology (left-hand panel). Endothelial cell phenotype was further 
confirmed by positive staining (green) for von Willebrand Factor (middle and right-hand panels). 
(B) Successful isolation of smooth muscle cells from human saphenous vein was determined by 
observation of characteristic ‘hill and valley’ morphology in culture (left-hand panel) and positive 
staining (green) for smooth muscle cell-α-actin (middle and right-hand panels). For both cell types, 
nuclei are stained red (propidium iodide). 
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3.3.4 HSVEC Superoxide Production 
3.3.4.1 Lucigenin-Enhanced Chemiluminescence 
 
To determine whether endothelial cells isolated from vascular tissue retained the elevated 
O2- phenotype, levels of basal O2- production in cultured HSVECs were investigated. 
Lucigenin chemiluminescence was greater in HSVECs isolated from patients with CAD 
compared to control subjects (16.246 ± 1.262 vs 11.294 ± 1.024 nmol/mg/min; P=0.0382; 
Figure 3.5), consistent with elevated O2- production in these samples.  
 
 
3.3.4.2 Electron Paramagnetic Resonance Spectroscopy 
 
In order to confirm lucigenin chemiluminescence findings showing increased O2- 
production in HSVECs isolated from CAD patients, EPR spectroscopy was employed. 
Results demonstrated a trend towards elevated O2- levels in patients with CAD as 
compared to control subjects but just failed to reach statistical significance (0.371 ± 0.012 
vs 0.308 ± 0.019 µmol/min; P=0.061; Figure 3.6). On stratifying CAD patients according 
to the presence or absence of T2D, O2- levels were observed to be elevated in patients with 
T2D on comparison with control subjects (0.391 ± 0.034 vs 0.308 ± 0.019 µmol/min; 
P=0.058; Figure 3.6) and CAD patients without T2D (0.391 ± 0.034 vs 0.360 ± 0.011 
µmol/min; P=0.537; Figure 3.6). However, results did not reach statistical significance. 
 
 
3.3.5 HSVEC Superoxide Dismutase Expression 
 
Given results indicating a trend towards increased O2- production in HSVECs isolated from 
patients with CAD as compared to control subjects and in those CAD patients with T2D as 
compared to those without, it was of interest to investigate expression of the superoxide 
dismutases, SOD1, SOD2 and SOD3, in cells from all patient groups.  
 
Expression of SOD3 mRNA was undetectable in HSVECs from all patient groups. 
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Figure 3.5 HSVEC Basal Superoxide Production Measured by Lucigenin 
Chemiluminescence. Basal superoxide levels were assessed in HSVECs isolated from controls 
(n=3) and patients with CAD (n=3). Superoxide production was observed to be significantly 
elevated in HSVECs from patients with CAD as compared to controls. *, P < 0.05 
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Figure 3.6. HSVEC Basal Superoxide Production Measured by Electron Paramagnetic 
Resonance Spectroscopy. Basal superoxide levels were assessed in HSVECs isolated from 
controls (n=4) and patients with CAD (n=8). A trend towards elevated superoxide production was 
observed in HSVECs from patients with CAD as compared to controls but results failed to reach 
statistical significance. Within the group of patients with CAD, there was a trend towards increased 
basal superoxide levels in HSVECs from patients with type 2 diabetes (T2D, n=4) as compared to 
those from patients with CAD alone (ND, n=4) and control subjects but again numbers were not 
statistically significantly different. 
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As shown in Figure 3.7, no significant difference in HSVEC SOD1 mRNA expression was 
observed between patient groups, although a trend towards increased expression in CAD 
patients relative to control subjects (∆Ct, -0.818 ± 0.335 vs -0.078 ± 0.313; P=0.250) was 
noted, consistent with elevated O2- levels in cells from CAD patients. Levels of SOD1 
mRNA appeared slightly lower in HSVECs from CAD patients with T2D than in those 
with CAD alone (-0.669 ± 0.379 vs -0.846 ± 0.395; P=0.853; Figure 3.7) but, as stated, 
results failed to reach statistical significance. 
 
Expression of SOD2 mRNA in HSVECs was found to be increased by approximately 
three-fold in cells from CAD patients relative to those from control subjects (∆Ct, -5.522 ± 
0.821 vs -3.904 ± 1.224; P=0.34; Figure 3.8A). When stratified according to T2D status, 
there was a greater than two-fold increase in SOD2 expression in cells from CAD patients 
with T2D as compared to those without (∆Ct, -6.514 ± 0.815 vs -5.191 ± 1.061; P=0.338;  
Figure 3.8B) but results did not reach statistical significance. No significant increase was 
observed in CAD patients without T2D as compared to controls (∆Ct, -5.191 ± 1.061 vs -
3.905 ± 1.203; P=0.501; Figure 3.8A) but there was a significant, almost six-fold increase 
in those CAD patients with T2D (∆Ct, -6.514 ± 0.815 vs -3.922 ± 1.225; P=0.044; Figure 
3.8A).  
 
This finding was confirmed at protein level (Figure 3.8B) using mouse anti-SOD2 primary 
antibody and rabbit anti-mouse IgG-HRP secondary antibody. Densitometry revealed 
significantly increased SOD2 protein expression in cells from patients with CAD relative 
to controls (7.691 ± 0.353 vs 4.766 ± 0.211 ODU/mm2; P=0.0001; Figure 3.8C) and in 
both CAD patients with (8.380 ± 0.131 vs 4.766 ± 0.211 ODU/mm2; P=0.0002; Figure 
3.8C) and without T2D (7.232 ± 0.382 vs 4.766 ± 0.211 ODU/mm2; P=0.0008; Figure 
3.8C) relative to controls. While expression of SOD2 was observed to be greater in cells 
from CAD patients with T2D as compared to those without (8.380 ± 0.131 vs 7.232 ± 
0.382 ODU/mm2; P=0.107; Figure 3.8C), results were not statistically significant. 
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Figure 3.7. HSVEC SOD1 mRNA Expression Relative to β-actin (ACTB) as Assessed by 
TaqMan® qRT-PCR. Expression of SOD1 was investigated in HSVECs isolated from controls 
(n=6) and patients with CAD (n=23), stratified according to the absence (ND, n=17) or presence 
(T2D, n=6) of type 2 diabetes. A trend towards increased expression was observed in cells from 
CAD patients relative to those from controls but results did not reach statistical significance. 
Reactions were carried out in singleplex. RQ, relative quantitation. 
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Figure 3.8. HSVEC SOD2 mRNA and Protein Expression. (A) Using TaqMan® qRT-PCR, 
expression of SOD2 relative to β-actin (ACTB) was investigated in HSVECs isolated from controls 
(n=5) and patients with CAD (n=24). Reactions were carried out in singleplex. A trend towards 
increased expression in cells from CAD patients relative to those from controls was observed. 
SOD2 expression was greater in those patients with CAD and type 2 diabetes (T2D, n=6) than in 
those with CAD alone (ND, n=18) and expression was significantly elevated in T2D patients as 
compared to controls. *, P < 0.05 vs controls. (B) SOD2 protein expression in HSVECs isolated 
from controls (n=5) and CAD patients (n=5) with (T2D, n=2) and without (ND, n=3) type 2 
diabetes was assessed by western blotting. A representative immunoblot is shown. (C) 
Densitometry revealed significantly increased SOD2 expression in cells from the CAD patient 
population as a whole, CAD patients with ND, and CAD patients with T2D relative to controls 
with the greatest protein expression observed in HSVECs from T2D patients. ‡, †, *, P < 0.001 vs 
control. 
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3.3.6 Relative Quantitation of HSVEC Mitochondria by qRT-PCR 
 
Relative to control subjects, no differences in Ct ratios were observed in the CAD patient 
population as a whole (1.367 ± 0.062 vs 1.416 ± 0.037; P=0.500; Figure 3.9), CAD 
patients with T2D (1.367 ± 0.062 vs 1.421 ± 0.064; P=0.577; Figure 3.9) and patients with 
CAD alone (1.367 ± 0.062 vs 1.412 ± 0.052; P=0.602; Figure 3.9). In addition, Ct ratios 
were not significantly different between HSVECs from patients with and without T2D 
(1.421 ± 0.064 vs 1.412 ± 0.052; P=0.914; Figure 3.9). 
 
 
3.3.7 Characterisation of Enzymatic Sources of Superoxide Generation 
 
3.3.7.1 Mitochondria 
 
Based on SOD2 expression data (Figure 3.8), it was of interest to investigate mitochondrial 
O2- production in HSVECs. On pretreating HSVECs with rotenone, the respiratory chain 
inhibitor, a trend towards a greater reduction in O2- levels in patients with CAD as 
compared to control subjects, as assessed by EPR spectroscopy, was observed (Figure 
3.10). However, the inhibitor caused no significant reduction in basal O2- levels in cells 
from either control subjects (0.308 ± 0.019 vs 0.317 ± 0.004 µmol/min; P=0.755; Figure 
3.10) or patients with CAD (0.371 ± 0.012 vs 0.343 ± 0.010 µmol/min; P=0.0.151; Figure 
3.10). On stratifying CAD patients according to T2D status, no significant decreases in 
basal O2- levels were observed in cells from either patients with CAD and T2D (0.391 ± 
0.034 vs 0.356 ± 0.006 µmol/min; P=0.359; Figure 3.10) or those with CAD alone (0.360 
± 0.011 vs 0.336 ± 0.013 µmol/min; P=0.297; Figure 3.10). 
 
In the absence of serum, preincubating HSVECs with the mitochondria-targeted 
antioxidant, MitoQ10 caused a significant increase, rather than decrease, in basal O2- levels 
(0.400 ± 0.012 vs 0.519 ± 0.044 µmol/min; P=0.0233; Figure 3.11A), as determined by 
EPR spectroscopy. Pretreatment with decylTPP bromide (DTPP), the non-active control 
for MitoQ10 (324), had no significant effect on HSVEC basal O2- production (0.400 ± 
0.012 vs 0.442 ± 0.008 µmol/min; P=0.056; Figure 3.11A). In the presence of serum [20%  
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Figure 3.9. Comparison of HSVEC Mitochondrial Numbers by Polymerase Chain Reaction. 
DNA was extracted from HSVECs isolated from controls (n=3) and patients with CAD (n=7), 
stratified according to the presence (T2D, n=3) or absence (ND, n=4) of type 2 diabetes. Using 
TaqMan® probes for single copy nuclear β-haemoglobin (HBB) and mitochondrially encoded 
cytochrome b (MT-CYB), the abundance of mitochondrial DNA relative to nuclear DNA was 
determined by calculating Ct (cycle value threshold value) ratios for each patient. No differences in 
Ct ratio were observed, suggesting mitochondrial numbers are similar between patients, 
irrespective of disease status. 
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Figure 3.10. Effects of Mitochondrial Respiratory Chain Inhibition on HSVEC Superoxide 
Production as Assessed by Electron Paramagnetic Resonance Spectroscopy. HSVECs isolated 
from controls (n=4) and patients with CAD (n=8) were incubated with (+) and without (-) rotenone, 
an inhibitor of the mitochondrial respiratory chain. CAD patients were stratified according to the 
presence (T2D, n=4) or absence (ND, n=4) of type 2 diabetes. On preincubation with rotenone, a 
greater decrease in O2- production in cells from CAD patients as compared to controls was 
observed, with the slightly larger reduction in CAD patients with T2D. However, results failed to 
reach statistical significance. 
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Figure 3.11. Effects of a Mitochondria-Targeted Antioxidant on HSVEC Superoxide 
Production as Assessed by Electron Paramagnetic Resonance Spectroscopy. HSVECs isolated 
from patients with CAD (n=3) were incubated with (+) and without (-) the mitochondria-targeted 
antioxidant, MitoQ10 (MQ10), and the non-active control compound, decylTPP bromide (DTPP). 
(A) In the absence of serum, preincubation with MitoQ10 resulted in a significant increase in 
cellular O2- levels, not observed on pretreatment with DTPP. *, P < 0.05. (B) In the presence of 
serum, neither MitoQ10 nor DTPP had a significant effect on HSVEC O2- levels.  
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(v/v)], preincubation with neither MitoQ10 (0.430 ± 0.023 vs 0.441 ± 0.032 µmol/min; 
P=0.800; Figure 3.11B ) nor DTPP (0.430 ± 0.023 vs 0.468 ± 0.025 µmol/min; P=0.496; 
Figure 3.11B) had a significant effect on cellular O2- levels. 
 
 
3.3.7.2 Endothelial Nitric Oxide Synthase 
 
With results revealing impaired endothelium-dependent relaxation in vessels from patients 
with CAD (Figure 3.2) and elevated O2- production in both vessels and HSVECs from 
these patients (Figures 3.3, 3.5 and 3.6), the contribution of uncoupled eNOS to O2- 
generation in HSVECs from CAD patients was investigated.  
 
Expression studies revealed no difference in NOS3 mRNA levels between patient groups 
(Figure 3.12A), consistent with modulation of enzyme activity via post-translational 
phosphorylation. Relative to control subjects, no differences in expression were observed 
in the CAD patient population as a whole (∆Ct, -6.090 ± 0.482 vs -6.211 ± 0.279; 
P=0.841; Figure 3.12A), CAD patients with T2D (∆Ct, -6.090 ± 0.482 vs -6.447 ± 0.533; 
P=0.630; Figure 3.12A) and patients with CAD alone (∆Ct, -6.090 ± 0.482 vs -6.128 ± 
0.335; P=0.952; Figure 3.12A). In addition, NOS3 expression was not significantly 
different between HSVECs from patients with and without T2D (∆Ct, -6.447 ± 0.533 vs -
6.128 ± 0.335; P=0.627; Figure 3.12A). As shown in Figure 4.7, no difference in eNOS 
protein expression or eNOS Ser1177 phosphorylation was observed between HSVEC 
lysates from patients with CAD and T2D and those with CAD alone. 
 
Preincubating HSVECs with the eNOS inhibitor, L-NAME resulted in a non-significant, 
approximately equal, 20% increase in O2- production for all patient groups (Figure 3.12B), 
as assessed by EPR spectroscopy.  
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Figure 3.12. eNOS mRNA Expression & Contribution to Superoxide Production in HSVECs. 
(A) Using TaqMan® qRT-PCR, expression of NOS3 relative to β-actin (ACTB) was investigated in 
HSVECs isolated from controls (n=6) and patients with CAD (n=23), stratified according to the 
presence (T2D, n=6) or absence (ND, n=17) of type 2 diabetes. Reactions were carried out in 
multiplex. No difference in expression was observed between patient groups. (B) HSVECs isolated 
from controls (n=4) and patients with CAD (n=8) were incubated with (+) and without (-) L-
NAME. CAD patients were again stratified according to the presence (T2D, n=4) or absence (ND, 
n=4) of type 2 diabetes. Incubation with L-NAME resulted in a non-significant, approximately 20% 
increase in O2- for all patient groups, as assessed by EPR. 
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3.3.7.3 NAD(P)H Oxidase 
 
In order to establish the contribution of NAD(P)H oxidase to O2- production in the 
endothelium of patients with CAD, mRNA expression of CYBA, encoding the enzyme’s 
p22phox subunit, was investigated in HSVECs. Results demonstrated no significant 
difference in CYBA mRNA expression between patient groups (Figure 3.13A) although a 
trend towards increased expression in CAD patients with T2D relative to both control 
subjects (∆Ct ,4.465 ± 0.384 vs 4.889 ± 0.287; P=0.387; Figure 3.13A) and CAD patients 
without T2D (∆Ct ,4.465 ± 0.384 vs 4.791 ± 0.266; P=0.524; Figure 3.13A) was observed.  
 
Attempts to confirm these findings at protein level proved unsuccessful, with failure to 
observe bands of the correct size on photographic film despite the use of 5 different anti-
p22phox primary antibodies (Table 3.2) and varying incubation and exposure times. 
 
However, on pretreating HSVECs with the NAD(P)H oxidase inhibitor, DPI, a statistically 
significant reduction in basal O2- production, as measured by EPR spectroscopy, was 
observed in cells from CAD patients (0.371 ± 0.012 vs 0.270 ± 0.024 µmol/min; P=0.021; 
Figure 3.13B) but not in those from control subjects (0.308 ± 0.019 vs 0.300 ± 0.020 
µmol/min; P=0.803; Figure 3.13B). Similarly, incubation with apocynin resulted in an 
approximate 12% reduction in basal O2- levels in HSVECs from patients with CAD (0.371 
± 0.012 vs 0.326 ± 0.032 µmol/min; P=0.263; Figure 3.13B) while only an approximately 
3% reduction was observed in cells from control subjects (0.308 ± 0.019 vs 0.298 ± 0.024 
µmol/min; P=0.774; Figure 3.13B). 
 
On stratifying patients according to the presence of T2D, incubation with DPI caused a 
significant, approximate 32% decrease in basal O2- production in HSVECs from patients 
with CAD alone (0.360 ± 0.011 vs 0.246 ± 0.035 µmol/min; P=0.010; Figure 3.13B) and 
an approximate 18% decrease in cells from patients with CAD and T2D (0.391 ± 0.034 vs 
0.319 ± 0.034 µmol/min; P=0.113; Figure 3.13B). Pretreatment with apocynin resulted in 
an approximate 16% reduction in basal O2- levels in CAD patients without T2D (0.360 ± 
0.011 vs 0.302 ± 0.001 µmol/min; P=0.257; Figure 3.13B) but only an approximately 4% 
decrease in those patients with CAD and T2D (0.391 ± 0.034 vs 0.375 ± 0.012 µmol/min; 
P=0.753; Figure 3.13B). 
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Figure 3.13. p22phox mRNA Expression and NAD(P)H Oxidase Contribution to Superoxide 
Production in HSVECs. (A) Using TaqMan® qRT-PCR, expression of CYBA relative to β-actin 
(ACTB) was investigated in HSVECs isolated from controls (n=7) and patients with CAD (n=23), 
stratified according to the presence (T2D, n=6) or absence (ND, n=17) of type 2 diabetes. 
Reactions were carried out in singleplex. No difference in expression was observed between patient 
groups. (B) HSVECs isolated from controls (n=4) and patients with CAD (n=8) were incubated 
with (+) and without (-) diphenylene iodonium (DPI) and apocynin (apo) and O2- production 
investigated using EPR. CAD patients were again stratified according to the presence (T2D, n=4) 
or absence (ND, n=4) of type 2 diabetes. Preincubation with both inhibitors caused a greater 
decrease in O2- production in cells from CAD patients as compared to controls, with the larger 
reduction in ND patients. Pretreatment with DPI caused a greater reduction in O2- levels than 
pretreatment with apocynin for all patients groups. †, P < 0.05 vs untreated (-) cells from CAD 
patients. *, P < 0.05 vs untreated (-) cells from ND patients. 
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3.4 Discussion 
 
This study involved comparison of endothelial function and O2- production in human 
saphenous veins. Previous studies have demonstrated human arterial and venous basal O2- 
generation are closely related (318;334), such that results were not affected by the choice 
of vessel. For practical reasons, molecular studies focused on primary endothelial cells 
isolated from human saphenous veins. However, it is recognised that VSMCs, fibroblasts 
and other components of the adventitia play important roles in vascular function and 
pathogenesis. 
 
As stated, endothelial dysfunction occurs in conjunction with CAD (208). Previous 
investigations within the group have demonstrated endothelial dysfunction in saphenous 
veins from patients with CAD (159) and results obtained during the course of this project 
have confirmed these findings (Figure 3.2A). Risk factors for CVD are almost universally 
associated with a degree of endothelial dysfunction in humans (87) and indeed, abnormal 
vascular endothelial function is a prominent feature of T2D (100;162). As shown in Figure 
3.2B, a significantly greater depression of relaxation to calcium ionophore was observed in 
saphenous veins from patients with CAD and T2D as compared to those from patients with 
CAD alone, confirming poorer endothelial function in individuals with this additional 
CVD risk factor. 
 
Increased vascular oxidative stress has been proposed as one potential mechanism 
underlying impaired endothelial function in patients with CAD and T2D (179). 
Investigations carried out within this laboratory have revealed endothelial dysfunction in 
saphenous veins from CAD patients to be associated with elevated O2- levels throughout 
the vessel wall (159), but did not consider the effect of T2D on this O2- production. 
However, a study by Guzik et al. has previously demonstrated significantly elevated basal 
O2- release in saphenous veins from patients with CAD and T2D relative to those with 
CAD alone (179). The present study served to confirm that O2- generation is increased in 
vessels from CAD patients as compared to control subjects (Figure 3.3A). However, on 
comparison of O2- levels in vessels from CAD patients with and without T2D, no 
statistically significant increase in O2- production in patients with T2D was observed 
(Figure 3.3B). Conversely, a trend towards reduced vascular O2- production was evident 
(Figure 3.3B). This phenomenon is likely the result of more aggressive primary and 
secondary prevention strategies in this vulnerable group of patients (335). Indeed, as 
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shown in Table 2.1, a higher percentage of study participants with CAD and T2D (78%) 
were found to have been prescribed ACE inhibitors/ARBs than those with CAD alone 
(57%). Furthermore, on comparison with T2D patients recruited by Guzik and colleagues 
(179), participants in the present study were subject to more intensive treatment. 
 
To investigate the molecular basis for the increased O2- production and impaired 
endothelium-dependent relaxation in vessels from patients with CAD, endothelial cells 
were isolated from vascular tissue (Figure 3.4A). As isolated cells were maintained in 
culture for several weeks prior to investigation of O2- production, it seemed likely that the 
effects of pharmacological treatments would be lost, allowing more accurate insight into 
endothelial O2- production, particularly in vessels from patients with CAD and T2D. 
However, an obvious limitation of studying cultured primary endothelial cells is that there 
is currently no clear evidence to suggest these cells, free from physiological stresses, retain 
the in vivo phenotype.  
 
Using lucigenin chemiluminescence, O2- levels were measured and found to be 
significantly elevated in HSVECs from patients with CAD relative to control subjects 
(Figures 3.5), appearing to support results obtained using intact vessel sections and 
implicating excess O2- production in attenuation of endothelium-dependent relaxation in 
CAD patients. However, n values were low (n=3) for these experiments and results 
interpreted with caution.  
 
On increasing patient numbers and assessing O2- production using EPR spectroscopy, a 
more sensitive technique, a trend towards increased O2- generation was observed in cells 
isolated from patients with CAD (Figure 3.6) but numbers failed to reach statistical 
significance, raising the possibility that in culture the in vivo phenotype of these cells is not 
preserved.  
 
The cell permeable spin probe, CMH (332) was used in conjunction with EPR 
spectroscopy to investigate O2- production. CMH detects both extra- and intracellular O2- 
(331;332;336) but does not directly react with H2O2 (331;337;338). As described, the 
superoxide dismutases catalyse the conversion of O2- to H2O2 and molecular oxygen 
(188;233;234) and increased SOD2 mRNA and protein expression was observed in 
HSVECs from patients with CAD (Figure 3.8). These findings provide an alternative 
explanation for the lack of a significant increase in O2- generation in cells from patients 
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with CAD and suggest it may be useful to investigate and compare cellular H2O2 levels in 
the future. 
 
Despite initial findings of EPR spectroscopy, CAD patients were stratified according to 
T2D status and O2- production again measured using EPR. Here, a trend towards increased 
O2- production in patients with T2D was observed (Figure 3.6), linking elevated O2- 
production in cells of the endothelium to endothelial dysfunction and indicating reduced 
O2- levels found in intact vessels could indeed be the result of enhanced pharmacological 
intervention within this patient group. 
 
With results demonstrating a trend towards increased O2- production in HSVECs isolated 
from patients with CAD as compared to control subjects and in those CAD patients with 
T2D as compared to those without, expression of the superoxide dismutases, SOD1, SOD3 
and, as previously mentioned, SOD2, was investigated in cells from all patient groups.  
 
Expression of SOD3 mRNA was found to be undetectable in cells from both control 
subjects and patients with CAD. This may be due to the fact that unlike SOD1 and SOD2, 
expressed throughout the vessel wall, SOD3 is largely expressed in VSMCs (339). Indeed, 
studies have shown SOD3 expression to be lacking in human cultured endothelial cell lines 
(340;341). 
 
SOD1 is thought to be the predominant SOD isoform in the endothelium (167). 
Consequently, given the significantly elevated O2- levels observed in vessels from CAD 
patients, a significant difference in SOD1 expression may have been expected between 
patient groups. However, while a trend towards increased SOD1 mRNA expression was 
observed in cells from patients with CAD relative to control subjects (Figure 3.7), 
consistent with an adaptive response to elevated O2- production, results did not reach 
statistical significance, nor was there a significant difference in expression between CAD 
patients with and without T2D (Figure 3.7). These findings were not surprising given 
results obtained on assessment of cellular O2- production by EPR spectroscopy (Figure 
3.6). In addition, there is evidence to suggest SOD1 expression is increased in the initial 
stages of atherosclerosis but decreases as the condition progresses (342) and, as outlined, 
HSVECs were isolated from vessels of patients with advanced CAD. Furthermore, SOD1 
expression is known to be upregulated in response to shear stress (343), again raising the 
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question of whether cultured cells retain the in vivo phenotype and indicating it may be 
prudent to examine SOD1 mRNA expression in vascular tissue homogenates.  
 
Another possible explanation for cellular SOD1 expression data may centre on the 
increased expression of SOD2 mRNA and protein in HSVECs isolated from vessels of 
patients with CAD (Figure 3.8), an increase clearly demonstrated as not being due to 
differences in number of mitochondria, as determined by abundance of mtDNA (MT-CYB) 
relative to nuclear DNA (HBB) (Figure 3.9). Induction of SOD2 mRNA expression is 
known to occur in response to oxidative stress (344), suggesting the increase represents an 
adaptive response to elevated mitochondrial O2- production in HSVECs from CAD 
patients, in particular those patients with T2D. Mitochondria may therefore be a principal 
source of excess O2- production in the endothelium of patients with CAD and T2D. 
 
In order to investigate the contribution of mitochondria to endothelial O2- production in 
patients with CAD, cells were treated with rotenone, the respiratory chain inhibitor. As 
shown in Figure 3.10, a trend towards a greater reduction in cellular O2- levels was 
observed in CAD patients relative to control subjects and in patients with CAD and T2D 
relative to those with CAD alone. However, reductions in O2- generation were not 
significant as may have been expected given SOD2 mRNA and protein expression data 
(Figure 3.8). Interestingly, O’Malley and colleagues (325) demonstrated rotenone 
markedly decreased ROS production in bovine aortic endothelial cell (BAEC) 
mitochondria as detected by fluorescence but had no effect on O2- production as assessed 
by EPR spectroscopy, while Guzik and colleagues (179) showed rotenone had only a 
minimal effect on O2- production in saphenous veins from CAD patients. In addition, as 
previously mentioned, rotenone is not a specific mitochondrial antioxidant (320) and, as 
such, cells were subsequently treated with MitoQ10.  
 
Preincubating cells from CAD patients with MitoQ10 caused a significant increase, rather 
than the anticipitated decrease, in O2- levels (Figure 3.11A). This increase was not evident 
on preincubation of cells with the non-active control for MitoQ10, DTPP (Figure 3.11A), 
which comprises the lipophilic TTP cation but lacks the ubiquinone moiety of the 
antioxidant (324). Despite suggestion that MitoQ10 acts to reduce mtROS production 
(326;345-347), like all quinones, it can redox cycle to produce O2-, thus acting as a 
prooxidant  (325;348;349). Indeed, MitoQ10 has been shown to enhance both mitochondrial 
and cellular ROS production in intact endothelial cells (348;350). Serum-free conditions 
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are known to greatly exacerbate MitoQ10 redox cycling [(324) and personal 
communication with Dr Michael Murphy, MRC Mitochondrial Biology Unit, Cambridge, 
U.K.) and, as shown in Figure 3.11, this was confirmed to be the case in HSVECs isolated 
from patients with CAD. In the presence of serum, pretreatment with MitoQ10 had no 
significant effect on HSVEC O2- levels (Figure 3.11B). This result may be explained, at 
least in part, by data indicating MitoQ10 reacts poorly with O2- per se (351), exerting its 
antioxidant effect by reacting with products of lipid peroxidation (326;351;352). 
 
With experiments involving rotenone and MitoQ10 failing to provide conclusive results, it 
would have been of interest to examine mitochondrial O2- production further in isolated 
mitochondria by means of EPR spectroscopy (325) or in intact cells using methods such as 
aconitase inactivation (353) and/or oxidation of the mitochondrially targeted hydroethidine 
derivative, MitoSOX™ (Invitrogen) (354;355). Unfortunately, limited vascular material 
and time constraints meant such investigations were not possible. 
 
As outlined, in addition to mitochondria, uncoupled eNOS is a principal source of O2- 
production in the endothelium (173). With vessels from CAD patients, particularly those 
with T2D, displaying attenuated endothelium-dependent relaxation, HSVEC eNOS mRNA 
expression, phosphorylation and contribution to elevated O2- production were investigated 
in CAD patients.  
 
It has been suggested that endothelial dysfunction could be due to decreased eNOS 
expression (170). However, several studies have shown that CVD risk factors are 
associated with an increase, rather than a decrease, in eNOS expression (356). Increased 
expression of eNOS in vascular tissue is thought to be a consequence of an excess 
production of H2O2 which can increase eNOS mRNA expression through transcriptional 
and posttranscriptional mechanisms (357). No significant difference in HSVEC NOS3 
expression was observed between patient groups (Figure 3.12A), perhaps surprising given 
elevated levels of SOD2 expression (Figure 3.8), associated with increased H2O2 
production (358), in cells from CAD patients. A number of drugs with favourable effects 
on CAD phenotype, including ACE inhibitors, ARBs and statins, also upregulate eNOS 
mRNA expression (356). With a high percentage of this study cohort prescribed such 
medications (Table 2.1), HSVEC NOS3 expression data may serve to support the 
hypothesis that effects of pharmacological treatments are not maintained during the cell 
culture process. Additional findings showed eNOS protein expression and levels of eNOS 
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Ser1177 phosphorylation to be similar in HSVEC lysates from patients with CAD and T2D 
and those with CAD alone (Figure 4.7), suggesting no difference in eNOS activity between 
these patient groups.  
 
Despite the apparent lack of change in HSVEC eNOS expression and activity between 
patient groups, poorer endothelial function in vessels from CAD patients indicates eNOS 
may be uncoupled, producing O2- rather than NO. Indeed, previous work within our group 
demonstrated significantly reduced O2- production in saphenous veins of CAD patients on 
pretreatment with the eNOS inhibitor, L-NAME (302). Dysfunctional eNOS has also been 
identified as a source of O2- production in vessels from patients with CAD and T2D (179). 
However, on preincubating HSVECs with L-NAME, cells from both control subjects and 
CAD patients demonstrated elevated O2- production (Figure 3.12B). Numbers failed to 
reach statistical significance, making it difficult to draw a clear conclusion from these 
findings, but it is possible that in cultured HSVECs, eNOS is not a major source of O2-. 
HSVEC eNOS may instead reduce vascular O2- release through production of NO, such 
that inhibiting NO production causes an increase in O2- levels. This has previously been 
shown to be the case in vessels from CAD patients denuded of endothelium (179). 
Alternatively, the possibility must be considered that free from physiological stresses, 
cultured HSVECs do not retain the in vivo phenotype. In the future, investigation of 
cellular NO and ONOO- production may provide additional insight into HSVEC eNOS 
activity. 
 
NAD(P)H oxidase has been shown to be a major source of O2- in intact vessels from 
patients with CAD (208), in particular those CAD patients with T2D (179). The p22phox 
membrane-bound NAD(P)H oxidase subunit has been identified as crucial for enzymatic 
function (199) and p22phox expression is significantly increased in coronary arteries from 
patients with CAD relative to those from control subjects (208), and in vessels from CAD 
patients with T2D as compared to those from patients with CAD alone (179). To date, 
similar comparisons have not been carried out in primary human vascular endothelial cells. 
This study found no significant difference in HSVEC p22phox mRNA expression between 
patient groups (Figure 3.13A), indicating the increased expression previously observed by 
Guzik and colleagues (208) may be specific to arteries or non-endothelial cells of the 
vasculature.  
 
115 
Attempts to confirm p22phox expression data at the protein level proved unsuccessful 
despite using a number of anti-p22phox primary antibodies under a variety of conditions. As 
described, cellular extracts were used for immunoblotting. Given p22phox is a membrane-
bound protein, it may have been useful to perform western blotting of cellular membrane 
preparations. Of note, previous studies have successfully investigated p22phox protein 
expression in vascular homogenates (179;208) and mononuclear cells (210). However, 
such investigations have not previously been performed in primary human vascular 
endothelial cells. As a result, with no change in p22phox mRNA expression observed, it was 
necessary to assume a change in protein expression between patient groups would have 
been unlikely.  
 
In contrast to p22phox expression studies, inhibition of endothelial NAD(P)H oxidase 
indicated enzyme activity is altered in individuals with CAD (Figure 3.13B). DPI and 
apocynin, inhibitors of NAD(P)H oxidase, have been shown to significantly reduce O2- 
production in intact portions of saphenous veins from CAD patients (159;302;318). 
Pretreating HSVECs with these inhibitors caused a greater reduction in O2- production in 
CAD patients than in control subjects (Figure 3.13B). As expected, the greater of these 
reductions was on preincubation with the less specific of the two inhibitors, DPI, which 
caused a significant decrease in CAD patients. In addition to NAD(P)H oxidase, DPI 
inhibits nitric oxide synthases (359), xanthine oxidase (360), mitochondrial complex I 
(361) and cytochrome P-450 reductase (362). An attempt to address this lack of specificity 
was made by performing additional experiments involving apocynin which blocks 
assembly of the NAD(P)H oxidase complex (159). Although not statistically significant, 
the differential reduction in O2- levels achieved by the two inhibitors implicates the 
aforementioned flavoproteins in endothelial O2- generation in CAD. However, it has been 
suggested that apocynin could itself lack selectivity and may require to be metabolised by a 
peroxidase enzyme in order to become active (363).  
 
Interestingly, both DPI and apocynin were observed to cause a greater decrease in cellular 
O2- production in patients with CAD alone (Figure 3.13B), suggesting NAD(P)H oxidase 
may contribute to O2- production to a lesser extent in T2D patients. This finding would 
support the earlier hypothesis that mitochondria are a major source of O2- generation in the 
endothelium of patients with CAD and T2D. 
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While the contribution of xanthine oxidase to O2- generation in HSVECs was not 
considered during the course of this project, it is recognised that the enzyme has been 
identified as a key source of ROS production in both coronary arteries (208) and saphenous 
veins (159;302) from patients with CAD. In light of these published data and results 
obtained on treating cells with DPI and apocynin, investigation of xanthine oxidase activity 
and expression may represent a focus of future studies. 
 
In summary, the findings presented in this chapter demonstrate elevated O2- levels and 
endothelial dysfunction in saphenous veins from patients with CAD, with poorer 
endothelial function in those CAD patients with the additional CVD risk factor, T2D. 
Results show increased levels of SOD2 expression in HSVECs from CAD patients, 
suggesting mitochondria may be a principal source of O2- production in the endothelium of 
these patients, in particular those with T2D. Findings also suggest that while HSVEC 
eNOS is not a major source of O2- generation in CAD, NAD(P)H oxidase contributes to 
excess O2- production in the endothelium of patients with this condition. Taken together, 
results support the idea that inhibition of vascular NAD(P)H oxidase represents a means of 
reducing vascular oxidative stress and progression of cardiovascular disease (364;365) and 
suggest that mitochondrially-targeted antioxidants, such as MitoQ10, may have therapeutic 
potential in patients with CAD and T2D. 
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4. Endothelial AMP-activated Protein Kinase 
Activity in Coronary Artery Disease 
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4.1 Introduction 
 
Vascular endothelial cells are recognised as being highly glycolytic (228;366). Quintero 
and colleagues confirmed this to be the case in HUVECs, leading them to propose that 
mitochondria in these cells are not preferentially used for bioenergetic purposes but 
function primarily in the generation of ROS which act as signalling molecules, facilitating 
activation of enzymes such as AMPK (228). AMPK is now recognised as a potential target 
for therapeutic intervention in hyperglycaemia-induced endothelial dysfunction (section 
1.5.1). Following the results outlined in Chapter 3, showing that there is increased 
expression of SOD2 in HSVECs isolated from patients with CAD and T2D, consistent 
with increased mtROS production, one objective of this project was to investigate the 
activity and activation of AMPK in the endothelium of patients with T2D.   
 
As outlined in section 1.5, AMPK is a widely conserved serine/threonine protein kinase 
involved in the regulation of cellular and whole body energy status and has a 
heterotrimeric structure, comprising a catalytic α-subunit (α1 or α2) and regulatory β- (β1, 
β2) and γ-subunits (γ1, γ2, γ3) each of which has two or more isoforms that are 
differentially expressed in various tissues (248). Both α1 and α2 catalytic subunits, 
encoded by PRKAA1 and PRKAA2 respectively, are expressed in liver, cardiomyocytes 
and skeletal muscle (367). However, the α1 subunit has been identified as the predominant 
form in endothelial cells (286;297).  
 
Activation of AMPK requires phosphorylation at Thr172 by an AMPKK. Two major 
AMPKKs have been identified to date, LKB1 and CaMKK (251;253;264). It has been 
proposed that LKB1 activity is constitutive, such that stimuli that increase the AMP/ATP 
ratio, including hypoxia, hypoglycaemia and ischemia, inhibit dephosphorylation at 
Thr172 permitting phosphorylation and activation by LKB1 (248). In contrast, activation 
of AMPK by Ca2+ is AMP-independent and mediated by the α and/or β isoforms of 
CaMKK (264;265). Very recently, a third upstream kinase, transforming growth factor-1β-
activated kinase, or TAK1, has been identified in yeast (368) and appears to be important 
in cardiac cells (369) but its role in other cell types is still largely undefined. Recent studies 
have also revealed activation of AMPK via an AMP-independent, ROS-mediated 
mechanism with NO (370), H2O2 (296) and ONOO- (289) all observed to activate the 
kinase in cultured cells.  
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There are numerous downstream targets of AMPK, including ACC and eNOS. Human 
ACC1 and ACC2 are phosphorylated and inhibited at Ser80 and Ser220 respectively by 
AMPK (287) while the kinase phosphorylates and activates eNOS at Ser1177 as previously 
described (176;282) (section 1.5.2). 
 
 
 
The aims of the experimental work outlined in this chapter were as follows: 
 
(1) to determine whether HSVECs, like HUVECs, favour glycolysis over oxidative 
phosphorylation; 
(2) to compare AMPK activity in HSVECs isolated from patients with CAD alone and 
with CAD and T2D; 
(3) to investigate upstream mediators of AMPK activation in HSVECs, including 
mtROS 
 
 
 
4.2 Materials & Methods  
 
4.2.1 Study Participants 
 
Patients with CAD were as described in section 2.2. 
 
 
4.2.2 Human Vascular Tissue & Primary Cell Culture 
 
Vascular tissue was obtained and prepared as described in section 2.3 and HSVECs 
isolated, characterised and cultured as outlined in section 2.4. For experimental procedures 
carried out in Professor Moncada’s laboratory (Wolfson Institute For Biomedical 
Research, University College London), HSVECs were cultured in endothelial cell growth 
medium, EGM 2 (PromoCell, Heidelberg, Germany), supplemented with 2% (v/v) FCS. 
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For all experiments, cells were used between passages 3 and 5 and procedures carried out 
when cells were approximately 80% confluent. 
 
 
4.2.3 Determination of ATP Production in HSVECs 
 
Determination of the contribution of oxidative phosphorylation and glycolysis to the 
generation of ATP in HSVECs was carried out in Professor Moncada’s laboratory, using 
the method of Quintero and colleagues (228). HSVECs were grown for 24 hours in 96-well 
plates [PerkinElmer (Waltham, MA) 3603 clear bottom, black walls, seeding density 
10,000 cells per well] in phenol-red free ECM2 supplemented with 2% (v/v) FCS. On the 
day of the experiment, fresh medium was added and cells pretreated with 20 mM 2-deoxy-
D-glucose (2DG) and 0.5 µM rotenone (both Sigma-Aldrich Company Ltd). 2DG is a 
glycolytic pathway inhibitor and rotenone, as stated, is an inhibitor of the mitochondrial 
respiratory chain (228). ATP was measured by the luciferin/luciferase method with the 
PerkinElmer ATPlite™ Luminescence Assay System, following the manufacturer’s 
protocol. Chemiluminescence was determined in a TopCount (Packard Biosciences) and 
data analysed in Excel (Microsoft).  
 
 
4.2.4 Western Blot Analysis 
 
Cell lysates were prepared as outlined in section 2.6.3 unless experiments involved 
treatment of cells with AICAR, the artificial activator of AMPK. For these experiments, 
serum-free medium was removed following overnight incubation and replaced with 5 ml 
KRH buffer +/- 2 mM AICAR (Sigma). Cells were then incubated for 1 hour at 37ºC in a 
CO2–free incubator and lysates prepared as previously described. Total protein 
concentration of each sample was determined by Pierce BCA Protein Assay according to 
the manufacturer’s protocol and using the Wallac Victor2 plate reader. Western blots were 
then carried out as outlined in sections 2.8.1 unless otherwise indicated. 
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4.2.4.1 Primary Antibodies 
 
Primary antibodies utilised during this study are listed in Table 4.1.   
 
 
4.2.4.2 Secondary Antibodies 
 
Secondary antibodies utilised during this study are listed in Table 4.2. 
 
 
4.2.4.3 AMPK Thr172 Phosphorylation at Different Oxygen Concentrations 
 
Western blots to assess AMPK Thr172 phosphorylation at different O2 concentrations were 
carried out in Professor Moncada’s laboratory, using the method of Quintero and 
colleagues (228). On the day of the experiment, fresh medium was added and hypoxia 
achieved by incubating cells at 37ºC in an O2-controlled hypoxic chamber (Coy Laboratory 
Products, Ann Arbor, MI) for 2 hours. Cells were washed with PBS, scraped off in ice-cold 
PhosphoSafe™ Extraction Buffer (Novagen, Nottingham, U.K.) and centrifuged for 10 
minutes at 13,000 x g (4ºC). From clear supernatants, protein concentration was 
determined using the Bio-Rad DC Protein Assay kit (Bio-Rad, Herts, U.K.) using bovine 
serum albumin (BSA) as control. Sample aliquots were boiled for 2 minutes, and 20 µg of 
total protein with equal volumes of reducing loading dye electrophoresed in precast 
SDS/PAGE 4-15% gradient gels (Bio-Rad). Full Range Rainbow Molecular Weight 
Markers were included on blots. Proteins were transferred onto Hybond-P nitrocellulose 
membranes overnight at 25 volts in transfer buffer and assessed for equal loading / 
transference by Ponceau S Solution (Sigma-Aldrich) staining. Membranes were then 
blocked (with shaking) in TBS-T + 5% (w/v) fat-free milk powder for approximately 45 
minutes before a five hour incubation at 4ºC (with shaking) in a rabbit anti-phospho-
AMPK-α1-Thr-172 primary antibody solution, followed by a 45 minute incubation with 
HRP-conjugated goat anti-rabbit IgG. ECL (GE Healthcare) was used for detection. Films 
were exposed for between 30 seconds and 5 minutes and developed in a Kodak X-OMAT 
1000. 
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Epitope Clonality Host 
Species 
Dilution Diluent   
(w/v in  
TBS-T) 
Source 
α-ACC1     
N-term  
(cDEP)   
polyclonal sheep 1:1000 5% fat-free 
milk powder 
A generous gift from 
Prof. D.G. Hardie, 
University of 
Dundee, Dundee, 
U.K. 
 
CDEPSPLAKTLEL
NQ (C + residues 2-
15 of rat ACC) 
coupled to KLH 
α-ACC Ser79  polyclonal rabbit 1:1000 5% BSA Cell Signalling 
Technology, Beverly, 
MA, U.S.A.     
(#3661) 
α-AMPKα1 polyclonal sheep 1:1000 5% fat-free 
milk powder 
A generous gift from 
Prof. D.G. Hardie 
(371) 
α-AMPKα2 polyclonal sheep 1:1000 5% fat-free 
milk powder 
A generous gift from 
Prof. D.G. Hardie 
(371) 
α-AMPKα1 
Thr172  
polyclonal rabbit 1:1000 5% BSA Cell Signalling 
Technology, Beverly, 
MA, U.S.A.     
(#2531) 
α-CaMKKα  monoclonal 
(clone: F-2) 
mouse 1:200 5% fat-free 
milk powder 
Santa Cruz 
Biotechnology, CA, 
U.S.A.                   
(sc-17827) 
α-eNOS polyclonal 
 
rabbit  1:5000  1% BSA Sigma-Aldrich, St 
Louis, MO, U.S.A. 
N2643 
α-eNOS 
Ser1177  
 
polyclonal rabbit 1:1000 5% BSA Cell Signalling 
Technology, Beverly, 
MA, U.S.A.    
(#9571) 
 
Table 4.1. Primary Antibodies – continued overleaf 
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α-LKB1 polyclonal sheep 1:500 5% fat-free 
milk powder 
A generous gift from 
Prof. D.G. Hardie  
LKB1 antibody was 
raised against the 
whole protein in 
sheep and purified 
using protein G. 
 
Table 4.1. Primary Antibodies. BSA, bovine serum albumin; KLH, keyhole limpet haemocyanin 
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Linked 
Molecule 
Epitope Host 
Species 
Dilution Diluent       
(w/v in TBST) 
Source 
HRP α-mouse IgG  sheep 1:1000 5% fat-free 
milk powder or 
BSA 
GE Healthcare 
U.K. Ltd, Bucks, 
U.K.  
(#NA 931) 
 
HRP α-rabbit IgG  goat 1:5000 5% fat-free 
milk powder 
Vector 
Laboratories Inc., 
Burlingame, CA, 
U.S.A. 
(#PI-1000) 
HRP α-rabbit IgG  donkey 1:1000 5% fat-free 
milk powder or 
BSA 
GE Healthcare 
U.K. Ltd, Bucks, 
U.K. 
(#NA 934) 
 
HRP protein 
G−peroxidase 
from 
streptococcus sp.  
n/a 1:1000 5% fat-free 
milk powder or 
BSA 
Sigma-Aldrich, St 
Louis, MO, U.S.A. 
(#P8170) 
 
Table 4.2. Secondary Antibodies. BSA, bovine serum albumin; IgG, immunoglobulin G; n/a, not 
applicable 
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4.2.4.4 Densitometric Quantification of Protein Bands 
 
Densitometric quantification of protein bands, relative to an internal invariant control was 
carried out as outlined in section 2.8.2.  
 
 
4.2.5 PRKAA1 & PRKAA2 mRNA Expression 
 
RNA was extracted from HSVECs as per section 2.5 and PRKAA1 and PRKAA2 mRNA 
expression levels assessed as outlined in section 2.7 using Applied Biosystems Custom 
TaqMan® Gene Expression Assays for PRKAA1 (Hs01562315_m1) and PRKAA2 
(Hs00178903_m1) and TaqMan® Endogenous Control, GAPDH (4326317E). Reactions 
were carried out in singleplex. 
 
 
4.2.6 AMPK Activity Assay 
 
AMPK was immunoprecipitated from lysates and assayed using the SAMS substrate 
peptide (HMRSAMSGLHLVKRR), employing a variation on the method of Davies et al. 
(372) as outlined by Hardie and colleagues (373). SAMS peptide was synthesised by 
Pepceuticals Ltd (Nottingham, U.K.). 
 
 
4.2.6.1 Preparation of HSVEC Lysates 
 
Cell lysates were prepared as outlined in section 2.6.3 unless experiments involved 
treatment of cells with test substances, AICAR (2 mM), MitoQ10 (1 µM) and DTPP (1 µM). 
Concentrations of test substances were obtained from relevant literature (176;328). Serum-
free medium was removed following overnight incubation and replaced with 5 ml KRH 
buffer +/- test substances as indicated. Cells were then incubated for 1 hour at 37ºC in a 
CO2–free incubator and lysates prepared as previously described. Total protein 
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concentration of each sample was determined by Pierce BCA Protein Assay kit according 
to the manufacturer’s protocol and using the Wallac Victor2 plate reader. 
 
 
4.2.6.2 Immunoprecipitation of AMPK 
 
5 µl (packed volume) of Protein G-Sepharose™ 4 Fast Flow beads (GE Healthcare) were 
washed by centrifugation (14,000 x g, 20 seconds, 4ºC) with 3 x 1 ml of 
immunoprecipitate (IP) buffer [50 mM Tris-HCl, pH 7.4 at 4ºC, 150 mM NaCl, 50 mM 
NaF, 5 mM Na4P2O7, 1 mM EDTA, 1mM EGTA: 1 x stock was prepared and before use 
1mM dithiothreitol (DTT), 0.1 mM benzamidine, 0.1 mM PMSF, 5 µg/ml soybean trypsin 
inhibitor, 1mM NaVO3, 1% (v/v) glycerol, 1% (v/v) Triton X-100 (final concentrations) 
were added]. Beads were then resuspended in 200 µl IP buffer. 2 µg per sample of affinity-
purified sheep anti-AMPKα1 and α2 catalytic subunit isoform-specific antibodies were 
added to the Protein G-Sepharose™ slurry which was subsequently mixed by rotating for 1 
hour at 4ºC. 
 
The slurry was then centrifuged (14,000 x g, 3 minutes, 4ºC), supernatant removed and the 
remaining pellet washed, as before, with 1 ml ice cold IP buffer. The final pellet was 
resuspended in a volume of IP buffer sufficient to allow for one 20 µl slurry aliquot per 
sample. To each 20 µl aliquot, 200 µg of cell lysate was added and final volumes made 
approximately equal by adding 200 µl IP buffer per sample. Samples were then mixed by 
rotating for 2.5 hours at 4ºC. 
 
Following mixing, samples were centrifuged (14,000 x g, 3 minutes, 4ºC) and supernatants 
removed before pellets were washed with 2 x 1ml ice-cold IP buffer containing 1 M NaCl 
(to remove non-specifically bound protein), 2 x 1 ml ice-cold IP buffer and, finally, 1 x 1 
ml HEPES-Brij buffer [50 mM HEPES, pH 7.4, 1 mM DTT, 0.02% (v/v) Brij-35 (Sigma)]. 
All washes were by means of centrifugation at 14,000 x g and 4ºC for 20 seconds. After 
the final wash, as much supernatant as possible was removed and immunoprecipitates 
frozen at -20 ºC until activity assays were performed. 
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4.2.6.3 Assaying AMPK Activity 
 
Reaction mixtures (20 µl) containing 5 µl HEPES-Brij buffer, 5 µl 1 mM AMP in HEPES-
Brij buffer, 5 µl 1 mM SAMS peptide in HEPES-Brij buffer and 5 µl immunoprecipitate 
resuspended in HEPES-Brij buffer were prepared on ice and the reaction initiated by the 
addition of 5 µl [γ-32P]ATP (Amersham) solution [1 mM [γ-32P]ATP with a specific 
activity in the range of 250,000 to 500,000 counts per minute per nmol (cpm nmol-1), and 
25 mM MgCl2]. For each sample, reactions were carried out in duplicate. Negative control 
reactions were prepared for all samples by substituting SAMS with HEPES-Brij buffer. 
After incubation at 30ºC for 10 minutes, 15 µl of reaction mixture was removed and 
spotted onto 1 cm2 pieces of P-81 phosphocellulose paper (Whatman plc, Kent, U.K.). 
Paper was then dropped into 1% (v/v) phosphoric acid to stop the reaction. The P-81 paper 
squares were washed in fresh phosphoric acid 3 times and then rinsed with water. 
Incorporation of 32P into the substrate peptide was determined by liquid scintillation 
counting using a LS 6500 Scintillation Counter [Beckman Coulter (U.K.) Ltd - Biomedical 
Research, Bucks, U.K] after immersing filters in Ecoscint scintillation fluid [National 
Diagnostics (U.K.) Ltd, Yorkshire, U.K.] 
 
 
4.2.7 Statistical Analysis 
 
Statistical analyses were performed as outlined in section 2.9. 
 
 
 
4.3 Results 
 
4.3.1 HSVEC ATP Production 
 
In HSVECs isolated from 3 patients with CAD, on comparison with untreated cells, there 
was a greater decrease in intracellular ATP generation on pretreatment with 2DG (118.96 ± 
5.26 vs 36.26 ± 2.11 µmol/106 cells; P<0.0001; Figure 4.1) than on pretreatment with 
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rotenone (118.96 ± 5.26 vs 100.90 ± 5.26 µmol/106 cells; P=0.175; Figure 4.1) and an 
additive effect when inhibitors were used in combination (118.96 ± 5.26 vs 7.62 ± 6.85 
µmol/106 cells; P<0.0001; Figure 4.1). 
 
 
4.3.2 Effect of Oxygen Concentration on HSVEC AMPK Thr172 
Phosphorylation 
 
Western blotting to assess AMPK activation in HSVECs isolated from patients with CAD 
revealed marked phosphorylation of the enzyme across a range of oxygen concentrations, 
including 21% O2 or ‘normoxia’ (Figure 4.2).  
 
 
4.3.3 HSVEC AMPK Activity 
 
Based on results shown in Figure 4.2, total AMPK activity was assessed in HSVEC lysates 
from cells cultured at 21% O2 using a synthetic peptide kinase assay. As shown in Figure 
4.3, AMPK activity was increased in cells from patients with CAD as compared to those 
from control subjects (0.045 ± 0.007 vs 0.022 ± 0.006 nmol/min/mg; P=0.046). On 
comparison with control subjects, a greater increase in AMPK activity was observed in 
HSVECs from patients with CAD and T2D (0.062 ± 0.011 vs 0.022 ± 0.006 nmol/min/mg; 
P=0.007; Figure 4.3) than in cells from patients with CAD alone (0.031 ± 0.005 vs 0.022 ± 
0.006 nmol/min/mg; P=0.261; Figure 4.3). AMPK activity was also significantly higher in 
HSVECs from patients with CAD and T2D than in those from patients with CAD alone 
(0.062 ± 0.011 vs 0.031 ± 0.005 nmol/min/mg; P=0.014; Figure 4.3). Treating cells with 
AICAR resulted in an equal, approximately two- to three-fold, increase in kinase activity 
for all patient groups (Figure 4.3). 
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Figure 4.1. ATP Production in HSVECs. Using the luciferin/luciferase method, ATP production 
was assessed in HSVECs isolated from CAD patients (n=3). HSVECs were pretreated with (+) the 
glycolytic pathway inhibitor, 2-deoxy-D-glucose (2DG), and rotenone, an inhibitor of the 
mitochondrial respiratory chain. *, † P< 0.0001 relative to basal values for untreated cells.  
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Figure 4.2. Effect of Oxygen Concentration on AMPKα1 Thr172 Phosphorylation in 
HSVECs from CAD Patients. HSVECs isolated from 3 patients with CAD were incubated for 2 
hours at different oxygen (O2) concentrations (21%, 3% and <0.5%) in a controlled hypoxic 
chamber and AMPK Thr172 phosphorylation assessed by western blotting of cell lysates.  
patient #1 patient #2 patient #3
21 3 0.5 21 3 0.5 21 3 0.5
62 kDa 
% O2 
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Figure 4.3. Comparison of Total AMPK Activity in Immunoprecipitates from HSVEC 
Lysates Cultured at 21% Oxygen. HSVEC lysates were prepared from cells isolated from control 
subjects (n=8) and patients with CAD (n=10). These CAD patients were stratified according to 
absence (ND, n=5) or presence (T2D, n=5) of type 2 diabetes. Cells were incubated with (+) and 
without (-) AICAR. ‡, P < 0.05 and †, P < 0.01 vs control subjects. *, P < 0.05 vs CAD patients 
without diabetes. Incubation with AICAR resulted in a non-significant, approximately two- to 
three-fold increase in AMPK activity for all patient groups. 
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AMPK activation at 21% O2 was further investigated and compared in HSVECs from CAD 
patients with and without T2D by means of western blot analysis using sheep anti-
AMPKα1 and rabbit anti-AMPKα1 Thr172 primary antibodies with donkey anti-rabbit IgG 
and protein G-peroxidase secondary antibodies respectively (Figure 4.4A). Patient samples 
were compared to an internal invariant control sample. Densitometry revealed no 
statistically significant difference in AMPKα1 expression between patient groups (Figure 
4.4B) and showed preincubating cells with AICAR had no effect on protein expression 
(Figure 4.4B). Densitometrical analysis demonstrated a trend towards higher levels of 
phosphorylation of AMPKα1 in cells from CAD patients with T2D but results did not 
reach statistical significance (Figure 4.4C). Treatment with AICAR caused an 
approximately equal, three-fold increase in AMPK phosphorylation in HSVECs from both 
patient groups (Figures 4.4A and 4.4C). 
 
 
4.3.4 HSVEC PRKAA1 & PRKAA2 mRNA Expression 
 
Despite increased AMPK activity in HSVECs from patients with CAD, no change in 
mRNA expression of PRKAA1, encoding the AMPKα1 catalytic subunit, was observed 
between patient groups (Figure 4.5), consistent with modulation of AMPK activity via 
post-translational phosphorylation.  
 
Expression of PRKAA2 mRNA, encoding the α2 subunit, was undetectable in HSVECs. 
 
 
4.3.5 HSVEC AMPK Substrate Phosphorylation 
 
Given the increased AMPK activity observed in HSVECs from patients with CAD, it was 
of interest to investigate phosphorylation of AMPK substrates, ACC and eNOS, in cells 
from these patients.  
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Figure 4.4 Comparison of AMPKα1 Thr172 Phosphorylation in HSVEC Lysates Cultured at 
21% Oxygen. (A) HSVECs were isolated from CAD patients with (T2D, n=5) and without (ND, 
n=5) type 2 diabetes and AMPKα1 Thr172 phosphorylation (pAMPKα1) in the presence (+) and 
absence (-) of AICAR assessed by western blotting of cell lysates. Representative immunoblots are 
shown. (B) Densitometrical analysis demonstrated no significant difference in AMPKα1 expression 
between patient groups. Pretreatment with AICAR (+) had no effect on AMPKα1 expression in 
cells from either group of patients. (C) Densitometry revealed a trend towards increased levels of 
pAMPKα1 in HSVECs from T2D patients in the absence (-) of AICAR. Pretreatment with AICAR 
(+) caused an approximate three-fold increase in AMPK phosphorylation in HSVECs from both 
patient groups. 
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Figure 4.5. HSVEC PRKAA1 mRNA Expression Relative to GAPDH as Assessed by 
TaqMan® qRT-PCR. Expression of PRKAA1 was investigated in HSVECs isolated from controls 
(n=5) and patients with CAD (n=20), stratified according to the absence (ND, n=15) or presence of 
type 2 diabetes (T2D, n=5). No difference in PRKAA1 expression was observed between patient 
groups. RQ, relative quantitation 
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Western blotting to assess ACC phosphorylation was carried out using rabbit anti-ACC-
Ser79, an antibody which recognises both phosphorylated ACC species (ACC1 and ACC2) 
(Figure 4.6A). Again, an internal invariant control sample was used as a standard. Treating 
cells with AICAR caused a marked increase in ACC phosphorylation in HSVECs from 
CAD patients both with and without T2D (Figure 4.6A). Due to technical issues, ACC 
phosphorylation was determined relative to AMPKα1 (Figure 4.4A). Densitometrical 
analysis demonstrated a trend towards increased ACC phosphorylation in cells from CAD 
patients with T2D and revealed a significant increase in ACC phosphorylation in HSVECs 
from both patients with CAD alone (0.122 ± 0.085 vs 5.06 ± 0.966; P=0.0009) and patients 
with CAD and T2D (0.441 ± 0.239 vs 3.86 ± 0.579; P=0.0006) on treatment with AICAR 
(Figure 4.6B). 
 
Phosphorylation of eNOS was also assessed by means of western blot using rabbit anti-
eNOS and rabbit anti-eNOS-Ser1177 antibodies using an internal invariant control sample 
as a standard (Figure 4.7A). Densitometry revealed a trend towards increased 
phosphorylation in HSVECs isolated from CAD patients with T2D as compared to those 
without and an increase in eNOS phosphorylation in cells from both patients groups on 
treatment with AICAR (Figure 4.7B). 
 
 
4.3.6 HSVEC AMPK Upstream Kinase Phosphorylation 
 
In order to determine the reason for increased AMPK activity in HSVECs from patients 
with CAD and T2D, protein expression of upstream AMPKKs, LKB1 and CaMKKα was 
investigated and compared in HSVECs from patients with CAD and T2D and CAD alone 
using an internal invariant control sample as a standard. 
 
LKB1 western blotting showed similar band intensities in samples from HSVECs from 
CAD patients with and without T2D (Figure 4.8A) and densitometry revealed equal levels 
of LKB1 expression in cells from both patient groups (Figure 4.8B). Sheep anti-LKB1 
primary antibody and protein G−peroxidase from streptococcus sp. secondary antibody 
were used. 
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Figure 4.6. Comparison of ACC Ser80 Phosphorylation in HSVEC Lysates Cultured at 21% 
Oxygen. (A) HSVECs were isolated from CAD patients with (T2D, n=5) and without (ND, n=5) 
type 2 diabetes and ACC Ser79 phosphorylation in the presence (+) and absence (-) of AICAR 
assessed by western blotting of cell lysates. A representative immunoblot is shown. (B) 
Densitometry revealed a trend towards increased levels of ACC phosphorylation at Ser79 in 
HSVECs from T2D patients in the absence (-) of AICAR. Pretreatment with AICAR (+) caused a 
significant increase in ACC Ser79 phosphorylation in HSVECs from both patient groups. †, 
P<0.001 vs T2D (- AICAR). *, P<0.001 vs ND (- AICAR). 
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Figure 4.7 Comparison of eNOS Ser1177 Phosphorylation in HSVEC Lysates Cultured at 
21% Oxygen. (A) HSVECs were isolated from CAD patients with (T2D, n=5) and without (ND, 
n=5) type 2 diabetes and eNOS Ser1177 phosphorylation in the presence (+) and absence (-) of 
AICAR assessed by western blotting of cell lysates. Bands of the relevant size (140 kDa) were 
observed for the majority of patients but were of varying density. A representative immunoblot is 
shown. (B) Densitometry revealed a trend towards increased levels of eNOS phosphorylation at 
Ser1177 in HSVECs from T2D patients in the absence of AICAR. Pretreatment with AICAR 
caused no significant increase in eNOS Ser1177 phosphorylation in HSVECs from either patient 
group. 
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Figure 4.8. Comparison of LKB1 Protein Expression in HSVEC Lysates Cultured at 21% 
Oxygen. (A) HSVECs were isolated from CAD patients with (T2D, n=5) and without (ND, n=5) 
type 2 diabetes and LKB1 protein expression in the presence (+) and absence (-) of AICAR 
assessed by western blotting of cell lysates. Bands of the relevant size (50 kDa) were observed for 
all patients and appeared of approximately equal density. A representative immunoblot is shown. 
(B) Densitometrical analysis revealed approximately equal levels of LKB1 expression across 
patient and treatment groups. 
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Western blotting to assess CaMKKα expression was carried out using mouse anti-
CaMKKα primary antibody and sheep anti-mouse IgG secondary antibody (Figure 4.9A). 
Densitometrical analysis demonstrated no significant difference in CaMKKα expression in 
cells from either group on pretreatment with AICAR or between patient groups in the 
absence of AICAR (Figure 4.9B). However, on pretreatment with AICAR, expression was 
observed to be significantly different between patient groups (T2D vs ND; 1.184 ± 0.262 
vs 4.363 ± 1.258; P=0.04) (Figure 4.9B). 
 
 
4.3.7 Mitochondrial ROS-Mediated AMPK Activation in HSVECs 
 
The contribution of mtROS to AMPK activation was investigated by treating HSVECs 
from CAD patients with the mitochondria-targeted antioxidant, MitoQ10, in the presence 
and absence of AICAR. To control for non-specific effects of MitoQ10, cells were treated 
with the non-active control compound, DTPP which, as previously stated, comprises the 
lipophilic TTP cation but lacks the ubiquinone moiety of  MitoQ10 (324). Exposing 
HSVECs to MitoQ10 resulted in a reduction in AMPK activity which was attenuated on 
addition of AICAR (Figure 4.10). The MitoQ10-mediated decrease in AMPK activity was 
greater in HSVECs from CAD patients with T2D (0.056 ± 0.004 vs 0.009 ± 0.01 
nmol/min/mg; P=0.016) than in those from patients with CAD alone (0.035 ± 0.005 vs 
0.014 ± 0.0002 nmol/min/mg; P=0.052) for whom the effects of MitoQ10, in both the 
presence and absence of AICAR, were non-significant (Figure 4.10). 
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Figure 4.9. Comparison of CaMKKα Protein Expression in HSVEC Lysates Cultured at 21% 
Oxygen. (A) HSVECs were isolated from CAD patients with (T2D, n=5) and without (ND, n=5) 
type 2 diabetes and CaMKKα protein expression in the presence (+) and absence (-) of AICAR 
assessed by western blotting of cell lysates. Bands of the relevant size (63 kDa) were observed for 
all patients but were of varying density. (B) Densitometry revealed no significant difference in 
CaMKKα expression in cells from either group on pretreatment with AICAR or between patient 
groups in the absence of AICAR. CaMKKα expression was observed to be significantly different 
between patient groups on pretreatment with AICAR. *, P < 0.05 vs ND (+ AICAR). 
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Figure 4.10. Effect of Mitochondrial-ROS on AMPK Activation in HSVEC Lysates Cultured 
at 21% Oxygen. Cells from CAD patients without type 2 diabetes (ND, n=5) and with type 2 
diabetes (T2D, n=5) were incubated in the presence (+) and absence of AICAR, MitoQ10 and 
decylTPP bromide (DTPP). Total AMPK was immunoprecipitated from lysates which were then 
assayed for AMPK activity. *, P < 0.05 vs basal value for cells from ND patients, †, P < 0.05 vs 
basal value for T2D patients, ‡ P < 0.01 vs value in presence of DTPP for T2D patients. 
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4.4 Discussion 
 
Vascular endothelial cells are highly glycolytic (228;366) and this has been confirmed as 
being the case for HSVECs with results suggesting that in terms of ATP production, 
HSVECs can compensate more effectively when the electron transport chain is blocked 
than when glycolysis is blocked (Figure 4.1). A potential reason for the favouring of 
glycolysis by endothelial cells has been proposed by Quintero and colleagues, whereby 
mitochondria are not preferentially used bioenergetically in HUVECs, allowing them to 
function primarily in the generation of ROS for signalling purposes (228).  
 
It is well documented that AMPK is activated in response to hypoxic stress with 
phosphorylation of the enzyme observed at low O2 concentrations in HUVECs but 
undetectable at 21% O2 or ‘normoxia’ (228). However, as shown in Figure 4.2, constitutive 
AMPK phosphorylation was observed in HSVECs isolated from patients with CAD, 
indicating cardiovascular disease phenotype is linked to enzyme activation. Indeed, at 21% 
O2, HSVEC AMPK activity was significantly greater in cells from patients with CAD 
relative to control subjects (Figure 4.3). Furthermore, on stratifying patients according to 
the presence of T2D, AMPK activity was significantly increased in cells from patients with 
CAD and T2D as compared to both control subjects and patients with CAD alone (Figure 
4.3). As previously outlined, the anti-diabetic drug, metformin exerts a portion of its effect 
through AMPK and approximately 43% of T2D patients studied were being treated with 
the drug. However, for the purpose of this study, the effect of metformin treatment on 
AMPK activation was not considered relevant as cells were cultured for several weeks 
prior to preparation of lysates such that effects of pharmacological treatments were likely 
to have been lost. Observed differences were consequently considered to be the result of 
differences in the genetic backgrounds of patients.  
 
Incubating HSVECs with AICAR resulted in a non-significant, approximately equal 
increase in AMPK activity for all patient groups, suggesting disease status does not affect 
sensitivity of cells to this artificial activator of AMPK.  
 
On comparison of AMPKα1 Thr172 phosphorylation in HSVEC lysates cultured at 21% 
oxygen, AICAR again caused an approximately equal increase in phosphorylation in cells 
from patients with and without T2D (Figure 4.4). A trend towards higher levels of 
phosphorylation in HSVECs from patients with CAD and T2D was observed but, unlike 
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for the activity assay, results failed to reach significance. This can perhaps be explained by 
the fact that results obtained via western blotting are far less quantifiable than those 
obtained by means of the more sensitive kinase assay. 
 
Despite the increase in AMPK activity in patients with CAD relative to controls and in 
those CAD patients with T2D relative to both those without T2D and control subjects, no 
difference in AMPKα1 mRNA (Figure 4.5) or protein (Figures 4.4A and 4.4B) expression 
was observed between patient groups, confirming modulation of AMPK activity via post-
translational phosphorylation. In addition, PRKAA2 mRNA expression was undetectable in 
HSVECs isolated from patients from each group, corroborating findings that the α1 subunit 
is the predominant form in endothelial cells. 
 
Increased AMPK activity in HSVECs from patients with CAD and T2D relative to those 
with CAD alone was not mirrored by any significant increase in phosphorylation of 
downstream targets, ACC and eNOS, at Ser80 and Ser1177 respectively (Figures 4.6 and 
4.7). However, a trend towards increased phosphorylation of both substrates in cells from 
T2D patients was observed (Figures 4.6 and 4.7). Again, this may be due to the fact that 
analysis of western blots is less quantitative than the kinase assays carried out to determine 
AMPK activity. Also, while there was a narrow range of expression of AMPK, there was 
substantial variation in expression of eNOS particularly. Furthermore, it should be noted 
that AMPK assays are performed in saturating AMP, and therefore reflect the increase in 
activity of the kinase due to phosphorylation at Thr172. However, the ACC and eNOS 
phosphorylation observed reflect AMPK activation that is a combination of increased 
phosphorylation and increased allosteric activation by AMP. As such, it is perhaps not 
surprising that increased AMPK activity in HSVECs from patients with CAD and T2D did 
not translate to a significant increase in phosphorylation of substrates. 
 
Expression of upstream AMPKKs, LKB1 and CaMKKα, was investigated in an attempt to 
determine the mechanisms underlying the observed increase in AMPK activity in HSVECs 
from patients with CAD and T2D. While AICAR has no effect on expression of these 
kinases, lysates from HSVECs pretreated with AICAR were used in an attempt to keep 
samples consistent throughout experimental procedures. 
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As shown in Figure 4.8, LKB1 expression remained constant irrespective of patient disease 
status and, as expected, preincubation of cells with AICAR. Therefore, increased HSVEC 
AMPK activity in T2D patients does not occur as a result of elevated LKB1 expression.  
 
For CaMKKα, immunoblots indicated substantial variation in protein expression between 
individual patient samples (Figure 4.9A). However, in lysates from cells not subject to 
preincubation with AICAR, CaMKKα expression was not found to be statistically 
significantly different in CAD patients with T2D as compared to those with CAD alone 
(Figure 4.9B), suggesting observed differences may simply represent natural variation in 
the human population. Interestingly, pretreatment with AICAR had no statistically 
significant effect on CaMKKα expression within patient groups but caused a significant 
difference in expression between groups (Figure 4.9B). As stated, AICAR does not directly 
affect expression of CaMKK. Consequently, the changes upon AMPK stimulation may 
reflect changes in subcellular localisation of CaMKKα such that there are apparent changes 
in expression within the lysates examined.  
 
Limited cellular material meant expression of CaMKKβ was not investigated. The β 
isoform is thought to predominate in terms of AMPK activation (264;265) and so 
additional studies focusing on expression of this isoform are crucial in order to obtain 
accurate and comprehensive insight into CaMKK expression in HSVECs. Furthermore, 
with immunoblotting for CAMKKα yielding variable results, for future studies it may be 
useful to employ an alternative method for investigation of CaMKK-mediated AMPK 
activation, such as assaying AMPK activity after treatment of cells with the CaMKK 
inhibitor, STO-609 (287). 
 
Given the apparent lack of change in activity of upstream AMPK kinases, the glycolytic 
nature of these cells and the increased expression of SOD2 (Figure 3.8), it seems likely that 
endothelial AMPK activation in CAD patients occurs, at least in part, in an mtROS-
mediated manner and that this activation is enhanced in those CAD patients with T2D who 
display severe endothelial dysfunction (Figure 3.2B) and increased SOD2 expression 
(Figure 3.8), consistent with increased mtROS production. As previously described, within 
the mitochondrial matrix, SOD2 catalyses the conversion of O2- to H2O2 and molecular 
oxygen (234). Interestingly, H2O2 has been shown to activate AMPK under hypoxic 
conditions in cultured cells (295;296).  
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In order to test this hypothesis concerning the mtROS-mediated activation of AMPK, 
HSVECs isolated from vessels of CAD patients were treated with the mitochondria-
targeted antioxidant, MitoQ10. As outlined in Chapter 3, MitoQ10 has been shown to react 
poorly with O2- (351) but is reported to scavenge oxidants, including H2O2, ONOO- and 
their derivatives, under hyperglycaemic conditions in cultured endothelial cells (374). 
Treatment with MitoQ10 caused a significant decrease in AMPK activation in cells from 
CAD patients with type 2 diabetes which was attenuated on addition of AICAR, known to 
stimulate kinase activity in cultured endothelial cells (262;297;375) (Figure 4.10). The 
non-active control for MitoQ10, DTPP, had no effect on AMPK activity in a parallel 
experiment (Figure 4.10), indicating results can be attributed to the antioxidant action of 
MitoQ10 specifically. The same effect was not seen in cells from CAD patients without 
T2D (Figure 4.10). 
 
Taken together, these findings indicate a novel, mtROS-mediated activation of AMPK in 
the endothelium of patients with CAD and T2D and suggest a role for AMPK in defence 
against oxidative stress and endothelial dysfunction. Indeed, as described, activated AMPK 
phosphorylates eNOS at Ser1177 in cultured endothelial cells (176;282) and has been 
shown to increase endothelium-dependent vasodilation in an animal model (252). 
Furthermore, the anti-diabetic drug, metformin which exerts a portion of its effect through 
AMPK, has been reported to decrease intracellular production of mtROS in aortic 
endothelial cells (376), while activation of AMPK has been shown to reduce 
hyperglycaemia-induced mtROS production by induction of SOD2 in HUVECs (377). In 
addition, Colombo and Moncada have recently shown that in HUVECs, AMPKα1 is 
responsible for the expression of a number of genes involved in antioxidant defence, 
including SOD2 (378). Thus, AMPK activation would appear to have a beneficial effect on 
endothelial function by suppressing oxidative stress and increasing NO bioavailability in 
endothelial cells.  
 
In summary, these findings suggest AMPK is part of a feedback or adaptive mechanism in 
the endothelium of patients with CAD and T2D, with a role in defence against oxidative 
stress. It seems likely that the elevated mtROS production of T2D results in activation of 
AMPK which, in turn, activates eNOS, thus increasing NO bioavailability and attenuating 
endothelial dysfunction. Under conditions of oxidative stress, NO may react with O2- to 
form ONOO- which has been shown to activate AMPK in the endothelium (297;379). 
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Endothelial AMPK may also induce SOD2 activity, resulting in production of H2O2 which 
may itself activate AMPK (295;296) (Figure 4.11). 
 
Results support a novel, mtROS-mediated mechanism for AMPK activation in the 
endothelium and suggest mitochondria contribute to increased O2- production and 
endothelial dysfunction in patients with coronary artery disease and type 2 diabetes. 
Mitochondria-targeted antioxidants, used in combination with pharmacological activators 
of AMPK, may therefore have potential as an early intervention strategy in the treatment of 
endothelial dysfunction in these patients. 
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Figure 4.11. Proposed Mechanism of Mitochondrial Reactive Oxygen Species-Mediated 
AMPK Activation in Endothelial Cells. Results suggest a potentially mitochondrial reactive 
oxygen species (mtROS)-mediated increase in AMPK activity in patients with coronary artery 
disease and type 2 diabetes. AMPK may therefore be part of a feedback or adaptive mechanism 
with a role in defence against oxidative stress in the endothelium, regulating expression of 
antioxidant genes, including SOD2, and contributing to the control of vascular tone, via activation 
of endothelial nitric oxide synthase (eNOS).  
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5. Gene Expression Profiling of Endothelial Cells in 
Coronary Artery Disease 
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5.1 Introduction 
 
 
Microarray technology is a powerful tool, allowing exploration of genome complexity at a 
fundamental level (380). Transcriptional profiling using high-density microarrays has 
provided unique insight into disease mechanisms, drug responses, regulatory pathways and 
gene function, through comparison of mRNA transcript levels in cells / tisues in a given 
pathological state with an appropriate control (381).  
 
One such pathological state is CAD, where the application of microarray technology has 
resulted in identification of unique subsets of genes associated with specific disease 
processes (382). Indeed, transcript profiling has revealed associations of interesting genes, 
such as ICAM-2, with CAD (383) and identified a loss of coronary artery differentiated 
smooth muscle cell gene expression as a primary signature of disease progression in 
atherosclerosis (384).  
 
To date, few published studies have compared gene expression profiles of CAD patients 
with and without T2D (381;384;385). A study by Voisine and colleagues identified 
quantitative and qualitative differences in gene expression profile in atrial myocardium 
samples from patients with T2D undergoing cardiopulmonary bypass and cardioplegic 
arrest, with the majority of differentially expressed genes encoding transcription activators 
and mediators of the inflammatory response (381). Similarly, King et al. (384) assessed 
gene expression profiles of coronary artery segments and observed differential expression 
of a number of genes involved in insulin signalling in vessels from diabetic patients. 
However, it seems likely that many of the chronic endothelial effects of T2D will be 
reflected in transcriptional regulation at cellular level, either as a direct response to 
hyperglycaemia and abnormalities of insulin signalling, or as a secondary response to the 
effects of these stresses. This intimates the need to examine transcript profiles of isolated 
endothelial cells in order to identify pathways and candidate genes that may contribute to 
the more severe endothelial dysfunction observed in vessels from CAD patients with T2D 
(Figure 3.2B). As such, this study involved comparison of gene expression profiles in 
primary HSVECs isolated from CAD patients with and without T2D. 
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The aims of the experimental work outlined in this chapter were as follows: 
 
1) to identify differentially expressed genes in primary HSVECs isolated from CAD 
patients with and without T2D; 
2) to analyse microarray data using Ingenuity Pathway Analysis software in order to 
identify canonical metabolic pathways affected by differentially expressed genes; 
3) to confirm differential expression of selected genes using qRT PCR 
 
 
 
5.2 Materials & Methods 
 
5.2.1 Study Participants 
 
CAD patients with and without T2D were as described in section 2.2. Twelve patients with 
CAD alone and six patients with CAD and T2D were selected for the study. Selected 
patients were age, sex and smoking status matched. All patients were male, aged between 
60 and 72 years of age and non-smokers. 
 
 
5.2.2 Human Vascular Tissue & Primary Cell Culture 
 
Vascular tissue was obtained and prepared as described in section 2.3 and HSVECs 
isolated, characterised and cultured as outlined in section 2.4.  
 
 
5.2.3 RNA Extraction, Quantification & Validation 
 
Total RNA was extracted from HSVECs, DNase treated and quantified using the 
NanoDrop® ND-100 Spectrophotometer as per section 2.5. Total RNA sample integrity 
was then verified by electrophoresis of 500 ng on an Agilent Bioanalyzer 2100.  
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5.2.4 Biotinylated cRNA Synthesis 
 
The Illumina® TotalPrep RNA Amplification Kit was used to generate biotinylated, 
amplified cRNA for hybridisation with Illumina Sentrix® arrays, according to the 
manufacturer’s protocol. 
 
 
5.2.4.1 First & Second Strand cDNA Synthesis 
 
Reverse transcription to synthesise first strand cDNA was carried out by bringing 500 ng 
of total RNA to a volume of 11 µl with nuclease-free H2O before adding 9 µl Reverse 
Transcription Master Mix (prepared at room temperature and containing 1 µl T7 Oligo(dT) 
Primer, 2 µl 10 X First Strand Buffer, 4 µl dNTP Mix, 1 µl RNase Inhibitor and 1 µl 
ArrayScript for a single 20 µl reaction), mixing thoroughly by pipetting and incubating 
samples at 42ºC for 2 hours.  
 
Second strand cDNA was then synthesised immediately by adding 80 µl Second Strand 
Master Mix (prepared on ice and containing 63 µl nuclease-free H2O, 10 µl 10 X Second 
Strand Buffer, 4 µl dNTP Mix, 2 µl DNA Polymerase and 1 µl RNase H for a single 100 µl 
reaction) to each sample, mixing thoroughly by pipetting and flicking the tube 3-4 times 
before centrifuging briefly to collect the reaction in the bottom of the tube. Samples were 
then incubated for 2 hours at 16ºC in a thermal cycler. Following the 2 hour incubation, 
cDNA purification was carried out straight away. 
 
 
5.2.4.2 Double Stranded cDNA Purification 
 
cDNA was purified to remove RNA, primers, enzymes and salts that would inhibit in vitro 
transcription. 250 µl cDNA Binding Buffer was added to each sample and the mixture 
mixed thoroughly by pipetting and flicking the tube before being applied to the centre of a 
cDNA Filter Cartridge seated in a wash tube. Cartridges were centrifuged for a minute at 
10,000 x g, flow-through discarded and cartridges replaced in wash tubes. 500 µl Wash 
Buffer was the applied to each cDNA Filter Cartridge and cartridges centrifuged at 10,000 
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x g for a minute. Flow-through was discarded and cartridges centrifuged for an additional 
minute to remove traces of Wash Buffer. Next, cDNA Filter Cartridges were transferred to 
cDNA Elution Tubes, 10 µl nuclease-free H2O (preheated to 50-55ºC) applied to the centre 
of filters and samples incubated at room temperature for 2 minutes before centrifugation 
for 1.5 minutes at 10,000 x g. A further 9 µl preheated nuclease-free H2O was then applied 
to filters and samples centrifuged for 2 minutes at 10,000 x g to elute the double-stranded 
cDNA in an approximate volume of 17.5 µl. In vitro transcription (IVT) to synthesise 
complementary RNA (cRNA) was then carried out immediately. 
 
 
5.2.4.3 In Vitro Transcription to Synthesise cRNA 
 
Multiple copies of biotinylated cRNA were generated from the double-stranded cDNA 
template by adding 7.5 µl IVT Master Mix (prepared at room temperature and containing 
2.5 µl T7 10 X Reaction Buffer, 2.5 µl T7 Enzyme Mix and 2.5 µl Biotin-NTP Mix for a 
single 25 µl reaction) to each sample, mixing thoroughly by pipetting and flicking the tube 
and subsequently centrifuging briefly to collect the reaction mixture at the bottom of the 
tube. Samples were then incubated at 37ºC for between 4 and 14 hours before 75 µl 
nuclease-free H2O was added to each sample to stop the reaction and bring the final 
volume to 100 µl. Purification of cRNA was then performed immediately. 
 
 
5.2.4.4 cRNA Purification & Validation 
 
cRNA purification to remove unincorporated NTPs, salts, enzymes and inorganic 
phosphate involved adding 350 µl cRNA Binding Buffer followed immediately by 250 µl 
100% ethanol to each sample. Samples were then mixed by pipetting before being applied 
to the centre of a cRNA Filter Cartridge placed in a cRNA Collection Tube. Samples were 
subsequently centrifuged for 1 minute at 10,000 x g, flow-through discarded and cartridges 
replaced in collection tubes. Next, 650 µl Wash Buffer was applied to each cartridge which 
was then centrifuged for 1 minute at 10,000 x g. Flow-through was again discarded and 
cartridges centrifuged for an additional minute to remove trace amounts of Wash Buffer. 
Cartridges were then transferred to fresh cRNA Collection Tubes and 100 µl nuclease-free 
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H2O (preheated to 50-60ºC) added to the centre of the filter. Samples were left at room 
temperature for 2 minutes before being centrifuged for 1.5 minutes at 10,000 x g to elute 
purified cRNA. 
 
Purified cRNA was quantified using the NanoDrop® ND-100 Spectrophotometer and 
quality assessed via electrophoresis of 500 ng on an Agilent Bioanalyzer 2100.  
 
 
5.2.5 Microarray Hybridisation & Data Collection 
 
cRNA was prepared for hybridisation with Illumina® HumanWG-6 v3.0 Expression 
Beadchips, using the Illumina® Whole-Genome Expression Direct Hybridization Assay. 
Illumina® HumanWG-6 v3.0 Expression Beadchips contain 48,804 probes, targeting a total 
of 25,440 annotated genes. 1.5 µg of cRNA was brought to a total volume of 10 µl with 
RNase-free water and mixed before incubation at room temperature for 10 minutes to 
resuspend cRNA. Hybridisation reagents (GEX-HYB and GEX-HCB) were incubated at 
58ºC for 10 minutes to dissolve any salts that may have precipitated in storage. 20 µl GEX-
HYB was subsequently added to each cRNA sample. 200 µl GEX-HCB was then applied 
to each hybridisation chamber (Hyb Chamber) and BeadChips inserted into chambers. 
cRNA samples were preheated at 65ºC for 5 minutes then briefly vortexed and centrifuged 
to collect liquid. Samples were allowed to cool to room temperature before 30 µl was 
applied to each array. Samples were randomised on chips and technical duplicates of all 
T2D samples included. Hyb Chambers were incubated for 16-20 hours (overnight) in a 
58ºC oven rotating at 60 rpm. 
 
Beadchips were washed and stained following standard protocols. Following overnight 
incubation, BeadChips were removed from Hyb Chambers and submerged in 250 ml Wash 
E1BC solution (prepared by adding 3 ml E1BC buffer to 1 L RNase-free H2O) before 
being incubated for 10 minutes in 1 X High-Temp Wash Buffer (prepared by adding 50 ml 
10 X stock to 450 ml RNase-free H2O) preheated to 55ºC. After 10 minutes, BeadChips 
were transferred to a fresh 250 ml Wash E1BC solution at room temperature and placed on 
an orbital shaker at maximum speed for 5 minutes. Chips were then transferred to a 250 ml 
100% ethanol solution and placed on the orbital shaker (maximum speed) for 10 minutes. 
A 2 minute wash in a fresh Wash E1BC solution was performed before each chip was 
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blocked in 4 ml Block E1 buffer for 10 minutes at medium rocking speed and room 
temperature. Detection was performed by placing chips in 2 ml Block E1 buffer with 
streptavidin-Cy3 (2 µl 1 mg/ml stock per chip), covering to protect from light and rocking 
at medium speed for 10 minutes. A third room temperature wash in 250 ml Wash E1BC 
was then carried out with shaking for 5 minutes. Finally, to dry chips, they were 
centrifuged for 4 minutes at 275 rcf and room temperature.  
 
Following completion of the hybridisation procedure, BeadChips were scanned and images 
extracted using specific protocols on an Illumina® BeadArray Reader. 
 
 
5.2.6 Microarray Data Analysis  
 
5.2.6.1 Quality Control 
 
Illumina® Gene Expression Beadchips have internal control features to monitor both 
sample-independent and sample-dependent data quality. Control data results were 
visualised with BeadStudio software. 
 
 
5.2.6.2 Gene Expression Data Analysis 
 
5.2.6.2.1 Illumina® BeadStudio Analysis 
 
Initial analysis of microarray data was performed using Illumina® BeadStudio software. 
Quantile normalisation of the data was carried out without background subtraction. Each 
probe is represented by multiple beads (30 on average) on an Illumina® Gene Expression 
Beadchip. Normalised values for each bead representing a given probe were averaged to 
obtain the estimate of expression for that probe. Unpaired 2 sample t-tests were then 
conducted on these averaged values using the Illumina® custom error model (386). 
Differentially expressed probes were identified using a difference (diff) score cut-off of +/- 
13.0103, equating to a P value ≤ 0.05. Differentially expressed probes were then uploaded 
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to Ingenuity Pathway Analysis (IPA) software (387) and analysed to identify canonical 
metabolic pathways of interest containing most significantly differentially expressed genes. 
 
 
5.2.6.2.2 Ingenuity Pathway Analysis 
 
Canonical pathways analysis identified the pathways from the IPA library of canonical 
pathways that were most significantly associated with the data set. Genes from the data set 
that met the P value cut-off of 5% and were associated with a canonical pathway in the 
Ingenuity Pathways Knowledge Base (IPKB) were considered for the analysis. The 
significance of the association between the data set and the canonical pathway was 
measured in two ways. Firstly, a ratio of the number of genes with differentially expressed 
probes from the data set that mapped to the canonical pathway divided by the total number 
of genes with probes in the data set that mapped to the pathway was displayed. Secondly, 
in addition to this ratio, Fisher’s exact test was used to calculate a P value determining the 
probability that the association between the significant genes in the data set and the 
canonical pathway could be explained by chance alone. 
 
 
5.2.6.2.3 Rosetta Resolver® Analysis 
 
Additional analysis of microarray data was carried out by uploading raw data from 
BeadStudio software to the Rosetta Resolver® Gene Expression Data Management and 
Analysis System. Data were normalised using Rosetta error models (388) to give one 
averaged, normalised value for each probe before principal component analysis (PCA) was 
performed. PCA is a data reduction method which identifies linear combinations of probes 
that explain the most variability in the data and can be used to visualise data for quality 
assessment purposes (389). The PCA revealed an outlier in one sample from the T2D 
group of patients and, after further investigation, this outlier was removed from subsequent 
analysis. Following PCA, an error weighted analysis of variance (ANOVA) with a false 
discovery rate (FDR) (390) threshold of 0.05 was used on the remaining data to identify 
differentially expressed probes. Again, differentially expressed probes were uploaded to 
IPA and analysed to identify the canonical metabolic pathways most associated with 
significantly differentially expressed genes.  
156 
5.2.6.2.4 Integration of Analyses Results 
 
The number of differentially expressed genes common to BeadStudio and Rosetta 
Resolver® analyses was identified using a Venn diagram.  
 
 
5.2.7 TaqMan® Real-Time RT-PCR 
 
TaqMan® qRT-PCR was utilised to confirm differential expression observed in microarray 
experiments. The same total RNAs isolated for microarray experiments were used as 
templates for the synthesis of cDNA as per section 2.7.1 and mRNA expression levels 
assessed as outlined in section 2.7.2. Applied Biosystems Custom TaqMan® Gene 
Expression Assays for ACAD11 (Hs00259854_m1), AGTR2 (Hs00169126_m1), ATP5G3 
(Hs00266085_m1), IDH3G (Hs00188065_m1), PIK3R2 (Hs00178181_m1), PRKAG1 
(Hs00176952_m1) and SDHC (Hs00818427_m1) were used with TaqMan® Endogenous 
Control, β-actin (ACTB, 4326315E). Reactions were carried out in singleplex or multiplex 
as indicated. 
 
 
 
5.3 Results 
 
5.3.1 Total RNA & cRNA Validation 
 
Electrophoresis of HSVEC total RNA samples on the Agilent Bioanalyzer 2100 confirmed 
RNA quality prior to cDNA synthesis, as indicated by defined bands for 28S and 18S 
ribosomal RNA (rRNA) species and little evidence of small RNA species below the 18S 
band (Figure 5.1). RNA Integrity Numbers (RINs) were consistently above 9.0.  
 
Following in vitro transcription to synthesise biotinylated cRNA, cRNA quality was also 
assessed by electrophoresis on the Agilent Bioanalyzer 2100. Results demonstrated 
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Figure 5.1. Agilent Bioanalyzer 2100 Assessment of Total RNA Quality. (A) Electrophoresis of 
representative total RNA samples revealed bands for 28S and 18S ribosomal RNA (rRNA). Green 
bands represent a 200 base pair size marker used to align samples and controls. kb, kilobases (B) A 
representative individual electropherogram showing sharp peaks for 28S and 18S rRNA. No RNA 
species smaller than 18S rRNA were observed, indicative of intact RNA. 
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approximately normal distribution of cRNA species for all samples and approximately 
equal concentrations (Figure 5.2). 
 
 
5.3.2 Microarray HSVEC mRNA Expression Profiling 
 
5.3.2.1 Microarray Data Quality Control 
 
Direct Hyb Control Plots obtained for samples were consistent with BeadStudio example 
control plots, verifying the validity of microarray gene expression data (Figure 5.3). 
 
 
5.3.2.2 Beadstudio Analysis 
 
Using Illumina® BeadStudio software, a total of 727 probes were found to be differentially 
expressed between HSVECs from patients with CAD and T2D and patients with CAD 
alone. Expression of 293 probes was upregulated in cells from patients with T2D while 
434 probes were downregulated in cells from these patients. A complete list of 
differentially expressed probes is included as Table A1 in the Appendix. 
 
 
5.3.2.2.1 Ingenuity Pathway Analysis 
 
Analysis of BeadStudio microarray data using IPA software identified the citrate cycle as a 
canonical metabolic pathway significantly affected by the presence of T2D (Figure 5.4), 
with significance based on the number of genes with differentially expressed probes 
mapping to the pathway (Table 5.1 and Figure 5.5). Given the role of mitochondria in T2D 
pathogenesis (section 1.3.4.3.1), ATP5G3, IDH3G and SDHC were selected as candidate 
genes for further study. However, SDHAL1 was identified as a pseudogene and 
consequently no attempt was made to confirm its differential expression. 
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Figure 5.2. Agilent Bioanalyzer 2100 Assessment of cRNA Quality. (A) Electrophoresis of 
representative samples showing the distribution of complementary RNA (cRNA) species on 
separation according to size. Green bands represent a 200 base pair (bp) size marker used to align 
samples and controls. kb, kilobases (B) Representative electropherogram showing approximately 
normal distribution of cRNAs. The sharp peak at the extreme left of the trace corresponds to the 
200 bp size marker. 
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Figure 5.3. Microarray Data Quality Control. Quality control results for microarray data were 
visualised using BeadStudio software. Direct Hyb Control Plots generated for samples (bottom 
panel) were consistent with Beadstudio Direct Hyb Control Plot examples (top panel), verifying the 
validity of gene expression microarray data. Details of BeadStudio control plots are provided in the 
table (right hand panel). *, sample-independent control metrics 
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ratio of the number of differentially expressed genes from the data set mapping to the canonical pathway divided by the total number of genes mapping to 
the pathway  
 
Figure 5.4. IPA Canonical Pathway Analysis of BeadStudio Microarray Data. Canonical metabolic pathways significantly affected by the presence of type 2 
diabetes were observed to cross the threshold value (P≤0.05). Significance is based on the number of differentially expressed genes in the pathway. Differentially 
expressed genes involved in the citrate cycle and retinoic acid receptor (RAR) activation were identified as candidate genes for further investigation.  
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Gene Symbol Gene Name Diff Score Fold Change 
ATP5G3 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C3 (subunit 9) -18.009 -1.397 
IDH3G isocitrate dehydrogenase 3 (NAD+) gamma 13.807 1.306 
SDHAL1 succinate dehydrogenase complex, subunit A, flavoprotein pseudogene 1 -15.807 -1.393 
SDHC succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa -26.557 -1.346 
 
 
Table 5.1. Differentially Expressed Citrate Cycle Genes. IPA canonical pathway analysis of BeadStudio microarray data identified 4 genes within the citrate cycle 
pathway as being differentially expressed in cells from patients with CAD and type 2 diabetes (T2D). ATP5G3, SDHAL1 and SDHC were observed to be 
downregulated in cells from patients with T2D, while IDH3G was upregulated in these patients. 
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Figure 5.5. Citrate Cycle Canonical Pathway. The citrate cycle metabolic pathway showing candidate genes differentially expressed in HSVECs from patients 
with type 2 diabetes (Ingenuity Pathway Analysis).  
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Expression of PRKAG1, encoding the regulatory γ1-subunit of AMPK, was observed to be 
significantly downregulated in CAD patients with T2D (Table A1) and involved in a 
number of significantly affected metabolic pathways, including retinoic acid receptor 
(RAR) activation, the most significantly affected canonical pathway (Table 5.2 and Figure 
5.6). With AMPK implicated in T2D (section 1.5.1 and Chapter 4), PRKAG1 was also 
selected as a candidate gene and its expression further investigated. 
 
 
5.3.2.2.2 Confirmation of Differential Expression of Candidate Genes by 
TaqMan® Real-Time RT-PCR 
 
On attempting to confirm differential expression of microarray candidate genes by 
TaqMan® qRT-PCR, no statistically significant difference in HSVEC ATP5G3 (∆Ct, 5.706 
± 0.412 vs 5.477 ± 0.680; P=0.763; Figure 5.7A) and IDH3G (∆Ct, 3.429 ± 0.168 vs 3.659 
± 0.223; P=0.418; Figure 5.7B) mRNA expression was found in cells isolated from CAD 
patients with and without T2D. Similarly, no significant difference in HSVEC SDHC 
mRNA expression was observed between patients with CAD and T2D and patients with 
CAD alone (∆Ct, 3.556 ± 0.176 vs 3.708 ± 0.392; P=0.692; Figure 5.7C). However, the 
direction of change in SDHC expression reflected that observed on analysis of microarray 
data with a trend towards decreased expression in patients with CAD and T2D (Figure 
5.7C).  
 
As shown in Figure 5.7D, no significant difference in HSVEC PRKAG1 mRNA expression 
was observed between patients with CAD and T2D and patients with CAD alone (∆Ct, 
1.315 ± 0.317 vs 1.487 ± 0.417; P=0.746) but, a trend towards decreased expression in 
CAD patients with T2D was noted, reflecting the direction of change observed on analysis 
of microarray data (Figure 5.7D). 
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Gene Symbol Gene Name Diff Score Fold Change 
CCNH cyclin H -20.875 -1.289 
GTF2H1 general transcription factor IIH, polypeptide 1, 62kDa 13.661 1.223 
IL3RA interleukin 3 receptor, alpha (low affinity) -14.374 -1.263 
MAP2K4 mitogen-activated protein kinase kinase 4 -15.044 -1.228 
MAP3K1 mitogen-activated protein kinase kinase kinase 1 15.91 1.259 
PIK3CA phosphoinositide-3-kinase, catalytic, alpha polypeptide 14.406 1.223 
PRKAG1 protein kinase, AMP-activated, gamma 1 non-catalytic subunit -14.846 -1.255 
PRKCI protein kinase C, iota 14.289 1.222 
RDH5 retinol dehydrogenase 5 (11-cis/9-cis) 15.75 1.249 
RDH11 retinol dehydrogenase 11 (all-trans/9-cis/11-cis) 16.835 1.253 
 
 
Table 5.2. Differentially Expressed Genes Involved in Retinoic Acid Receptor (RAR) Activation. IPA canonical pathway analysis of BeadStudio microarray 
data identified 10 genes involved in the RAR activation metabolic pathway, including PRKAG1, as being differentially expressed in cells from patients with CAD 
and type 2 diabetes. 
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Figure 5.6. Retinoic Acid Receptor (RAR) Activation Canonical Pathway. RAR metabolic 
pathway showing candidate gene PRKAG1 as being differentially expressed in HSVECs from 
patients with type 2 diabetes (Ingenuity Pathway Analysis). 
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Figure 5.7. BeadStudio Candidate Gene mRNA Expression Relative to β-actin (ACTB) as 
Assessed by TaqMan® qRT-PCR. (A) ATP5G3,(B) IDH3G, (C) SDHC and (D) PRKAG1 mRNA 
expression was investigated and compared in HSVECs isolated from CAD patients with (T2D, 
n=5) and without (ND, n=10) type 2 diabetes. No statistically significant differences in mRNA 
expression were observed. For ATP5G3, IDH3G and PRKAG1, reactions were carried out in 
singleplex. For SDHC, reactions were carried out in multiplex. RQ, relative quantitation 
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5.3.2.3 Rosetta Resolver® Analysis 
 
Using Rosetta Resolver® software, a total of 92 probes were found to be differentially 
expressed in HSVECs from patients with CAD and T2D as compared to those from 
patients with CAD alone (Figure 5.8). In certain cases, more than one probe corresponded 
to a particular gene. This, coupled with the fact that IPA does not yet recognise all 
Illumina® probes, meant data generated from IPA revealed 77 genes to be differentially 
expressed in cells from patients with T2D. Of these 77 genes, expression of 15 genes was 
upregulated and expression of the remaining 62, downregulated. A complete list of these 
differentially expressed genes is included as Table A2 in the Appendix.  
 
Expression of ACAD11, encoding acyl-Coenzyme A dehydrogenase family, member 11, 
was observed to be significantly downregulated in CAD patients with T2D (Table A2). 
Given the role of acyl-Coenzyme dehydrogenases in β-oxidation of fatty acids in the 
mitochondria and the fact that mitochondria and AMPK have been implicated in T2D, 
ACAD11 was selected as a candidate gene for further investigation. 
 
 
5.3.2.3.1 Ingenuity Pathway Analysis 
 
Analysis of Rosetta Resolver® microarray data using IPA software identified G-protein 
coupled receptor signalling as the canonical metabolic pathway most significantly affected 
by the presence of T2D in patients with CAD (Figure 5.9). As previously described, 
significance was based on the number of genes with differentially expressed probes 
mapping to the pathway (Table 5.3 and Figure 5.10). AGTR2, and PI3KR2 were selected as 
candidate genes for further study.  
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Figure 5.8. Differentially Expressed Probes Identified by Rosetta Resolver® Analysis. (A) The 
Illumina® probes’ false discovery rates (FDRs) ordered on a log10 scale. The 92 in blue are below 
the 5% FDR cut-off, indicated by the red dashed line. Remaining probes (‘Unchanged’ and 
‘Invariant’) are non-significantly differentially expressed. (B) Data displayed as log-ratios on the y-
axis against mean intensity ratios on the x-axis. The 92 significantly differentially expressed probes 
are shown in blue, whilst remaining probes are in grey. 
A 
B 
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ratio of the number of differentially expressed genes from the data set mapping to the canonical pathway divided by the total number of genes mapping to 
the pathway  
  
 
Figure 5.9. IPA Canonical Pathway Analysis of Rosetta® Resolver Microarray Data. Canonical metabolic pathways significantly affected by the presence of 
type 2 diabetes were observed to cross the threshold value (P≤0.05). Significance is based on the number of differentially expressed genes in the pathway. 
Differentially expressed genes involved in G-protein coupled receptor signalling were identified as candidate genes for further investigation. 
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Gene Symbol Gene Name Fold Change P-value 
AGTR2 angiotensin II receptor, type 2 1.453 0.0239 
PDE8A phosphodiesterase 8A -1.263 0.0319 
PIK3R2 phosphoinositide-3-kinase, regulatory subunit 2 (beta) -1.221 0.0358 
 
 
Table 5.3. Differentially Expressed G-protein Coupled Receptor Signalling Genes. IPA canonical pathway analysis of BeadStudio microarray data identified 3 
genes within the G-protein coupled receptor signalling pathway as being differentially expressed in cells from patients with CAD and type 2 diabetes (T2D). AGTR2 
was observed to be upregulated in cells from patients with T2D, while PDE8A and PIK3R2 were downregulated in these patients. 
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Figure 5.10. G-protein Coupled Receptor Signalling Canonical Pathway. G-protein coupled 
receptor signalling metabolic pathway showing candidate genes differentially expressed in 
HSVECs from patients with type 2 diabetes (Ingenuity Pathway Analysis).  
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5.3.2.3.2 Confirmation of Differential Expression of Candidate Genes by 
TaqMan® Real-Time RT-PCR 
 
As shown in Figure 5.11A, no significant difference in HSVEC ACAD11 mRNA 
expression was observed between patients with CAD and T2D and patients with CAD 
alone (∆Ct, 7.815 ± 0.236 vs 7.185 ± 0.301; P=0.205) as assessed by TaqMan® qRT-PCR. 
Similarly, HSVEC PI3KR2 mRNA expression was found not be statistically significantly 
different in HSVECs isolated from CAD patients with and without T2D (∆Ct, 6.161 ± 
0.186 vs 5.527 ± 0.151; P=0.067; Figure 5.11B). Expression of AGTR2 mRNA was 
undetectable in HSVECs from either patient group. 
 
 
5.3.2.4 Identification of Differentially Expressed Genes Common to 
BeadStudio & Rosetta Resolver® Microarray Data 
 
A total of 45 differentially expressed genes were found to be common to both BeadStudio 
and Rosetta Resolver® data sets as represented in a Venn diagram (Figure 5.12) and listed 
in Table 5.4. Commonly differentially expressed genes included candidate genes, ACAD11 
and AGTR2. Other candidate genes were not found to be differentially expressed in both 
data sets. 
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Figure 5.11. Rosetta Resolver® Candidate Gene mRNA Expression Relative to β-actin 
(ACTB) as Assessed by TaqMan® qRT-PCR. Expression of (A) ACAD11 and (B) PIK3R2 
mRNA expression was investigated in HSVECs isolated from CAD patients with (T2D, n=5) and 
without (ND, n=10) type 2 diabetes. No statistically significant differences in mRNA expression 
were observed. Reactions were carried out in singleplex. RQ, relative quantitation 
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Figure 5.12. Differentially Expressed Genes Common to BeadStudio & Rosetta Resolver® 
Analyses of Microarray Data. Venn diagram illustrating that 45 differentially expressed genes 
were found to be common to both BeadStudio and Rosetta Resolver® data sets. For both analyses, 
numbers indicate differentially expressed genes rather than probes. 
 
 
45 32 576 
Rosetta Resolver® 
(77) 
BeadStudio 
(621) 
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Gene Symbol Gene Name 
ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 
ACAD11 acyl-Coenzyme A dehydrogenase family, member 11 
AFG3L1 AFG3 ATPase family gene 3-like 1 (S. cerevisiae) 
AGTR2 angiotensin II receptor, type 2 
AMT aminomethyltransferase 
AMY2A amylase, alpha 2A (pancreatic) 
CCDC113 coiled-coil domain containing 113 
CFDP1 craniofacial development protein 1 
CROP cisplatin resistance-associated overexpressed protein 
DGKQ diacylglycerol kinase, theta 110kDa 
E4F1 E4F transcription factor 1 
EFHD1 EF-hand domain family, member D1 
ERGIC2 ERGIC and golgi 2 
FAP fibroblast activation protein, alpha 
GNRH1 gonadotropin-releasing hormone 1 (luteinizing-releasing hormone) 
HIP1R huntingtin interacting protein 1 related 
KIAA1328 KIAA1328 
LOC283932 hypothetical LOC283932 
LOC727762 similar to NADH:ubiquinone oxidoreductase B15 subunit 
LOC729137 hypothetical protein LOC441528 
LRCH4 
leucine-rich repeats and calponin homology (CH) domain 
containing 4 
LZTFL1 leucine zipper transcription factor-like 1 
MFSD1 major facilitator superfamily domain containing 1 
MGC42630 family with sequence similarity 27, member E3 
NSUN5B NOL1/NOP2/Sun domain family, member 5B 
NUTF2 nuclear transport factor 2 
PDE8A phosphodiesterase 8A 
RAB22A RAB22A, member RAS oncogene family 
RALBP1 ralA binding protein 1 
RDH5 retinol dehydrogenase 5 (11-cis/9-cis) 
RIC8B resistance to inhibitors of cholinesterase 8 homolog B (C. elegans) 
SAA4 serum amyloid A4, constitutive 
SETD6 SET domain containing 6 
SLC23A3 solute carrier family 23 (nucleobase transporters), member 3 
SLC38A6 solute carrier family 38, member 6 
STK36 serine/threonine kinase 36, fused homolog (Drosophila) 
TDRD9 tudor domain containing 9 
TM9SF3 transmembrane 9 superfamily member 3 
USHBP1 Usher syndrome 1C binding protein 1 
WDR60 WD repeat domain 60 
ZBTB12 zinc finger and BTB domain containing 12 
ZNF266 zinc finger protein 266 
ZNF439 zinc finger protein 439 
ZNF569 zinc finger protein 569 
ZNF83 zinc finger protein 83 
 
Table 5.4. Differentially Expressed Genes Common to BeadStudio & Rosetta Resolver® 
Analyses of Microarray Data. A total of 45 differentially expressed genes were found to be 
common to both BeadStudio and Rosetta Resolver® data sets 
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5.4 Discussion 
 
Experimental work described in this chapter explored differential gene expression in 
primary HSVECs isolated from CAD patients with and without the additional CVD risk 
factor, T2D. These studies were performed in an attempt to identify candidate genes and 
pathways contributing to the more severe endothelial dysfunction observed in vessels from 
patients with CAD and T2D (Figure 3.2B). This work represents a novel investigation as 
previous attempts to identify differences in gene expression profiles between CAD patients 
with and without T2D have focused on intact cardiac tissue (381;384). 
 
Expression profiles of over 25,000 annotated genes were assessed using Illumina® 
HumanWG-6 v3.0 Expression BeadChips. Primary analysis of microarray data was carried 
out using BeadStudio software which generated a list of 727 differentially expressed 
probes (Table A1).  
 
On uploading BeadStudio data to IPA, the citrate cycle was identified as a canonical 
metabolic pathway significantly affected by T2D (Figure 5.4). As outlined in section 
1.3.4.3.1, electron donor overproduction by the citrate cycle is known to contribute to 
increased mtROS production in T2D, thus facilitating progression of endothelial 
dysfunction (230). Furthermore, reduced glucose oxidation and storage in T2D have been 
observed to occur in parallel with reduced activity of the citrate cycle (391) and microarray 
analysis has revealed expression of a number of citrate cycle genes to be reduced in muscle 
biopsies from patients with T2D, including ATP5G3 and SDHC (392), genes observed to 
be downregulated here (Table 5.1). Consequently, ATP5G3, SDHC and a third 
differentially expressed gene affecting the citrate cycle metabolic pathway, IDH3G (Table 
5.1), were selected as candidate genes for further study. As shown in Table 5.1, SDHAL1 
was also recognised as a differentially expressed gene involved in the citrate cycle. 
However, it was identified as a pseudogene and thus no attempt was made to confirm its 
differential expression. 
 
Fold changes in citrate cycle gene expression were relatively modest (Table 5.1) and 
therefore it is perhaps not surprising that differential expression of ATP5G3, IDH3G and 
SDHC was not confirmed using TaqMan® qRT-PCR and the 2-∆∆Ct comparative method, a 
method limited in its ability to accurately detect less than a two-fold change in gene 
expression (301). Given the complex nature of T2D, it seems likely that modest changes in 
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expression of several genes in a given pathway will be important and, as stated, previous 
studies have suggested that coordinated reduction in expression of genes of oxidative 
metabolism are implicated in T2D (392). Of note, analysis of microarray data revealed 
downregulation of ATP5G3 expression and upregulation of IDH3G expression in cells 
from CAD patients with T2D (Table 5.1). The fact that TaqMan® qRT-PCR demonstrated 
a trend towards a change in expression in the opposite direction for both genes (Figure 
5.7A and B), may be explained by the fact that due to limited human cellular material, 
qRT-PCR experiments did not incorporate the entire microarray patient group.  
 
Interestingly, although not confirmed by qRT-PCR, downregulation of ATPG3 and SDHC 
in HSVECs from patients with T2D could lead to reduced flux through the citrate cycle 
and a decrease in ATP synthesis which, in turn, would lead to an increase in AMPK 
activity (248). Reduced expression of citrate cycle genes in the endothelium of CAD 
patients with T2D may therefore contribute to the increased AMPK activity observed in 
HSVECs isolated from these patients (Figure 4.3). 
 
PRKAG1 encodes the regulatory γ1-subunit of AMPK and was observed to be involved in 
a number of metabolic pathways significantly affected by T2D, including IGF-1 signalling 
(Figure 5.4) and the most significantly affected pathway, RAR activation (Figure 5.4, 
Table 5.2 and Figure 5.6). As outlined, AMPK is recognised as a therapeutic target in T2D 
(137;143) and with results suggesting AMPK activity is increased in HSVECs isolated 
from patients with both CAD and T2D (Figure 4.3), PRKAG1 was selected as a fourth 
candidate gene from BeadStudio microarray data. Again, BeadStudio analysis revealed a 
modest reduction in PRKAG1 expression which was not confirmed by TaqMan® qRT-
PCR. This finding was perhaps to be expected as AMPK subunits do not exist as single 
entities, found only within heterotrimers of α-, β- and γ-subunits (248) and expression of 
all three should therefore remain the same. No difference in expression of PRKAA1, 
encoding the α1-catalytic subunit, was observed in HSVECs from CAD patients with T2D 
(Figure 4.5). Therefore, if PRKAG1 expression was indeed downregulated in cells from 
these patients, it would follow that expression of PRKAG2 and/or PRKAG3, encoding the 
γ2- and γ3-subunits respectively, would be upregulated. However, neither PRKAG2 nor 
PRKAG3 were identified as being differentially expressed on analysis of microarray data 
and, as such, downregulation of PRKAG1 appears to be a spurious finding, potentially 
representing a false positive outcome. 
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NRF2-mediated oxidative stress response and IGF-1 signalling, canonical metabolic 
pathways significantly affected by the presence of T2D (Figure 5.4), were of potential 
interest in terms of T2D pathogenesis. However, it should be noted that BeadStudio 
analysis had limited statistical merit as no FDR cut-off was applied or background 
subtraction of data performed. This may explain why differential expression of candidate 
genes was not confirmed by qRT-PCR and is why, with human cellular material limited, 
differentially expressed genes involved in additional canonical pathways were not 
investigated further. Instead, a more statistically robust analysis of microarray data using 
Rosetta Resolver® software was performed. 
 
Uploading microarray data to the Rosetta Resolver® Gene Expression Data Management 
and Analysis System permitted identification of an outlier using PCA. This outlier, a T2D 
patient, was subsequently excluded from further analysis. Rosetta Resolver® analysis, 
incorporating more stringent statistical limits, generated a list of fewer significantly 
differentially expressed genes (Table A2) than BeadStudio analysis. In addition, IPA 
revealed a decrease in the number of canonical metabolic pathways significantly affected 
(Figure 5.9). G-protein coupled receptor signalling was observed to be the pathway most 
significantly affected by the presence of T2D (Figure 5.9) with AGTR2 and PIK3R2 
identified as differentially expressed genes involved in this metabolic process (Table 5.3).  
 
Expression of AGTR2, encoding the Ang II type 2 receptor, was found to be modestly 
upregulated in HSVECs from patients with T2D (Table 5.3). Ang II is one of the main 
effector molecules of the RAS, known to play a deleterious role in the initiation and 
progression of atherosclerosis (393). Ang II mediates its physiological effects by binding 
Ang II type 1 (AT1) and type 2 (AT2) receptors on the cell membrane (394;395) (Figure 
5.13). AT1 receptor binding has been shown to mediate vasoconstrictor responses and cell 
growth and proliferation of VSMCs, cardiomyocytes and coronary endothelial cells. As 
such, the AT1 receptor has been implicated in various cardiovascular pathologies, 
including atherosclerosis and stroke (393;395) and ARBs act to block the adverse effects 
of Ang II through direct interaction with this receptor (393;396). Conversely, the AT2 
receptor mediates vasodilatory responses and biological processes that counteract the 
trophic responses mediated through AT1 receptor (395;397).  
 
Previously described findings of this study suggest CAD patients with T2D have poorer 
endothelial function (Figure 3.2) and are subject to increased oxidative stress in the  
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Figure 5.13. Renin-Angiotensin System Enzymatic Cascades. The main effector molecule of the 
renin-angiotensin system (RAS), angiotensin II (Ang II), can be generated in an angiotensin 
converting enzyme (ACE)-dependent or independent manner. ACE-dependent Ang II formation 
occurs via a two step reaction: renin catalyses the conversion of angiotensinogen to angiotensin I 
(Ang I) which is subsequently hydrolysed by ACE to form Ang II. Alternatively, the direct 
conversion of angiotensinogen to Ang I can occur independently of ACE via enzymes such as 
tissue plasminogen activator (tPA), cathepsin G and tonin. In addition, chymase and cathepsin G 
are able to catalyse the ACE-independent hydrolysis of Ang I to Ang II. Ang II mediates its 
physiological effects by binding angiotensin II type I (AT1) and angiotensin II type 2 (AT2) 
receptors on the cell membrane. The receptors display a heterogenous tissue distribution with the 
AT1 receptor present in adult cardiovascular tissues and the AT2 receptor observed to be highly 
expressed during foetal development. AT1 receptor binding has been shown to mediate 
vasoconstrictor responses. Conversely, the AT2 receptor mediates vasodilatory responses. A 
recently discovered ACE-related carboxypeptidase (ACE2) catalyses the cleavage of Ang I to 
angiotensin 1-9 (Ang 1-9) and mediates the transformation of Ang II into angiotensin 1-7 (Ang 1-
7), a known vasodilator (398;399). Ang 1-9 may also be directly converted to Ang 1-7 by ACE. 
Adapted from (395;396). 
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endothelium (Figure 3.8) as compared to patients with CAD alone. As such, it seemed 
possible that upregulation of AGTR2 expression in cells from T2D patients represented an 
adaptive response to adverse effects of the AT1 receptor. However, while analysis of 
microarray data revealed differential expression of AGTR2, expression levels detected 
were very low. Consequently, on attempting to confirm differential expression of the gene 
using TaqMan® qRT-PCR, AGTR2 mRNA levels were undetectable. This finding is 
concordant with previous studies which have found that the AT2 receptor is highly 
expressed during foetal development, with mRNA levels less abundant in adult 
cardiovascular tissue (394;395). 
 
Identified as a second candidate gene from the Rosetta Resolver® data set (Table 5.3 and 
Figure 5.10), PIK3R2 encodes the regulatory (IRS-binding) subunit of PI3K, p85β (400). 
As outlined in section 1.1, PI3K plays a pivotal role in insulin signalling and development 
of T2D and the p85β subunit has been shown to be involved in insulin sensitivity in mice 
(401). Differential expression of PIK3R2 in the endothelium of patients with T2D could 
therefore contribute to reduced sensitivity to insulin, leading to a decrease in NO synthesis 
and the attenuated endothelial function observed in these patients (Figure 3.2). In this 
instance, microarray data analysis again revealed a modest fold change in gene expression 
which was not confirmed by TaqMan® qRT-PCR (Figure 5.11B). Indeed, once more qRT-
PCR demonstrated a trend towards a change in expression in the direction opposite to that 
observed on analysis of microarray data (Table 5.3 and Figure 5.11B), possibly the result 
of PCR experiments involving only a subset of microarray patients. Given the potential 
significance of differential PIK3R2 expression in the endothelium of patients with T2D, 
this kinase may merit further investigation in the future. 
 
Although not observed to be involved in metabolic pathways significantly affected by 
T2D, ACAD11 was found to be differentially expressed on Rosetta Resolver® analysis of 
microrray data (Table A2). The gene encodes one of the most recently identified subtypes 
of the acyl-Coenzyme A dehydrogenase (ACAD) family and is, as yet, of unknown 
function (402). However, with a number of ACAD subtypes involved in mitochondrial β-
oxidation of fatty acids (402;403), a process implicated in development of T2D and insulin 
resistance (230), ACAD11 was selected for further investigation. 
 
ACAD11 expression was observed to be downregulated in cells from patients with T2D on 
Rosetta Resolver® analysis of microarray data (Table A2). Although presently 
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uncharacterised, if ACAD11 represents an ACAD family member required for β-oxidation 
of fatty acids, downregulation of its expression may imply impaired β-oxidation and thus 
reliance on glucose oxidation in the endothelium of patients with T2D. This situation could 
potentially be associated with the increased AMPK activity observed in HSVECs isolated 
from patients with CAD and T2D (Figure 4.3), as increasing activity of the kinase, with a 
view to stimulating fatty acid oxidation, could be an attempt to overcome the problem of 
increased glucose oxidation. However, TaqMan® qRT-PCR failed to confirm differential 
expression of ACAD11, instead revealing a trend towards increased expression in CAD 
patients with T2D (Figure 5.11A).  
 
On examination of both microarray data sets, a total of 45 differentially expressed genes 
were identified as being common to both BeadStudio and Rosetta Resolver® analyses 
(Table 5.4 and Figure 5.12). Perhaps unsurprisingly, given the limited statistical merit of 
the analysis, none of the candidate genes identified from the BeadStudio data set were 
included in the list of common genes, supporting the notion that this analysis may have 
given rise to a number of false positives. AGTR2 and ACAD11, candidate genes selected 
from Rosetta Resolver® analysis, were found to be common to both lists of differentially 
expressed genes. However, PIK3R2 was not identified as a common gene. This gene was 
selected from the more statistically robust Rosetta Resolver® data set and so despite its 
absence from the BeadStudio list, it is still an interesting candidate. PDE8A, encoding 
phosphodiesterase 8A, was another gene identified as common to both data sets. Rosetta 
Resolver® analysis revealed PDE8A to be modestly downregulated in patients with T2D 
and involved in G-protein coupled receptor signalling (Figure 5.9 and Table 5.3). Further 
investigation of PDE8A expression was not carried out due to limited human cellular 
material and time constraints but, with the isoenzyme, PDE8B suggested to have a role in 
insulin response to glucose in rat pancreatic β-cells (404), PDE8A may represent a focus of 
future studies.  
 
The transcriptional profiling described in this chapter represents the first human microarray 
study to be carried out within this laboratory and was not without limitations and 
difficulties. The application of stringent statistical limits resulted in relatively few genes 
being identified as differentially expressed between patient groups. There may be a number 
of potential explanations for this, including, as previously suggested, that human 
endothelial cells fail to retain the in vivo phenotype in culture. One possible strategy to 
overcome this issue could involve microarray analysis of pooled RNAs from passage 0 
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cells. Furthermore, complex diseases, such as T2D, are likely to be the result of low-
magnitude alterations in expression of multiple genes and therefore the small subject 
numbers in this study limits the power to detect differences between groups. In addition, as 
previously discussed, using TaqMan® qRT-PCR and the 2-∆∆Ct method to validate 
differential expression means anything less than a two-fold change in gene expression is 
considered insignificant (301). Given these limitations, complementary methodologies, 
including proteomics and microRNA (miRNA) profiling, may aid in the elucidation of 
molecular mechanisms adversely affected in the endothelium of patients with CAD and 
T2D. With increasing evidence to implicate endothelial dysfunction in T2D disease 
progression (162), integration of these technologies, allowing examination of gene 
transcription and translation in the endothelium of CAD patients with T2D, seems key to 
understanding diabetic vascular complications. 
184 
 
 
 
 
 
6. General Discussion 
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Endothelial dysfunction occurs in conjunction with CAD and is observed in both the 
coronary and peripheral vasculature (405). Accumulating evidence suggests a causative 
role for vascular oxidative stress in endothelial dysfunction and the pathogenesis of CAD 
(159). The prevalence of CAD in patients with T2D is more than ten times greater than in 
the general population and poorer clinical outcomes are observed in CAD patients with 
T2D than in those without (335;406;407). Previous investigations carried out within this 
laboratory have demonstrated endothelial dysfunction and elevated O2- production in 
saphenous veins from patients with advanced CAD (159). In addition to confirming these 
findings, this study has considered the effects of T2D on endothelial function and vascular 
O2- production, revealing more severe endothelial dysfunction in vessels from those CAD 
patients with T2D. Through application of a wide range of molecular techniques, cellular 
mechanisms underlying this oxidative stress and endothelial dysfunction have been 
investigated in primary endothelial cells isolated from CAD patients.  
 
Having confirmed elevated O2- production in vessels from patients with CAD and with Al 
Benna et al. reporting that this increase occurs throughout the vessel wall (159), 
preliminary cellular work involved investigation of HSVEC O2- production. EPR 
spectroscopy failed to confirm significantly increased O2- release in cells from CAD 
patients relative to those from controls, raising the possibility that cultured primary cells, 
free from physiological stresses, do not retain the in vivo phenotype. While it is 
acknowledged that this may represent a potential limitation of the study, in focusing on 
cultured primary endothelial cells, a pragmatic approach to the exploration of endothelium-
specific mechanisms of oxidative stress has been adopted.  
 
Subsequent investigations revealed increased HSVEC SOD2 protein and mRNA 
expression in CAD patients, in particular those with T2D. This increase in SOD2 
expression is likely to represent an adaptive response to elevated mitochondrial O2- 
production as accumulating evidence suggests mitochondrially-derived ROS contribute to 
oxidative stress and endothelial dysfunction in a range of cardiovascular pathologies, 
including CAD and T2D (222;224;225). Attempts to establish the contribution of 
mitochondria to cellular O2- production involved treatment of HSVECs with rotenone and 
MitoQ10. The results of these studies were inconclusive but the role of mitochondria in 
HSVEC O2- generation clearly merits further investigation. As such, alternative methods, 
including MitoSOX™ (Invitrogen) staining, will be employed to this end in the future. 
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With HSVECs isolated from CAD patients failing to retain the significantly elevated O2- 
phenotype but displaying increased SOD2 expression, H2O2 may represent a more useful 
marker of oxidative stress in the endothelium of these patients. Known to induce 
endothelial dysfunction (408), H2O2 is a more stable molecule than O2- which may render 
its detection in HSVECs less challenging. Thus, in addition to assessment of mitochondrial 
O2- production, future studies are likely to involve comparisons of cellular H2O2, using 
Amplex® Red (Invitrogen) technology or EPR spectroscopy, employing the method 
recently described by Dikalov and colleagues (409). 
 
Expression of SOD2 mRNA was significantly increased in HSVECs from CAD patients 
with T2D relative to those from patients with CAD alone, as assessed by TaqMan® qRT-
PCR. However, this differential expression was not confirmed on comparison of global 
gene expression profiles in cells from these patients. This was perhaps not surprising, 
given qRT-PCR and microarray experiments did not involve investigation of gene 
expression in cells isolated from the same clinical subjects, a consequence of limited 
vascular material. This finding therefore serves to highlight the difficulty of studying gene 
expression in outbred human populations.  
 
Despite obvious limitations of the microarray experiment described in Chapter 5, it 
remains the first study of its kind to examine global gene expression in primary endothelial 
cells from CAD patients with and without T2D. Furthermore, in revealing differential 
expression of a number of genes potentially linked to mitochondrial function, the study 
serves to support a key role for mitochondrial dysfunction in the pathogenesis of CAD and 
T2D. However, the difficulties associated with small subject numbers and confirmation of 
differential expression of candidate genes, in addition to the possibility that cultured cells 
do not retain the in vivo phenotype, indicates alternative or complementary technologies 
may prove more successful in elucidating molecular mechanisms adversely affected in 
patients with CAD and T2D. Proteomics, which involves the identification of polymorphic 
protein expression and isoforms between samples, is increasingly being applied in complex 
disease research and has been utilised within this laboratory in the context of CAD; urinary 
protein biomarkers were assayed in control subjects and patients with CAD and a signature 
polypeptide pattern specific to CAD patients distinguished (410).  
 
In addition to proteomics, miRNA technology has attracted considerable research interest 
in recent years. MicroRNAs are non-coding RNA molecules involved in post-
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transcriptional control of gene expression (411). The ability of miRNAs to affect 
expression of complex diseases such as CAD and T2D is considered likely since they are 
known to target multiple mRNAs (412). Indeed, genome-wide expression profiling of 
miRNAs in patients with heart disease (ischaemic cardiomyopathy, dilated 
cardiomyopathy and aortic stenosis) revealed disease-specific miRNA expression patterns 
particular to each condition on comparison with healthy control subjects (413). In terms of 
diabetes, specific miRNAs involved in insulin production, secretion and action have been 
identified in recent years (414;415). In particular, studies involving murine models have 
reported miR-9 and miR-375 to be involved in regulation of insulin secretion (416;417), 
while miR-124a2 has recently been implicated in pancreatic β-cell development and 
function (418). However, despite growing evidence that miRNAs are important in T2D, 
few studies of global miRNA expression in human insulin target tissues have been 
published to date. The present study was limited due to the majority of samples being 
collected before well established techniques to capture miRNAs became available but 
future studies may focus on these small RNA components. 
 
While the microarray experiment of Chapter 5 represents a novel piece of work, the key 
findings of this project centre around AMPK. Recently identified as a potential therapeutic 
target in vascular disease (419), AMPK is currently the subject of extensive research. A 
paper from Professor Salvador Moncada’s group, published in 2006, revealed that the 
kinase is activated in a mtROS-mediated manner in endothelial cells (228). Consequently, 
the finding that SOD2 expression is significantly increased in HSVECs from patients with 
CAD, consistent with increased mtROS production, led to investigation of AMPK activity 
in these cells. Activity of the kinase was observed to be significantly increased in the 
endothelium of CAD patients with T2D despite no change in activity of upstream kinases, 
LKB1 and CaMKK, suggesting an alternative, potentially mtROS-mediated method of 
activation in these individuals. Indeed, it seemed likely that these patients, with an extra 
risk factor for CVD, poorer endothelial function and significantly increased endothelial 
SOD2 expression, would be subject to increased mitochondrially-produced ROS in the 
endothelium, resulting in the increased AMPK activity observed. As described in Chapter 
4, treatment of cells with the mitochondria-targeted antioxidant, MitoQ10 revealed AMPK 
is indeed activated in a mtROS-mediated manner in the endothelium of patients with CAD 
and T2D, representing the major, novel finding of this project.  
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In terms of what mtROS-mediated activation of AMPK means in relation to enzymatic 
function, it appears AMPK is part of a feedback or adaptive mechanism with a role in 
defence against oxidative stress in the endothelium of patients with CAD and T2D. The 
kinase may contribute to control of vascular tone through phosphorylation of eNOS and 
stimulation of NO production (176;282), or by inducing expression of genes involved in 
antioxidant defence, including SOD2 itself (377;378). As such, assessment of HSVEC 
SOD2 expression following treatment of cells with AICAR and MitoQ10 will be carried out 
in the near future.  
 
In addition to inducing expression of SOD2, there is now evidence to suggest AMPK 
inhibits production of O2- by NAD(P)H oxidase. A recent study by Alba and colleagues 
demonstrated that AMPK inhibits activation of NAD(P)H oxidase in neutrophils by 
phosphorylating the p47phox subunit, thus preventing its translocation to the plasma 
membrane (420). The findings described in Chapter 3 of this thesis indicate a lesser 
contribution of vascular NAD(P)H oxidase to O2- production in endothelial cells of patients 
with CAD and T2D than in cells from patients with CAD alone. This result may therefore 
be explained by the fact that increased endothelial AMPK activity in CAD patients with 
T2D results in suppression of NAD(P)H oxidase activation in the endothelium of these 
patients. 
 
With vascular complications the leading cause of death in patients with CAD and T2D 
(8;30), the body of work presented here further supports the idea that a well tolerated 
therapeutic activator of AMPK should successfully improve glycaemic control while 
maintaining or restoring endothelial function. Agents presently known to activate AMPK, 
such as metformin, appear to act indirectly and exhibit a number of unpleasant side effects 
(419). Attempts have been made to generate alternative AMPK-activating agents, 
including the thienopyridone A769662, which induces AMPK activity via a mechanism 
involving the β- and γ-subunits (421). However, this compound may have potentially 
limiting side effects and is reported to inhibit the function of the 26S proteasome by an 
AMPK-independent mechanism, leading to cell cycle arrest in mouse embryonic 
fibroblasts in vitro (422). Despite this observation, treatment of ob/ob mice with A769662 
lowered plasma glucose, reduced body weight gain, and significantly decreased both 
plasma and liver triglyceride levels (423). It remains to be determined whether the 
compound can improve vascular function.  
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Results presented here suggest activators of AMPK will prove most useful when 
administered in conjunction with mitochondria-targeted antioxidants, such as MitoQ10. The 
ubiquinone has recently been shown to improve endothelial function and attenuate cardiac 
hypertrophy in a rodent model of CVD, the SHRSP (424). In addition, it has reached two 
human phase 2 clinical trials and is reported to be protective against liver damage in a 
small study of patients with chronic hepatitis C (425) and well tolerated when taken over 
the period of a year by patients with Parkinson’s disease (426). At the time of writing, an 
application has been made by this group to the Medicines and Healthcare products 
Regulatory Agency (MHRA) for a clinical trial of MitoQ10 in patients with CAD 
undergoing CABG surgery. Should this application prove successful, the contribution of 
mitochondrially-derived ROS to oxidative stress and endothelial dysfunction, and the 
translational relevance of modulation of AMPK activity by mtROS could be determined 
through examination of vessels and cells isolated from trial participants. Alternatively, 
future in vivo studies may utilise the SHRSP, with investigations of mtROS production and 
kinase activity following oral administration of MitoQ10. 
 
In conclusion, the findings presented in this thesis confirm CAD is associated with 
endothelial dysfunction and elevated vascular O2- production and provide insight into the 
cellular mechanisms underlying these processes in the endothelium. This study 
demonstrates a novel, mtROS-mediated mechanism for AMPK activation in the 
endothelium of patients with coronary artery disease and type 2 diabetes and suggests 
mitochondria contribute to increased O2- production and endothelial dysfunction in these 
patients. In terms of clinical perspective, results indicate that mitochondria-targeted 
antioxidants, used in combination with pharmacological activators of AMPK, may have 
therapeutic potential as an early intervention strategy in the treatment of endothelial 
dysfunction in these patients. 
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Illumina® 
Probe ID 
Gene 
Symbol 
T2D Diff 
Score 
Illumina® 
Probe ID Gene Symbol 
T2D Diff 
Score 
ILMN_1862910  -51.512 ILMN_1776428 STK17A -20.689 
ILMN_1722397 LOC729137 -41.691 ILMN_1813769 ARRDC3 -20.636 
ILMN_1788955 PDLIM1 -40.376 ILMN_1750722 RPS7 -20.494 
ILMN_1752269 ACSS1 -33.752 ILMN_1694075 GADD45A -20.261 
ILMN_1719949 LOC644019 -31.901 ILMN_1699022 ENDOD1 -20.221 
ILMN_1740466 FAM46A -28.802 ILMN_1777849 IL7R -20.189 
ILMN_1663765 LOC647346 -28.787 ILMN_1696810 ADMR -20.078 
ILMN_1669404 KISS1 -28.355 ILMN_1765633 FAM10A7 -20.03 
ILMN_1732575 SEC14L1 -27.921 ILMN_1675684 APOBEC3C -19.899 
ILMN_1730201 DTNA -27.194 ILMN_1874778 LOC729310 -19.813 
ILMN_1703140 NEDD4 -27.098 ILMN_1705364 BAT3 -19.752 
ILMN_1696537 DDIT4L -26.676 ILMN_1731639 CASP3 -19.464 
ILMN_1746241 SDHC -26.557 ILMN_1675797 EPDR1 -19.464 
ILMN_1652763 LOC389203 -26.039 ILMN_1656327 GLT1D1 -19.396 
ILMN_1659365 LOC653071 -25.739 ILMN_1803375 ODZ1 -19.368 
ILMN_1794505 SHFM1 -24.905 ILMN_1794038 FAM49A -19.24 
ILMN_1759344 LOC652226 -24.892 ILMN_1662097 SLC25A43 -19.035 
ILMN_1720430 C20orf149 -24.198 ILMN_1683494 TMEM154 -18.807 
ILMN_1806266 RAP1GDS1 -23.93 ILMN_1694100 PRIM2 -18.801 
ILMN_1665865 IGFBP4 -23.751 ILMN_1821335  -18.582 
ILMN_1652638 LRRC58 -23.634 ILMN_1655222 LOC389833 -18.483 
ILMN_1749078 TIMP2 -23.12 ILMN_1725705 CLPP -18.439 
ILMN_1745578 ETS2 -22.945 ILMN_1705630 LOC641700 -18.309 
ILMN_1745593 STMN1 -22.764 ILMN_1707356 CFL2 -18.264 
ILMN_1880421  -22.471 ILMN_1830906  -18.235 
ILMN_1757387 UCHL1 -22.451 ILMN_1836185  -18.189 
ILMN_1666022 
TNFRSF10
D -22.167 ILMN_1675312 LOC389833 -18.144 
ILMN_1716407 SORBS2 -22.01 ILMN_1770466 ATP5G3 -18.009 
ILMN_1655236 GFPT2 -21.798 ILMN_1695872 LOC641992 -17.995 
ILMN_1673676 SNX5 -21.759 ILMN_1654563 EFNB1 -17.95 
ILMN_1687538 ETS1 -21.695 ILMN_1742065 GCNT4 -17.95 
ILMN_1667970 LOC728825 -21.661 ILMN_1717855 PFDN1 -17.881 
ILMN_1751851 CECR1 -21.569 ILMN_1767556 C10orf10 -17.85 
ILMN_1702168 HSD17B12 -21.535 ILMN_1665736 LOC648024 -17.809 
ILMN_1655046 NUTF2 -21.535 ILMN_1764261 TMEM128 -17.782 
ILMN_1675156 CDC42 -21.522 ILMN_1665682 IL15RA -17.762 
ILMN_1701613 RARRES3 -21.431 ILMN_1736356 STK32B -17.664 
ILMN_1698478 SNAPC2 -21.333 ILMN_1764225 GAGE6 -17.569 
ILMN_1800837 CFDP1 -21.281 ILMN_1780060 FCN3 -17.45 
ILMN_1718182 THRA -21.167 ILMN_1674620 SGCE -17.404 
ILMN_1716518 NACA -21.145 ILMN_1662016 SCRN2 -17.269 
ILMN_1694569 LOC650224 -20.899 ILMN_1800131 LOC652826 -17.267 
ILMN_1721535 COG5 -20.883 ILMN_1726415 CCNA1 -17.258 
ILMN_1742250 CCNH -20.875 ILMN_1693108 RUVBL1 -17.253 
ILMN_1808041 RPL10A -20.855 ILMN_1774545 LOC339240 -17.21 
ILMN_1656651 MR1 -20.853 ILMN_1756862 APOL3 -17.115 
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ILMN_1792814 FLJ43870 -17.075 ILMN_1683375 MCL1 -15.397 
ILMN_1726523 OR10G3 -17.072 ILMN_1841025  -15.39 
ILMN_1660248 WTAP -17.061 ILMN_1779213 TFG -15.371 
ILMN_1911874  -17.033 ILMN_1836965  -15.352 
ILMN_1801661 KRT7 -16.965 ILMN_1772743 PIGK -15.351 
ILMN_1810941 COMT -16.964 ILMN_1677483 EXOSC1 -15.309 
ILMN_1750225 MYCT1 -16.914 ILMN_1815032 SOX7 -15.298 
ILMN_1765701 LOC399942 -16.887 ILMN_1788283 COTL1 -15.296 
ILMN_1677610 OVCA2 -16.768 ILMN_1676289 NCAM1 -15.273 
ILMN_1869431  -16.701 ILMN_1831325  -15.236 
ILMN_1676173 PARVB -16.676 ILMN_1783681 MRPL34 -15.235 
ILMN_1711899 ANXA2 -16.659 ILMN_1671267 NF2 -15.219 
ILMN_1908488  -16.655 ILMN_1774086 CBX3 -15.209 
ILMN_1690063 LOC651143 -16.52 ILMN_1827211  -15.168 
ILMN_1729142 PRR6 -16.439 ILMN_1912500  -15.145 
ILMN_1713574 LOC643493 -16.369 ILMN_1669376 DRAM -15.13 
ILMN_1705982 LOC645284 -16.347 ILMN_1748591 ODC1 -15.11 
ILMN_1889126  -16.313 ILMN_1754249 LOC442535 -15.106 
ILMN_1726354 EXOSC7 -16.276 ILMN_1673363 CD97 -15.088 
ILMN_1658639 SLC46A3 -16.275 ILMN_1690125 PDLIM7 -15.067 
ILMN_1781270 LOC646071 -16.236 ILMN_1739534 MAP2K4 -15.044 
ILMN_1737163 SH3BGRL3 -16.163 ILMN_1763989 SEC63 -15.036 
ILMN_1697665 LOC653972 -16.162 ILMN_1877681  -15.035 
ILMN_1762071 C17orf80 -16.112 ILMN_1661825 TNFRSF6B -15.027 
ILMN_1727402 HCLS1 -16.11 ILMN_1687887 PSMC4 -15.018 
ILMN_1801020 ADK -16.064 ILMN_1815656 SERINC3 -15.012 
ILMN_1682935 LYPLAL1 -15.954 ILMN_1853049  -14.97 
ILMN_1680579 ATP2B4 -15.918 ILMN_1882522  -14.941 
ILMN_1757347 C22orf9 -15.897 ILMN_1667597 LOC644865 -14.935 
ILMN_1906438  -15.836 ILMN_1763688 C17orf49 -14.877 
ILMN_1707815 SDHALP1 -15.807 ILMN_1758939 RIPK2 -14.855 
ILMN_1740591 LOC649292 -15.771 ILMN_1774687 PRKAG1 -14.846 
ILMN_1846641  -15.752 ILMN_1854518  -14.841 
ILMN_1794875 MAG1 -15.672 ILMN_1801043 GSN -14.836 
ILMN_1711928 FLJ20920 -15.665 ILMN_1775634 AGTR2 -14.792 
ILMN_1691048 
SLC22A18
AS -15.663 ILMN_1785284 ALDH6A1 -14.756 
ILMN_1661417 MAGED2 -15.652 ILMN_1716859 TDO2 -14.737 
ILMN_1690566 RASSF4 -15.652 ILMN_1732916 CCDC17 -14.723 
ILMN_1672922 CYTL1 -15.634 ILMN_1827239  -14.715 
ILMN_1654322 ATP1B3 -15.567 ILMN_1697945 FRMD4B -14.703 
ILMN_1787750 CD200 -15.555 ILMN_1800487 CDC26 -14.693 
ILMN_1685240 PTRH1 -15.513 ILMN_1660718 GABBR2 -14.691 
ILMN_1652549 DTNA -15.496 ILMN_1808713 HSD17B2 -14.68 
ILMN_1790249 F8A1 -15.423 ILMN_1658053 DYNLRB1 -14.668 
ILMN_1739103 MPZL1 -15.404 ILMN_1790271 EEF1B2 -14.658 
ILMN_1705116 C6orf85 -15.403 ILMN_1678312 LOC388397 -14.656 
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ILMN_1817598  -14.654 ILMN_1740777 ZBTB12 -13.921 
ILMN_1820226  -14.647 ILMN_1708605 LOC652481 -13.884 
ILMN_1682112 PCDHA10 -14.627 ILMN_1829475  -13.88 
ILMN_1669923 SSR2 -14.591 ILMN_1886034  -13.878 
ILMN_1870248  -14.501 ILMN_1879243  -13.871 
ILMN_1689467 CCDC86 -14.497 ILMN_1894376  -13.828 
ILMN_1912718  -14.49 ILMN_1774949 PIGP -13.82 
ILMN_1688178 CGI-96 -14.448 ILMN_1795944 PRR13 -13.818 
ILMN_1785692 LOC728098 -14.445 ILMN_1651329 LOC651538 -13.797 
ILMN_1851746  -14.428 ILMN_1862963  -13.796 
ILMN_1767006 PSMB8 -14.425 ILMN_1856010  -13.745 
ILMN_1676333 LOC645465 -14.388 ILMN_1807492 LOC643668 -13.736 
ILMN_1747344 IL3RA -14.374 ILMN_1728914 PRUNE -13.732 
ILMN_1714752 ZNF658 -14.366 ILMN_1730553 DDR2 -13.73 
ILMN_1679949 SLC25A23 -14.352 ILMN_1852928  -13.701 
ILMN_1741259 LOC649209 -14.32 ILMN_1686610 APBA3 -13.675 
ILMN_1652205 LOC645785 -14.309 ILMN_1916026  -13.643 
ILMN_1743432 DGUOK -14.3 ILMN_1839168  -13.628 
ILMN_1884228  -14.27 ILMN_1886655  -13.603 
ILMN_1764573 XIST -14.267 ILMN_1917294  -13.585 
ILMN_1766643 HOP -14.255 ILMN_1794046 MTX2 -13.568 
ILMN_1710482 APLP2 -14.251 ILMN_1749907 LOC441241 -13.539 
ILMN_1679133 SERPINB1 -14.249 ILMN_1674315 POLA -13.522 
ILMN_1692077 MXRA7 -14.223 ILMN_1666174 CECR1 -13.512 
ILMN_1665040 RBMS3 -14.189 ILMN_1780988 LOC401720 -13.504 
ILMN_1915629  -14.177 ILMN_1751124 RGMB -13.504 
ILMN_1680280 LOC644923 -14.175 ILMN_1728071 KRAS -13.484 
ILMN_1870679  -14.167 ILMN_1807981 SIGIRR -13.482 
ILMN_1769027 CDC42SE1 -14.164 ILMN_1880671  -13.467 
ILMN_1879882  -14.155 ILMN_1657348 LOC650909 -13.436 
ILMN_1822952  -14.146 ILMN_1732750 CHCHD8 -13.43 
ILMN_1800000 FAM131B -14.14 ILMN_1888844  -13.424 
ILMN_1752562 CXCL5 -14.087 ILMN_1663754 ZNF442 -13.42 
ILMN_1899777  -14.086 ILMN_1656621 CHMP2A -13.418 
ILMN_1706571 SLC35D2 -14.079 ILMN_1679700 LOC389672 -13.404 
ILMN_1815081 AQP1 -14.075 ILMN_1712347 LOC644422 -13.404 
ILMN_1689669 MDK -14.074 ILMN_1914595  -13.396 
ILMN_1740487 CMTM7 -14.062 ILMN_1811303 NR5A2 -13.363 
ILMN_1800224 NOLC1 -14.044 ILMN_1814998 FKSG30 -13.323 
ILMN_1661351 C17orf81 -14.038 ILMN_1912586  -13.298 
ILMN_1692733 NRARP -14.026 ILMN_1694140 AFAP1L1 -13.29 
ILMN_1658743 CCNDBP1 -14.004 ILMN_1803277 MVP -13.29 
ILMN_1692916 LOC646135 -13.969 ILMN_1693233 KIAA0513 -13.227 
ILMN_1654462 LOC440084 -13.966 ILMN_1709440 CPM -13.207 
ILMN_1884842  -13.962 ILMN_1817948  -13.193 
ILMN_1753924 KRT19 -13.956 ILMN_1888230  -13.191 
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ILMN_1704471 NR1D2 -13.188 ILMN_1802096 ABTB1 13.398 
ILMN_1850685  -13.161 ILMN_1694399 ICA1 13.429 
ILMN_1770071 IFITM4P -13.157 ILMN_1811535 JUB 13.451 
ILMN_1905101  -13.143 ILMN_1720431 ZNF420 13.457 
ILMN_1851207  -13.139 ILMN_1789074 HSPA1A 13.46 
ILMN_1718852 PLCL1 -13.113 ILMN_1688479 LRRC42 13.468 
ILMN_1733841 TCF7L1 -13.112 ILMN_1735765 RAB14 13.481 
ILMN_1709643 TMEM69 -13.11 ILMN_1699206 KIAA1727 13.488 
ILMN_1714144 GPR108 -13.101 ILMN_1673817 REP15 13.489 
ILMN_1786331 TRIM16 -13.076 ILMN_1719149 LOC653663 13.494 
ILMN_1712525 UBE2E3 -13.049 ILMN_1859908  13.497 
ILMN_1915123  -13.04 ILMN_1782247 GCN5L2 13.5 
ILMN_1797666 SLC27A6 -13.039 ILMN_1752510 FAM13A1 13.504 
ILMN_1903877  -13.032 ILMN_1655702 ABHD5 13.526 
ILMN_1680341 PPIE -13.027 ILMN_1809139 AHCTF1 13.535 
ILMN_1768867 AP3B1 -13.021 ILMN_1722423 SHPRH 13.539 
ILMN_1811222 LOC643213 -13 ILMN_1881865  13.542 
ILMN_1839051  13.005 ILMN_1707464 MST1 13.589 
ILMN_1736901 ZDHHC23 13.017 ILMN_1709227 CCDC84 13.617 
ILMN_1728180 CROP 13.028 ILMN_1664139 FAM29A 13.624 
ILMN_1708485 BIN3 13.033 ILMN_1743402 SIX4 13.643 
ILMN_1655167 ZNF502 13.043 ILMN_1799381 SNORD14A 13.643 
ILMN_1687303 ACAD10 13.046 ILMN_1707481 BTBD15 13.654 
ILMN_1806809 ZNF189 13.057 ILMN_1726693 GTF2H1 13.661 
ILMN_1696806 CTNND1 13.06 ILMN_1810385 ATR 13.667 
ILMN_1786024 POLR3H 13.07 ILMN_1832120  13.685 
ILMN_1717112 LOC642787 13.083 ILMN_1701991 SYNJ1 13.692 
ILMN_1804111 CETN3 13.089 ILMN_1793290 WDR60 13.703 
ILMN_1699767 PDE8A 13.099 ILMN_1776094 PPCS 13.725 
ILMN_1799688 CDC23 13.118 ILMN_1725644 UBE2D2 13.731 
ILMN_1662130 LOC730316 13.12 ILMN_1915783  13.735 
ILMN_1737878 FLJ34047 13.164 ILMN_1708110 TMEM144 13.738 
ILMN_1730118 ZNF644 13.204 ILMN_1753393 OSGEP 13.752 
ILMN_1720844 SSX2IP 13.232 ILMN_1716733 MYOM2 13.755 
ILMN_1743288 LOC652570 13.236 ILMN_1737635 RAD1 13.771 
ILMN_1696757 TTC14 13.244 ILMN_1685820 RAB40B 13.772 
ILMN_1884750  13.258 ILMN_1863592  13.777 
ILMN_1743078 LOC643031 13.3 ILMN_1655922 SAPS2 13.779 
ILMN_1724017 LOC732450 13.307 ILMN_1713752 SERINC3 13.781 
ILMN_1813603 SF3B1 13.307 ILMN_1703891 TBC1D9 13.801 
ILMN_1736077 LIAS 13.314 ILMN_1682762 IDH3G 13.807 
ILMN_1870668  13.327 ILMN_1659082 ZCRB1 13.807 
ILMN_1708064 MAP4 13.36 ILMN_1767665 LOC493869 13.812 
ILMN_1749081 AUTS2 13.361 ILMN_1767642 C11orf46 13.816 
ILMN_1666082 HEATR3 13.373 ILMN_1812208 SUV420H2 13.822 
ILMN_1669982 CCDC85A 13.397 ILMN_1698365 LOC387921 13.824 
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ILMN_1785661 FAM108B1 13.828 ILMN_1759074 DUSP19 14.451 
ILMN_1717263 PRELID2 13.849 ILMN_1761833 SLC40A1 14.458 
ILMN_1798448 IDS 13.869 ILMN_1749838 MZF1 14.497 
ILMN_1700896 SAP30 13.872 ILMN_1656132 PNLDC1 14.5 
ILMN_1821052  13.889 ILMN_1701434 RAP1B 14.529 
ILMN_1672302 STK32C 13.891 ILMN_1806601 GRSF1 14.598 
ILMN_1692429 PQBP1 13.911 ILMN_1701247 LOC132241 14.616 
ILMN_1684183 RAD9A 13.916 ILMN_1707240 PTBP2 14.621 
ILMN_1671992 LOC650128 13.917 ILMN_1807704 LOC338799 14.632 
ILMN_1856932  13.931 ILMN_1736042 ME1 14.657 
ILMN_1711828 ANKRD10 13.94 ILMN_1914800  14.669 
ILMN_1895385  13.942 ILMN_1794522 EIF5A 14.683 
ILMN_1690783 TREML1 13.954 ILMN_1840934  14.685 
ILMN_1704431 LOC554203 13.981 ILMN_1717834 MGC11102 14.695 
ILMN_1800164 PPFIA1 14.02 ILMN_1692041 POT1 14.715 
ILMN_1751474 ARHGAP29 14.046 ILMN_1765310 TCEAL2 14.72 
ILMN_1704398 FZD9 14.061 ILMN_1765019 SACM1L 14.728 
ILMN_1772658 KIAA0947 14.063 ILMN_1707434 LOC653778 14.735 
ILMN_1688464 MAP6D1 14.083 ILMN_1757052 SLC16A1 14.738 
ILMN_1786976 RAB22A 14.086 ILMN_1667510 C12orf65 14.742 
ILMN_1688056 UGP2 14.104 ILMN_1853116  14.771 
ILMN_1775328 MTG1 14.141 ILMN_1683533 CCDC66 14.773 
ILMN_1671839 TAF1C 14.16 ILMN_1784436 KIAA1688 14.79 
ILMN_1733084 LOC147645 14.172 ILMN_1770818 LOC642342 14.792 
ILMN_1668027 LOC727762 14.175 ILMN_1728517 FNTB 14.806 
ILMN_1784037 ZBTB40 14.179 ILMN_1683129 CCNL1 14.813 
ILMN_1697024 LOC730432 14.198 ILMN_1664833 MRPL50 14.815 
ILMN_1800676 TMEM49 14.208 ILMN_1812559 SLC7A6 14.815 
ILMN_1691290 CELSR3 14.211 ILMN_1758679 TMEM168 14.816 
ILMN_1727738 RAB33B 14.223 ILMN_1866464  14.822 
ILMN_1810514 SLC25A44 14.254 ILMN_1795407 CRYZL1 14.85 
ILMN_1698007 LOC651872 14.27 ILMN_1712027 RSBN1L 14.862 
ILMN_1787826 SLC36A1 14.272 ILMN_1666178 TP53I13 14.863 
ILMN_1725188 PRKCI 14.289 ILMN_1913678  14.865 
ILMN_1684278 SNORD38A 14.315 ILMN_1752798 LOC642780 14.886 
ILMN_1747442 P4HA1 14.316 ILMN_1753413 TRIOBP 14.908 
ILMN_1716658 ZNF543 14.37 ILMN_1758941 REEP5 14.938 
ILMN_1757660 CAPS 14.391 ILMN_1661107 SNORD34 14.973 
ILMN_1677165 SF3B1 14.405 ILMN_1835722  14.978 
ILMN_1705468 PIK3CA 14.406 ILMN_1775423 C10orf88 14.986 
ILMN_1671221 GAPVD1 14.429 ILMN_1685703 ACOX2 14.99 
ILMN_1656656 COX19 14.43 ILMN_1665290 LOC643995 15.024 
ILMN_1789095 BMPR2 14.435 ILMN_1703985 C19orf25 15.055 
ILMN_1899404  14.436 ILMN_1830984  15.063 
ILMN_1761058 ACAD11 14.437 ILMN_1774945 NRG3 15.1 
ILMN_1904135  14.442 ILMN_1750256 ALS2 15.122 
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ILMN_1807031 C14orf28 15.165 ILMN_1788237 LOC652755 16.216 
ILMN_1767601 C21orf94 15.215 ILMN_1813240 EIF1AX 16.225 
ILMN_1706608 LOC338799 15.232 ILMN_1815035 DENND2C 16.254 
ILMN_1811117 LOC400986 15.256 ILMN_1803018 KIFC2 16.27 
ILMN_1696935 RBM39 15.318 ILMN_1723418 CEL 16.306 
ILMN_1753607 PNO1 15.319 ILMN_1785933 C19orf18 16.323 
ILMN_1664449 ALG5 15.364 ILMN_1652736 RPS6KA3 16.385 
ILMN_1703273 UACA 15.374 ILMN_1683112 FANCC 16.437 
ILMN_1672947 CAST 15.391 ILMN_1786789 FAM102B 16.445 
ILMN_1829768  15.446 ILMN_1682757 PFKFB2 16.447 
ILMN_1743933 TSHZ3 15.456 ILMN_1816925 LOC730459 16.487 
ILMN_1693538 STK36 15.466 ILMN_1675541 EEF1B2 16.554 
ILMN_1766195 ZNF558 15.476 ILMN_1689086 CTSC 16.634 
ILMN_1660125 SFMBT2 15.51 ILMN_1678904 ENO3 16.67 
ILMN_1694367 SNORD35B 15.534 ILMN_1768754 PILRB 16.694 
ILMN_1711208 CELSR2 15.542 ILMN_1715351 SCYE1 16.729 
ILMN_1707337 MSTO1 15.553 ILMN_1768004 PDCD4 16.745 
ILMN_1736623 NCKIPSD 15.568 ILMN_1736184 GSTM3 16.75 
ILMN_1770152 ADAMTS18 15.591 ILMN_1773992 CCRL1 16.772 
ILMN_1715096 C6orf168 15.64 ILMN_1736017 LOC643834 16.802 
ILMN_1706825 PKN2 15.654 ILMN_1768719 RDH11 16.835 
ILMN_1657619 DNAJB14 15.667 ILMN_1688455 KIAA0564 16.842 
ILMN_1762262 PKIA 15.698 ILMN_1766950 PCDHB13 16.863 
ILMN_1787813 SLC5A3 15.698 ILMN_1654518 LRCH4 16.866 
ILMN_1788778 Sep-11 15.701 ILMN_1664802 WSB1 16.941 
ILMN_1770892 YY1 15.707 ILMN_1715526 ZDHHC21 16.979 
ILMN_1773395 RDH5 15.75 ILMN_1656378 NMT2 17.001 
ILMN_1677963 TMCC1 15.757 ILMN_1852793  17.015 
ILMN_1785266 OFD1 15.796 ILMN_1782487 LOC400759 17.018 
ILMN_1786168 LOC400464 15.807 ILMN_1791840 RALBP1 17.036 
ILMN_1677484 SNAPC4 15.818 ILMN_1800401 ZNF69 17.061 
ILMN_1741506 LOC149134 15.843 ILMN_1745389 KIAA1328 17.096 
ILMN_1698521 SH2B1 15.86 ILMN_1683487 ZNF154 17.243 
ILMN_1723020 MAP3K1 15.91 ILMN_1665331 AMT 17.329 
ILMN_1734011 
RP13-
15M17.2 15.912 ILMN_1658809 SEZ6 17.35 
ILMN_1801869 WDR75 15.963 ILMN_1682038 SNORA25 17.392 
ILMN_1696043 FLVCR2 16.013 ILMN_1666690 ACRC 17.4 
ILMN_1683023 PDGFC 16.013 ILMN_1718932 MTRR 17.415 
ILMN_1862001  16.079 ILMN_1788931 DOCK8 17.518 
ILMN_1714283 TLE2 16.081 ILMN_1664096 ZNF491 17.548 
ILMN_1746208 CCAR1 16.086 ILMN_1813344 C20orf7 17.573 
ILMN_1774265 UNQ830 16.096 ILMN_1736237 DLAT 17.621 
ILMN_1774589 IQCC 16.102 ILMN_1741468 FAP 17.634 
ILMN_1739587 UTY 16.155 ILMN_1737561 LOC88523 17.697 
ILMN_1776347 TCP1 16.158 ILMN_1663532 RIC8B 17.699 
ILMN_1695079 ZNF101 16.204 ILMN_1748374 LOC400304 17.703 
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ILMN_1657701 TMEM137 17.711 ILMN_1666615 PREPL 19.068 
ILMN_1676946 AP3M2 17.723 ILMN_1721657 RSU1 19.093 
ILMN_1755222 C9orf82 17.747 ILMN_1743280 LRRC37B 19.162 
ILMN_1739583 ROCK1 17.761 ILMN_1695606 EFNB3 19.177 
ILMN_1712719 MAP7 17.79 ILMN_1698261 PDE6B 19.198 
ILMN_1664177 ATXN7L2 17.791 ILMN_1752117 TMEM55A 19.289 
ILMN_1729515 PIN4 17.856 ILMN_1813179 LOC401074 19.316 
ILMN_1685052 DNAH1 17.936 ILMN_1709747 ENDOGL1 19.475 
ILMN_1767279 LOC648245 18.061 ILMN_1724789 CD59 19.54 
ILMN_1741219 RRAGB 18.061 ILMN_1866216  19.562 
ILMN_1784706 GABRE 18.096 ILMN_1670752 KIAA0907 19.614 
ILMN_1890175  18.108 ILMN_1815705 LZTFL1 19.626 
ILMN_1660864 RHBDL1 18.139 ILMN_1767558 LRP5 19.668 
ILMN_1748427 ZNF239 18.146 ILMN_1892638  19.688 
ILMN_1764764 MUM1 18.163 ILMN_1908989  19.748 
ILMN_1682589 M6PR 18.173 ILMN_1801045 SPIN3 19.778 
ILMN_1860821  18.272 ILMN_1749253 TUBD1 19.817 
ILMN_1653794 C6orf160 18.306 ILMN_1723124 GALK2 19.907 
ILMN_1678998 LRRC14 18.328 ILMN_1784783 NME5 19.924 
ILMN_1760281 PRPF4B 18.391 ILMN_1677532 TARDBP 20.007 
ILMN_1795835 LOC338758 18.397 ILMN_1726989 C1orf86 20.083 
ILMN_1757910 HIP1R 18.404 ILMN_1810533 SLC6A15 20.147 
ILMN_1747650 BMP6 18.429 ILMN_1749915 C1orf63 20.209 
ILMN_1891455  18.465 ILMN_1727553 LOC63920 20.236 
ILMN_1738749 MAST3 18.483 ILMN_1706506 ZNF454 20.439 
ILMN_1720916 SETD7 18.49 ILMN_1868805  20.491 
ILMN_1681367 ZNF642 18.529 ILMN_1759084 INTS8 20.527 
ILMN_1768117 RBM25 18.55 ILMN_1778464 TMEM1 20.75 
ILMN_1691395 ZBTB11 18.565 ILMN_1722450 NSUN5B 20.769 
ILMN_1813430 TRIM69 18.584 ILMN_1672565 RG9MTD1 20.778 
ILMN_1679558 LOC283874 18.622 ILMN_1782222 KIAA1033 20.793 
ILMN_1707051 NFATC1 18.63 ILMN_1721034 ZNF227 20.839 
ILMN_1898124  18.764 ILMN_1798826 MRPS25 20.848 
ILMN_1674297 HCFC2 18.77 ILMN_1726368 ZNF135 20.957 
ILMN_1712798 ZNF608 18.778 ILMN_1759407 USHBP1 20.984 
ILMN_1669931 TM9SF3 18.79 ILMN_1796119 C6orf113 21.051 
ILMN_1721741 ATPBD1B 18.8 ILMN_1672122 PH-4 21.137 
ILMN_1757408 ZNF256 18.816 ILMN_1696469 LOC648509 21.184 
ILMN_1843756  18.865 ILMN_1734867 NR2C1 21.285 
ILMN_1893633 LOC439949 18.897 ILMN_1758105 ZNF791 21.299 
ILMN_1788118 SLC23A3 18.943 ILMN_1743427 SCYL3 21.302 
ILMN_1801762 PFDN4 18.952 ILMN_1716921 ZNF83 21.387 
ILMN_1790103 ZNF569 18.96 ILMN_1673478 C5orf5 21.414 
ILMN_1713744 C14orf132 18.977 ILMN_1746782 LRRC16 21.506 
ILMN_1792109 AFG3L1 19.025 ILMN_1779448 EFHD1 21.634 
ILMN_1670322 FCHO2 19.052 ILMN_1789364 ZNF789 21.681 
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ILMN_1657011 LOC286208 21.689 ILMN_1781361 LOC400986 24.518 
ILMN_1681760 LOC728518 21.713 ILMN_1910120 LOC730092 24.876 
ILMN_1703555 SNORD31 21.737 ILMN_1751362 FASTKD1 24.938 
ILMN_1756992 MUC1 21.765 ILMN_1898691  25.009 
ILMN_1668055 SAA4 21.911 ILMN_1652147 MRPL43 25.102 
ILMN_1798085 EID2B 21.916 ILMN_1809894 TMEM117 25.126 
ILMN_1714848 ZNF354A 21.965 ILMN_1747824 ZNF85 25.136 
ILMN_1665810 CCDC113 22.105 ILMN_1663646 DMXL1 25.519 
ILMN_1827736  22.113 ILMN_1735275 WDSUB1 25.636 
ILMN_1754757 SCNN1D 22.21 ILMN_1727466 KCNMB4 25.708 
ILMN_1730888 ZNF680 22.392 ILMN_1710954 LOC283932 25.954 
ILMN_1690839 PPAPDC3 22.455 ILMN_1759062 NIPBL 26.188 
ILMN_1788689 PHIP 22.456 ILMN_1782098 SMO 26.524 
ILMN_1720287 E4F1 22.493 ILMN_1753823 IL17D 26.709 
ILMN_1793578 ZFP37 22.555 ILMN_1745501 DNALI1 27.223 
ILMN_1791006 AHI1 22.619 ILMN_1712766 ERGIC2 27.338 
ILMN_1761044 GNB1L 22.632 ILMN_1849693  27.408 
ILMN_1670379 ANTXR1 22.692 ILMN_1802519 VPS36 27.821 
ILMN_1745790 MRPL42P5 22.696 ILMN_1807136 LOC729559 27.938 
ILMN_1814221 NPTX1 22.721 ILMN_1867188  28.015 
ILMN_1745991 GNRH1 22.742 ILMN_1676302 FAM113A 28.406 
ILMN_1684726 C2orf27 22.773 ILMN_1802053 ZNF91 28.983 
ILMN_1811050 CCDC88A 22.996 ILMN_1811029 TLK1 29.073 
ILMN_1719064 KCTD10 23.165 ILMN_1727923 ZNF140 29.289 
ILMN_1746924 ZNF610 23.185 ILMN_1716264 ANKRD1 29.505 
ILMN_1696004 LRRK1 23.209 ILMN_1651964 ABCC5 29.711 
ILMN_1892548  23.238 ILMN_1789751 MFSD1 29.818 
ILMN_1651364 PCBD2 23.25 ILMN_1737818 C12orf43 29.866 
ILMN_1719290 CRYZL1 23.268 ILMN_1913641  30.162 
ILMN_1665135 RBBP6 23.445 ILMN_1893511  31.152 
ILMN_1812666 DNAJC15 23.698 ILMN_1662147 MANEAL 32.856 
ILMN_1745852 WDR33 23.704 ILMN_1724009 SETD6 34.229 
ILMN_1691772 ZSCAN29 23.731 ILMN_1662038 LARGE 34.239 
ILMN_1753782 ZNF266 24.006 ILMN_1811110 TDRD9 35.458 
ILMN_1873278 LOC731895 24.021 ILMN_1698185 WDR90 36.252 
ILMN_1793017 DGKQ 24.026 ILMN_1806473 
NGFRAP1L
1 36.806 
ILMN_1801303 AMY2A 24.081 ILMN_1818617  37.692 
ILMN_1738124 ZNF772 24.146 ILMN_1716555 MGC42630 40.455 
ILMN_1751393 ZNF684 24.302 ILMN_1696622 SLC38A6 44.889 
ILMN_1811301 INPP5E 24.314 ILMN_1792972 ZNF439 47.176 
ILMN_1849186  24.316 ILMN_1725314 GBP3 49.23 
ILMN_1911717  24.513    
 
Table A1. Differentially Expressed Probes Identified on BeadStudio Analysis of Microarray 
Data. A total of 727 probes were found to be differentially expressed in endothelial cells from 
patients with coronary artery disease and type 2 diabetes (T2D). 
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ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 NM_005688.2 0.00958 -1.25529 
ACAD11 acyl-Coenzyme A dehydrogenase family, member 11 NM_032169.4 0.00412 -1.44834 
AFG3L1 AFG3 ATPase family gene 3-like 1 (S. cerevisiae) NR_003226.1 
3.00E-
05 -1.64806 
AGTR2 angiotensin II receptor, type 2 NM_000686.4 0.0239 1.45261 
AMT (includes EG:275) aminomethyltransferase NM_000481.2 0.03663 -2.06699 
AMY2A amylase, alpha 2A (pancreatic) NM_000699.2 0.04685 -1.52472 
BLZF1 basic leucine zipper nuclear factor 1 (JEM-1) NM_003666.2 0.01698 -1.23465 
C10ORF120 chromosome 10 open reading frame 120 NM_001010912.1 0.01645 1.23922 
C10ORF97 chromosome 10 open reading frame 97 NM_024948.2 0.02841 -1.17917 
C14ORF39 chromosome 14 open reading frame 39 NM_174978.1 0.03079 1.51268 
C17ORF54 chromosome 17 open reading frame 54 NM_182564.1 0.00842 1.5758 
C19ORF18 chromosome 19 open reading frame 18 NM_152474.3 0.03607 -1.54723 
C1ORF63 chromosome 1 open reading frame 63 NM_020317.3 0.00588 -1.88027 
C6ORF123 chromosome 6 open reading frame 123 NM_014356.2 0.02219 1.71414 
CCDC113 coiled-coil domain containing 113 NM_014157.2 0.00116 -1.45675 
CFDP1 craniofacial development protein 1 NM_006324.2 0.03607 1.37673 
CFL1 cofilin 1 (non-muscle) NM_005507.2 0.01086 1.17496 
CROP cisplatin resistance-associated overexpressed protein NM_006107.2 0.01538 -2.04803 
DGKQ diacylglycerol kinase, theta 110kDa NM_001347.2 0.03809 -1.33223 
E4F1 E4F transcription factor 1 NM_004424.3 0.01635 -1.33492 
EFHD1 EF-hand domain family, member D1 NM_025202.2 0.01086 -4.45841 
ERGIC2 ERGIC and golgi 2 NM_016570.2 0.03412 -1.28905 
FAP fibroblast activation protein, alpha NM_004460.2 0.01538 -2.34487 
FLJ21062 hypothetical protein FLJ21062 NM_001039706.1 0.03663 -1.30533 
GDF2 growth differentiation factor 2 NM_016204.1 0.01726 1.2736 
GNL2 guanine nucleotide binding protein-like 2 (nucleolar) NM_013285.1 0.026 -1.1826 
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GNRH1 gonadotropin-releasing hormone 1 (luteinizing-releasing hormone) NM_000825.3 0.0198 -1.58069 
HIP1R huntingtin interacting protein 1 related XM_001132864.1 0.03809 -1.52871 
KIAA0556 KIAA0556 NM_015202.1 0.04851 -1.23184 
KIAA0574 KIAA0574 protein XM_001127362.1 0.96044 1.07003 
KIAA1328 KIAA1328 NM_020776.1 0.03557 -1.40981 
KIAA2013 KIAA2013 NM_138346.1 0.02921 1.21295 
KLK4 kallikrein-related peptidase 4 NM_004917.3 0.02841 2.15663 
LOC283932 hypothetical LOC283932 NM_175901.3 0.03079 -1.42516 
LOC440748 hypothetical gene supported by AK124556 XM_498841.3 0.04054 1.39778 
LOC727762 similar to NADH:ubiquinone oxidoreductase B15 subunit XM_001125898.1 0.0238 -1.7181 
LOC729137 hypothetical protein LOC441528 XM_001129423.1 
1.10E-
04 2.9142 
LRCH4 
leucine-rich repeats and calponin homology (CH) domain 
containing 4 NM_002319.2 0.0238 -1.60402 
LSM14A LSM14A, SCD6 homolog A (S. cerevisiae) NM_015578.1 0.04685 -1.14405 
LZTFL1 leucine zipper transcription factor-like 1 NM_020347.2 0.01963 -1.30391 
MFSD1 major facilitator superfamily domain containing 1 NM_022736.1 
6.99E-
06 -1.39625 
MGC12760 ciliary rootlet coiled-coil, rootletin-like 1 XM_001130627.1 0.01784 -1.72953 
MGC42630 family with sequence similarity 27, member E3 NM_175923.3 0.01634 -1.51369 
NSUN5B NOL1/NOP2/Sun domain family, member 5B NM_001039575.1 0.01086 -1.57828 
NUTF2 nuclear transport factor 2 NM_005796.1 0.01086 1.41546 
PDE8A phosphodiesterase 8A NM_173457.1 0.03186 -1.2629 
PIK3R2 phosphoinositide-3-kinase, regulatory subunit 2 (beta) NM_005027.2 0.03585 -1.22074 
RAB22A RAB22A, member RAS oncogene family NM_020673.2 0.01199 -1.28058 
RALBP1 ralA binding protein 1 NM_006788.3 0.03117 -1.23267 
RDH5 retinol dehydrogenase 5 (11-cis/9-cis) NM_002905.2 0.03117 -1.43216 
RIC8B resistance to inhibitors of cholinesterase 8 homolog B (C. elegans) NM_018157.2 0.00412 -1.31425 
SAA4 serum amyloid A4, constitutive NM_006512.1 0.03762 -1.96613 
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SETD6 SET domain containing 6 NM_024860.1 7.70E-04 -1.5567 
SGSM2 small G protein signaling modulator 2 NM_014853.2 0.03186 -1.21567 
SLC23A3 solute carrier family 23 (nucleobase transporters), member 3 NM_144712.2 0.03607 -2.3497 
SLC25A28 solute carrier family 25, member 28 NM_031212.3 0.0238 -1.23134 
SLC38A6 solute carrier family 38, member 6 NM_153811.1 0.0092 -1.5712 
SRMS 
src-related kinase lacking C-terminal regulatory tyrosine and N-
terminal myristylation sites NM_080823.2 0.02963 -1.86829 
STK35 serine/threonine kinase 35 NM_080836.2 0.03186 -1.15512 
STK36 serine/threonine kinase 36, fused homolog (Drosophila) NM_015690.2 0.04624 -1.33175 
TCFL5 transcription factor-like 5 (basic helix-loop-helix) NM_006602.2 0.04014 -1.26548 
TDRD9 tudor domain containing 9 NM_153046.1 7.70E-04 -2.18596 
TM9SF3 transmembrane 9 superfamily member 3 NM_020123.2 0.01199 -1.2211 
TSPAN6 tetraspanin 6 NM_003270.2 0.02841 -1.18427 
ULK1 unc-51-like kinase 1 (C. elegans) XM_001133335.1 0.0092 -1.24957 
USHBP1 Usher syndrome 1C binding protein 1 NM_031941.3 0.01538 -2.16837 
WDR60 WD repeat domain 60 NM_018051.3 0.01226 -1.33403 
ZBTB12 zinc finger and BTB domain containing 12 NM_181842.1 0.01784 1.57687 
ZDHHC8 zinc finger, DHHC-type containing 8 NM_013373.2 0.01086 -1.266 
ZMYM2 zinc finger, MYM-type 2 NM_197968.1 0.00311 -1.26863 
ZNF212 zinc finger protein 212 NM_012256.2 0.01645 -1.20548 
ZNF266 zinc finger protein 266 NM_006631.2 4.00E-05 -1.33324 
ZNF439 zinc finger protein 439 NM_152262.2 0.01925 -1.68406 
ZNF486 zinc finger protein 486 XM_371152.3 0.0471 -1.24292 
ZNF569 zinc finger protein 569 NM_152484.2 0.01086 -1.29198 
ZNF83 zinc finger protein 83 NM_018300.2 0.02596 -1.47467 
ZUFSP zinc finger with UFM1-specific peptidase domain NM_145062.1 0.01949 -1.34485 
 
Table A2. Differentially Expressed Genes Identified From Ingenuity Pathway Analysis (IPA) of Rosetta Resolver® Microarray Data. IPA identified 77 
differentially expressed genes (P≤0.005) within the Rosetta Resolver® data set.  
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